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Abstract.
Production of mature infectious adenovirus type 2 depends on the action of the L3 coded 
23kd protease which is known to cleave 7 virus proteins and the host cell proteins 
cytokeratin K7 and K18. Previous studies have shown the enzyme to be a cysteine 
proteinase with a novel mechanism of activation requiring the presence of an 11 residue 
peptide derived from the C-terminus of virus structural protein pVI. It has been proposed 
that the protease is activated within the assembled virion, although other evidence suggests 
that the protease is active outwith the virus particle, and is partly responsible for the 
degradation of the intermediate filament system prior to virion release from the infected cell. 
The subcellular localisation of the 23kd protease during productive adenovirus infection was 
investigated using a panel of monoclonal antibodies generated during the course of this 
study. The monoclonal antibodies were partially characterised and those of interest were 
epitope mapped using a combination of techniques which included limited and chemical 
proteolysis, and deletion mutagenesis of the recombinant protein, and screening against 
overlapping peptides corresponding to specific regions within the 23kd protease.
The viral 23kd protease, capsid protein pVIII, and the Ll-52kd probable scaffold protein 
were shown to colocalise within virus-induced intranuclear clear amoiphous inclusions late 
in infection (24 h.p.i onwards). These inclusions were typically associated with crystalline 
arrays of assembled virions and are believed to be the same sites which contain relocated 
PML during the earlier stages of infection. The structural appearance of these inclusions 
varied depending on the fixation method used. The distribution of the viral protease, PML 
and another cellular protein P80-coilin during the late-phase of nuclear transformation was 
investigated with possible cleavage of both cellular proteins also partially determined.
The viral protease and protein pVIII were also shown to colocalise within cytoplasmic 
structures but were not found to be associated with cytokeratin K18. The degradation of 
cytokeratin K18 occurred as early as 20 to 22 h.p.i although the intranuclear distribution of 
pVI at this stage of infection suggested that the viral protease may be regulated by an as yet 
unknown mechanism. Isoforms of recombinant wild type 23kd protease (but not Ad2tsl) 
were detected in vitro which suggested that dimerisation may be an in vivo regulatory 
mechanism, possibly involving intranuclear trafficking.
ii
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1 Introduction
1.1 Adenoviruses
1.1.1 Epidemiology and classification.
First isolated from adenoidal tissue of chidren, Adenoviruses were reported as being distinct 
etiological agents in 1953 by Rowe et al. Since then, over 100 serotypes have been identified 
which infect different animal species. Human adenoviruses (Ad) are members of the genus 
Mastadenovirus, which together with Aviadenovirus make up the Adenoviridae family 
(Horwitz 1990b). Although the 15 serotypes of aviadenoviruses identified to date have 
economic implications within the poultry industry (Isibashi and Yasue,1984), most studies 
have concentrated on the mastadenoviruses which infect a broad range of mammalian species. 
These viruses share a common antigenic determinant which is located on the major viral coat 
protein, the Hexon (Norrby etal., 1977).
To date, 47 serotypes have been found to infect humans, however despite the large number 
and world-wide distribution, their clinical importance is largely restricted to epidemics of 
acute respiratory disease (ARD), an influenza like illness in military recruits, and to limited 
outbreaks among children (reviewed by Horwitz, 1990a). Types 7, 4 and 3 (in order of 
decreasing importance) are the viruses most frequently responsible for epidemics of acute 
respiratory, and ocular diseases, although types 11,14, 21, 40 and 41 have increasingly been 
implicated. Peculiarly, Ad4 commonly causes ARD in military recruits but rarely in civilians. 
There is as yet no explanation for this epidemiological behaviour.
Epidemiological studies indicate that adenoviruses annually cause at most 4 to 5% of viral 
respiratory illnesses in civilians. Person to person spread in respiratory and ocular secretions 
is the most common mode of viral transmission implicated in epidemics of 
pharyngoconjuctival fever and conjunctivitis. The spread of epidemic keratoconjunctivitis 
caused by types 8, 19 and 37 adenoviruses appears to be associated with conjunctival trauma 
produced by dust found in many working environments. Adenoviruses are commonly 
present in the faeces of infected persons, even those with ocular and respiratory infections, 
yet only types 40 and 41 (the agents of infantile gastro-enteritis most evident in developing 
countries) appears to be transmitted by the faecal-oral route.
In 1962, Trentin et al. discovered that adenovirus serotype 12 could induce tumours in 
rodents. This discovery led to an intense period of research on adenoviruses. Although no 
adenovirus serotype has been associated with human malignancy, the ability to transform 
rodent cells has served as a useful model to study the molecular basis of cell transformation 
(Graham, 1984).
The 47 human serotypes are arranged together into six subgroups (A to F) on the basis of 
several criteria (table 1.1) that include haemagglutination, morphology (for instance, length of 
fibre protein), %G+C content of the genomes, DNA sequence homologies, and the ability to 
induce tumours in laboratory rodents (Horwitz, 1990a). DNA sequence homologies between 
members of the same group are usually very high (48-85%) with most significant differences 
occurring in the coding regions for the major coat proteins. In contrast, less than 20% DNA 
sequence homology has been shown between viruses from different groups (Garon et al. , 
1973). Despite their differences, all the adenoviruses have the same basic organisation, with 
sequences of many functional proteins being highly conserved between viruses from different 
subgroups (Horwitz, 1990a).
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Subgroup Serotypes Oncogenic % GC in DNA
A 12, 18, 31 High 48-49
B 3, 7, 11, 14, 16, 21, 34, 35 Moderate 50-52
C 1, 2, 5, 6 Low or none 57-59
D 8, 9, 19, 37, 10, 13, 15, 17,
19, 20, 22-30, 32, 33, 36, 37,
38. 39, 42-47
Low or none 57-61
E 4 Low or none 57-59
F 40, 41 Unknown -
Table 1.1: Classification of the human adenoviruses. Classification based on DNA homologies 
and the ability to induce tumours in animals. Modified from Horwitz (1990a).
1.1.2 Virion structure.
Adenovirus virions are non-enveloped and icosahedral in structure containing a double 
stranded genome of approximately 34 to 36kb (Akusjarvi et al., 1984). In the 40 years since 
the discovery of this virus, a wide range of biophysical and biochemical techniques have been
3applied to understanding the structure of the virion. For instance, analysis of purified virions 
by SDS- Polyacrylamide gel electrophoresis revealed 12 distinct polypeptides which were 
termed n to XII according to their relative mobilities (Maizel et al., 1968a). Seven of these, 
namely II, III, Ilia, IV, VI, and IX have been shown to be associated with the viral coat, 
which can be removed from the viral cores by treatment with 0.5% deoxycholate or 5M urea 
(Russell et al., 1968). The cores are made up of the viral DNA, and a number of proteins 
including V, VII, mu (X), and the DNA linked terminal protein (Chatterjee et al., 1986). In 
addition, enzyme activity associated with the viral encoded 23kd protease has also been 
recovered from disrupted particles (Trembley etal., 1983; Anderson, 1990).
i) Structural proteins:
The capsid shell is composed of 252 capsomeres which comprise of 240 hexon capsomeres 
(protein II), and 12 penton capsomeres, which are in turn composed of 5 penton molecules 
(protein III) and three fibre proteins (protein IV). The hexon capsomeres assemble to form 
the 20 sides of the virion particle, while the penton capsomeres are isolated to the 12 vertices 
of the virion (Stewart and Burnett, 1995). The 3-dimensional structure of the entire particle 
has been determined by cryo-electron microscopy together with 3-dimensional image 
reconstruction (Stewart etal., 1991). A schematic illustration outlining the relative positions 
of the known virion components is shown in figure 1.1.
To date, the atomic structure of only one of the capsid components, the hexon derived from 
Ad2, has been determined (Roberts et al., 1986; Athapilly,1994). The hexon monomer has 
967 amino-acid residues with a predicted molecular weight of 109kd. In the virion coat, 3 
hexon monomers come together to form each of the 240 hexon capsomeres (Grutter and 
Franklin, 1974), a process facilitated by the virus encoded L4 lOOkd protein (Cepko and 
Sharp, 1983). Each monomer has two eight-stranded B-barrels and three extended loops, of 
which the latter intertwine in the trimer and are exposed on the surface of the virus. In the 
trimer, six B-barrels, two from each monomer, sit at the corners of a hexagon to generate a 
pseudohexagonal base. This shape is convenient for close packing of the hexon capsomers 
on the surface of the virion. It has been proposed that the N-terminal region of hexon 
interacts with the viral core DNA and protein (Stewart and Burnett, 1995). The hexon surface 
loops display the greatest variability between adenovirus serotypes and contain many of the
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4type specific epitopes (Toogood et al., 1989). Five hexons, known as peripentonal hexons 
have been shown in atomic detail to be closely associated with the penton base at the particle 
vertices. One of the two hexon B-barrels fits nicely into a groove on the side of the penton
base.
Each penton capsomer is composed of five copies of penton base, and three identical copies 
of fibre protein (Van Oostrum et al., 1987). The penton base contains 571 amino-acid 
residues, with an apparent molecular weight of 63kd (Stewart and Burnett, 1995). The five 
penton base monomers are non-covalently associated to give a ring like pentamer (Stewart et 
al., 1991) which has a 30A diameter central core, in which the N-terminal region of the fibre 
protein is linked (Devaux et al., 1987; Stewart and Burnett, 1995). This polypeptide is 582 
amino acid residues in length with a predicted molecular mass of 62kd in Ad2 (Herisse etal., 
1981). The fibre in this serotype is 37nm in length, however, the length of the 'shaft' varies 
between serotypes (Signas etal., 1985; Kidd etal., 1993), and within those which contain 
two types of fibre proteins (Ad40). In either case the length of the fibre depends on the 
amount of repeating units (15 amino acid residues in length) in the main body of the 
polypeptide, for instance, Ad2 has 22 repeated units, Ad3 has 6, and the two fibre Ad40 has 
21 and 12 repeated units (Green etal., 1983). At the C-terminal region of the fibre protein, a 
globular 6-barrel domain exists which is thought to confer receptor recognition.
Figure 1.1: Schematic illustration of the adenovirion. The currently predicted positions for both
core and capsid proteins are outlined (provided by Dr. D. Mathews, University of StAndrews).
Hexons have been shown to interact with another capsid protein, Ilia, which has 585 ammo 
acid residues and a predicted molecular mass of 65kd (Robertser al., 1984). Three­
dimensional difference mapping has revealed 60 copies of this elongated component (5 to 6 
copies per vertex) that appear to span the hexon capsid (Stewart and Burnett, 1995), an 
observation supported by the fact that recombinant Ilia polypeptide in 1M urea is long 
enough (200A) for this to be possible (Cuillel et al., 1990). It has been proposed that Ilia 
polypeptide interacts with two 6-barrel strands of hexon, with the C-terminal region, which is 
known to be cleaved by the L3 23kd protease (Anderson, 1990) possibly associating with 
core proteins V and VII (Boudin et al., 1980). Protein Ilia is phosphorylated early in 
infection, although the significance of this is not yet known (Tsuzuki and Luftig, 1983). 
Protein VI is derived by proteolysis from a 250 amino acid precursor (pVI) with a predicted 
molecular weight of 27kd. The precursor protein is processed by the viral 23kd protease 
which removes the N-terminal 33 amino acids (Akusjarvi and Persson, 1981; Anderson, 
1990). The mature VI is thought to have a role in linking the core complex to the capsid 
(Russell and Precious, 1982), and recent work (Mathews and Russell, 1994; Stewart and 
Burnett, 1995) has provided evidence that there is a strong interaction between the 
peripentonal hexons and mature VI. This interaction appears to be 300 times stronger than the 
interaction between hexon and pVI, suggesting that proteolytic maturation alters the 
conformation of mature VI, thereby facilitating tighter binding. Stewart and Burnett (1995) 
have suggested that VI exists as disordered dimers within the capsid. Interestingly, the 11 
amino acid C-terminus of pVI, functions as a cofactor which enhances proteolytic activity 
(Webster et al., 1993; Mangel etal., 1993).
Protein VIII, with a molecular mass of 15kd, is derived from a precursor protein of 
approximately 25kd (pVIII) which comprises of 227 amino acid residues (Pieniazek et al., 
1989). pVIII contains three potential processing sites (Webster et al., 1989a and b), 
however, the derivation of protein VIII from pVIII is still not completely understood. Initially 
it was thought that protein VIII was inside the capsid and associated with hexons (Everitt et
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al., 1975; Pettersson, 1984), however, recent evidence suggests that VIII is closely 
associated with the penton base and fibre at the vertices of the virion (Hong and Boulanger, 
1995). A temperature sensitive mutant of adenovirus which is defective for protein VIII, and 
termed H5sub304 (Lui et al., 1985), has a marked thermolability which indicates, like protein 
IX, that this protein could serve as a scaffolding protein and/or be involved in stabilising the 
final virion structure.
Protein IX has 139 amino acid residues with a predicted molecular weight of 15kd (Alestrom 
et al., 1980). Biochemical analysis (Furcinitti et al., 1989) has shown that 12 copies of 
polypeptide IX and 9 copies of hexon associate to form the group of nine hexon (GON) 
structure. These were confirmed by combined X-ray crystallography and scanning 
transmission electron microscopy studies (Stewart et al., 1993). Trimers of protein IX are 
shown to bind on the outer surface of closely packed hexon bases, with four trimers being 
associated with each of the 20 facets (Boulanger et al., 1979; Van Oostrum and Burnett, 
1985; Stewart et al., 1991). Mutant viruses lacking this protein can form intact virions (Colby 
and Shenk, 1981), but these are less stable than wild type virions.
ii) Core components:
At least four proteins, polypeptides V and VII (Philipson, 1983), polypeptide mu (Hosokawa 
and Sung, 1976), and the DNA binding terminal protein (Rekosh et al., 1977), are 
complexed with the DNA in the core of the virion. In addition, it has also been estimated that 
approximately half of the capsid component protein VI is disordered and interacting with the 
internal DNA (Stewart and Burnett, 1995). The 10 copies of the 23kd protease (Anderson, 
1990) have not been assigned to any particular location within the virion, although it seems 
possible like protein VI, that an interaction with the viral genome may exist (Mangel et al., 
1993). The Ad2 23kd protease is discussed in detail in section 1.1.5.
The exact structure of the adenovirus core within the virus particle is somewhat controversial, 
although it appears that the core DNA-protein complex is positioned in 12 globular domains 
with the outside loop of each domain in close proximity with each penton vertex (Brown et 
al., 1975; Newcomb et al., 1984). This may correlate well with the suggestion that 
disordered dimers of protein VI can interact with viral DNA.
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7Protein VII is the major component of the viral core, with an estimated 833 copies per virion 
(Hosokawa and Sung, 1976; Stewart and Burnett, 1995). The protein initially exists as a 
precursor of 197 amino acid residues in length, and a molecular mass of 21.8kd, which is 
cleaved by the 23kd protease to mature VII, with a predicted mass of 19.4kd and 174 amino 
acid residues in length (Anderson et al., 1973; Sung et al., 1983; Alestrom et al., 1984). 
Protein VII has a high content of both arginine (23%) and alanine (18.9%), and binds tightly 
to DNA, with 3M NaCl being required to dissociate the complex (Cupo et al., 1987).
The minor core protein, V, is 368 amino acid residues in length, with a predicted molecular 
mass of 41.6kd (Alestrom et al., 1984). This protein can be removed from viral DNA by 
relatively mild treatments leading to the suggestion that it forms a protein shell around the 
DNA-protein VII complex, perhaps forming the link between the core and the capsid 
(Nermut, 1979; Chatterjee etal., 1985). Chemical cross-linking studies have indicated that 
VII, mu, and V interact, although the only core protein to interact with capsid component 
protein VI is V. Protein V is moderately basic with 20% of residues being arginine or lysine. 
These residues are clustered to give a lysine rich N-terminus, and arginine rich C-terminus. 
Stoichiometric estimates range from 120 to 160 copies of protein V per virion (Hosokawa 
and Sung, 1976; Van Oostrum and Burnett, 1985). During virion assembly, protein V is 
highly phosphorylated, however, within the maturing virion the protein is dephosphorylated, 
a step which is blocked by the Ad2tsl mutation (section 1.1.5). This is suggestive that 
cleavage of precursor proteins and dephosphorylation of V are linked events which require 
functional viral protease (Weber and Khitoo, 1983).
Associated with protein V is the protein derived from a 79 amino acid precursor, pmu, which 
has a predicted molecular mass of llkd. mu has 19 amino acid residues, including 9 
arginines and 3 histidines and is known to bind tightly to DNA. There is an estimated 180 to 
340 copies per virion (Weber and Anderson, 1988). The viral protease is thought to cleave 
pmu at two sites releasing a 31 amino acid long N-terminus fragment and a 29 amino acid C- 
terminal region. Proteins XI and XII are believed to be products of viral protease processing. 
The above authors reported that XII may be derived from the N-terminal region of pVII and 
XI from pmu, although this has yet to be confirmed.
In addition to V,VII and mu, at least two other proteins are present in the viral cores at very 
low copy numbers. One of these, the terminal protein (TP), is made as a precursor (pTP)
which is proteolytically processed by the viral protease via an intermediate, iTP (Trembley et 
al., 1983, Webster et al., 1994). Terminal protein has a molecular mass of 55kd, and is 
covalently linked to the dCMP residue at the 5' end of each DNA strand (Rekosh et al., 1977; 
Smart and Stillman, 1982). pTP and TP are discussed in more detail in section 1.1.3iii.
Very little is known about the second low copy protein, IVa2, which is composed of 448 
amino acid residues, and has a molecular mass of 51kd (Russell and Precious, 1982; Russell 
and Kemp, 1995). IVa2 may be associated with the core (Weber etal., 1983), possibly being 
encapsidated with the viral genome, as it is known to specifically bind to viral DNA. The 
virus encoded LI 52kd and 55kd scaffold proteins have been shown to interact with IVa2 in 
immature virions (Lutz et al., 1996; Gustin et al., 1996). These authors suggest IVa2 may be 
involved in removing the scaffold proteins during virion assembly. Although IVa2 is present 
in immature virions it has only been detected in a phosphorylated state within mature virions 
(Weber and Khitoo, 1983). Interestingly, IVa2 has a motif for ATP/GTP binding (Russell 
and Kemp, 1995) and may facilitate phosphorylation events in virion maturation. Protein 
kinase activity has been associated with human adenoviruses (Blair and Russell, 1978), 
although it is unknown whether it is virus encoded or of cellular origin.
1.1.3 Infectious life cycle.
Adenovirus infection can persist for long periods in human lymphoid tissues. In normal 
circumstances, recurrent illness has not been shown to arise from these latent infections, 
although activation can occur in patients with immunosupression. It appears that latent 
persistent infections are readily established because infected cells are not lysed, and viral 
particles remain protected within nuclei. In nature this is confined to relatively few cells.
In contrast, cultured cells infected with human adenovirus can either be transformed by the 
integration of part or all of the viral DNA into their genome (Sharp, 1984; Boulanger and 
Blair, 1991) or play host to a full lytic infection, which can spread to uninfected cells and 
produce detectable cytopathic effects. Transformation takes place in semi- or non-permissive 
cells, and depends on virus serotype and the nature of the host cell. All of the human 
adenoviruses are able to transform new born rodent cells, but only serotypes from groups A 
and B are known to be oncogenic. Full lytic infections are best observed using cultured 
human epithelial cell lines such as HeLa or KB, where the human adenovirus types 2 and 5
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9have been shown to replicate very efficiently. Adenovirus infection in permissive cells can be 
divided into distinct stages which are outlined in this section.
i) Receptor recognition and cellular uptake:
Adenovirus attaches with high affinity to as yet unidentified cellular receptors via the fibre 
protein head domain (Philipson et al., 1968; Louis et al., 1994; Xia et al., 1995). Fibre 
length, which varies among serotypes, may have a role in facilitating the attachment of virus 
to more than one receptor if necessary (Kidd et al., 1993). The number of receptors available 
for virus binding has been determined for a range of cells (Defer et al., 1990; Belin and 
Boulanger, 1993) and varies from 3x to 6x 10^. The vitronectin and fibronectin binding 
integrins have recently been identified as the secondary receptors (Wickham et al., 1993), 
interacting with the conserved RGD motif of penton base proteins. Adsorption appears to be 
followed by an energy-dependent clustering of virus particles at the cell surface (Patterson 
and Russell, 1983), with internalisation occurring via clathrin-coated vesicles into endosomes 
(Greber et al., 1993).
During the course of receptor-mediated endocytosis, adenoviruses undergo multiple 
sequential uncoating steps as they move from the cell surface to the nuclear membrane 
(Svensson and Persson, 1984; Greber et al., 1993). Within 20 minutes, 80% of receptor 
bound virus is located in early endosomes, where the fibre, VIII and Ilia proteins are 
dissociated, thereby weakening the virion structure (figure 1.2). The acidification of the 
endosome may facilitate penetration of the virus into the cytoplasm (Bai et al., 1993; 
Rddriguez and Everitt, 1996). The first proteins to be eliminated at this stage are those located 
at the 12 vertices of the viral particle, including penton base, protein IX, and subpopulations 
of hexons. Fibre release may have a specific role at this stage in promoting virus escape from 
endosomes. Additionally, a cytopathic effect has been associated with the penton base protein 
(Valentine and Periera, 1965).
The degradation of protein VI at this stage of protein elimination has been attributed to the 
activity of the viral 23kd protease (Cotten and Weber, 1995; Greber et al., 1996). It has been 
suggested that the RGD-dependant interaction of the penton base with integrin receptors 
induces a conformational change in the vertex region of the capsid which exposes hidden 
protease cleavage sites in VI. The role of the viral protease in disassembly is best illustrated
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with studies incorporating the temperature sensitive mutant, Ad2tsl, which is protease 
deficient (Weber, 1976; Rancourt et al., 1995) and fails to uncoat (Mirza and Weber, 1979). 
With wild type Ad2 infection, between 40 and 60% of virus can be seen inside cells, with 20
to 35% located in the cytoplasm 30 minutes after uptake. After Ad2tsl infection, although 
80% of virus has been endocytosed, only 0.4% can be visualised in the cytoplasm (Russell 
and Kemp, 1995), the majority being retained in endosomes which are then recycled in the
cytoplasm (Greber et al., 1996).
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Figure 1.2: Steps involved in the uncoating process. The adenovirus binds to a high-affinity fibre 
receptor and endocytosis occurs after a lag period of 5 minutes. Efficient penetration from endosomes occurs 
after 15 minutes and after 45 minutes 50% of the cell-bound viruses have been completely disassembled and 
have released their DNA inside the nucleus (reproduced from Greber, 1993).
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Following uncoating, the virus particle resembles adenovirus cores with some of the hexons 
from the capsid shell still associated. The DNA genome is delivered to the cell nucleus, 
possibly directed by viral core proteins V and/or TP, both of which have nuclear localisation 
sequences (Russell and Kemp, 1995). The sequence within TP is highly conserved among all 
the serotypes in which the sequence is known. Protein V may dissociate at the nuclear 
membrane (Greber et al., 1993), with the viral genome complexed with TP, VII and mu 
being localised to the nuclear matrix. Nuclear localisation signals (NLS) could mediate 
transport of disassembled complexes in other viral systems. For instance, the structural 
Vp2/3 proteins of SV40 (Clever and Kasamatsu, 1991) and the nucleoprotein component of 
the viral RNA-protein complex of influenza virus contain nuclear localisation sequences 
which mediate events after release from endosomes (Davey et al., 1985). The gag matrix
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also contains an NLS which may be involved in the active transport of the pre-integration 
complex following infection (Bukrinsky et al., 1993).
ii) Early events in gene expression:
The first transcription units to be activated shortly after infection are classed as the immediate 
early (E1A), delayed early (E1B,E2A,E2B,E3 and E4), and intermediate genes (IVa2 and 
IX), with maximum levels of transcription from the late genes (LI to L5) occurring at 18 
hours post infection onwards (Lucas and Ginsberg, 1971). Figure 1.3 shows the 
transcriptional organisation of the Ad2 genome, which has been divided into 100 map units to 
readily identify individual genes (Akusjarvi et al., 1986).
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Figure 1.3: Schematic map of genes and transcription units encoded by the Ad2/5 
genomes. The linear dsDNA is depicted in the centre of the figure with r and 1 referring to rightward and 
leftward transcription. Thick lines indicate early mRNA's and thin lines indicate mRNA's expressed at 
intermediate times of infection. Open arrows show mRNA's expressed late after infection. Gaps in arrows 
denote the positions of introns. Arrowheads show the positions of 3'ends of the mRNA's and the promoter 
sites are indicated by brackets (reproduced from Akusjarvi et al., 1986).
The immediate early genes (EIA) are switched on within one hour post infection, encoding 
proteins involved in cellular transformation and trans-activation of viral and cellular 
transcription units (Flint and Shenk, 1989). Although five mRNA transcripts are generated
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through alternative splicing from the El A region, only two major mRNA's, which encode the 
ElA13s and ElA12s proteins (289 and 243 amino acid residues respectively) are generated 
early in infection (Moran and Mathews, 1987). The proteins share N-terminal sequences, and 
differ only in a 46 residue internal exon segment unique to the El Al 3s protein. This region 
(CR3) appears to stimulate transcription from several adenovirus promoters, including those 
requiring RNA polymerase II and IK (Green et al., 1988). ElA13s protein switches on the 
transcription of all viral early genes (E1B, E2A, E2B, E3 and E4) and also activates the major 
late promoter (MLP), probably functioning through various cis-acting elements such as the 
TATA-binding protein (which is shared by RNA polymerase II and III transcription 
systems), E2F (see below), ATF, AP-1, and the YY1 transcription factor (Lewis et al., 
1994). Such trans-activation is widespread among viral systems, for instance, the Herpes a- 
trans-activation factor (Michael et al., 1988), and the pseudorabies immediate early protein 
do not bind DNA directly, whereas the SV40 large T-antigen, and the papilloma E2 protein 
do (Philipson, 1995).
In adenovirus transformed cells, constitutively expressed Ela 12s protein can interact with 
unphosphorylated pRb, a cellular transcriptional regulation protein, and other pRb-like 
proteins (Whyte et al., 1988; Zamanian and La Thangue, 1992). Since phosphorylation of 
pRb is required for the normal cellular growth cycle, the elimination of pRb in a complex 
with ElA12s protein can lead to constitutive growth potential. Unphosphorylated pRb also 
binds to E2F, a transcriptional factor required for several genes involved in growth control, 
thereby inhibiting cell cycle progression (Helin et al., 1993). This association is disrupted by 
the E1A protein, liberating E2F from pRb thereby promoting expression of E2F dependent 
genes, leading to unrestricted growth.
These interactions would result in apoptosis in infected cells, however, the El A and E1B 
products work in synchrony to sustain productive infection in human cells, or in 
transforming of rodent cells. El A proteins initiate cellular proliferation which causes p53 (a 
tumour suppresser protein) accumulation and apoptosis (White et al., 1995). The E1B 55kd 
protein appears to protect against apoptosis by binding to, and inactivating p53, probably by 
suppressing p53-mediated trans-activation of death genes such as bax (Teodoro etal., 1995; 
White et al., 1995). The cellular mechanism of p53 control is through bcl-2 protein, which 
has an adenovirus homolog, the E1B 19kd protein. It is thought that the E1B 19kd protein
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may act similarly to bcl-2 by binding to the same antagonist, bax, to prevent induction of 
apoptosis.
In addition to its role in transformation, the E1B 55kd protein is important in exerting post­
transcriptional control, late in infection, of differentially spliced mRNA's derived from the 
IX, IVa2 and major late promoters (Pilder et al., 1986; Ornelles and Shenk, 1991; Leppard, 
1993). The stability and accumulation of viral mRNA's in the cytoplasm has been attributed 
to the E1B 55kd protein, complexed with the E4 34kd protein, located at specific nuclear 
inclusions that are believed to be sites of DNA replication and transcription. A number of 
different proteins are encoded by the E4 region, corresponding to seven different translational 
open reading frames (ORF's). Mutation in either ORF3 (E4 1 lkd protein), or 0RF6 (E4 
34kd protein) results in productive infection, however, a double mutation results in defects 
for DNA replication, late viral mRNA cytoplasmic accumulation, viral protein synthesis, and 
a failure in shutoff of host protein synthesis (Smiley et. al., 1990 and 1994; Doucas et al.-, 
1996). Little is known about the biological activities of these proteins, although they do 
exhibit functions characteristic of RNA splicing factors (Nordqvist et al., 1994).
The E4 19kd hybrid protein (E4 ORF6/7) transcriptionally activates the E2A gene by binding 
to the cellular factor E2F and consequently increasing its affinity for the E2A promoter (Neill 
et al., 1990). The binding of E4 19kd to E2F is enhanced in the presence of El A12s protein, 
probably releasing the cellular factor from interactions with other proteins. Transcription from 
the E2A and E2B promoter generates mRNA encoding the 59kd DNA binding protein 
(DBP), and the E2B 80kd preterminal protein (pTP), and 140kd Ad-polymerase, all of which 
are required for DNA replication (reviewed by Van Der Vleit, 1995). The mRNA's are 
transcribed early in infection from a single promoter at genome co-ordinate 75, however, late 
in infection, DBP transcription is initiated from a promoter at map position 72, and is 
independent of ElA13s protein activity.
DBP is a multi functional protein which has been implicated in a number of viral functions, 
including multiple roles in viral DNA replication (section 1.1.3iii), and early (Ricigliano et 
al., 1994) and late (Silverman and Klessig, 1989) gene expression. For each of these 
processes DBP appears to have several roles, for instance, in early gene expression DBP has 
been reported to alter transcription from E2 and E4 promoters, and to destabilise El
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mRNA's. It appears that the diverse nature of the processes in which DBP functions are, in
part, due to interactions with as yet unidentified cellular proteins.
The E3 region of adenovirus, like that of E2, is served by a single promoter early in 
infection, which is trans-activated by ElA13s protein. However, the promoter is unique in 
that it contains recognition sequences for NFkB transcription factor, that can lead to 
independent transcription in lymphoid cells (Wold and Gooding, 1991), which may explain 
why adenoviruses can persist in lymphoid tissue. During the early stages of infection, the E3 
promoter drives expression of about nine alternatively spliced mRNA, that are polyadenylated 
at either the E3A or E3B sites (figure 1.4), generating proteins that are not required for virus 
replication, but which counteract the host cell defences (Wold and Gooding, 1991; Tollefson 
et al., 1996a). Five of the E3 proteins are integral membrane proteins, the most abundant of 
which (Gp 19kd) prevents lysis of infected cells by cytotoxic T-lymphocytes (CTL) through 
binding to the major histocompatibility class-1 antigen (MHC-1) heavy chain, and blocking 
its transport to the cell surface. After EIA proteins have increased the infected cells 
susceptibility to tumour necrosis factor (TNF), expression of the E3 14.7kd and 10.5kd 
proteins, and the E3 19kd protein confer resistance to cy to lysis. The E3 11.6kd protein is of
particular interest as it is not expressed until late stages of infection, and may be involved in 
promoting cell lysis and virion release (Tollefson etal., 1996a and b).
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Figure 1.4: E3 transcription unit of Ad2. The split arrows depict the spliced structures of the 
mRNA; exons are solid, and the thickness implies the relative abundance. E3A and E3B are polyadenylation 
sites. The 3'end of mRNA i may be at the E3A or E3B site (reproduced from Wold et al., 1995).
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Transcription of the intermediate IX and IVa2 genes occurs at 6 to 8 hours post infection. The 
mRNA generated from the IX transcript is unique as it is the only adenovirus mRNA 
transcript not to be differentially spliced (Alestrom et al., 1980). If RNA splicing is a 
prerequisite for the generation, transport, and cytoplasmic stability of Ad2 mRNA then the IX 
transcript must be subject to different rules. The IX protein is also unique as it is synthesised 
before the other structural proteins, and augmented late in infection (Boulanger et al., 1979; 
Alestrom et al., 1980). This may signify that protein IX has alternative functions in the 
replicative cycle.
The IVa2 protein has been shown to be a late stage specific transcriptional activator of the 
major late transcription unit (MLTU) promoter after the onset of DNA synthesis (Lutz and 
Kedinger, 1995; Lutz et al., 1996). The IVa2 protein is a component of two complexes, 
DEF-A and DEF-B, that bind to sequence elements (DE) located downstream of the MLP 
start site. DEF-B consists of a IVa2 homodimer, and DEF-A of a IVa2 monomer complexed 
with a 40kd polypeptide thought to be the cleavage product of the LI 52kd/55kd scaffold 
proteins (Gustin etal., 1996). An interaction between IVa2 and the LI 52kd/55kd proteins 
has been demonstrated, and possible cleavage of the LI 52kd/55kd proteins has been 
additionally proposed (Hasson etal.., 1992; Diouri etal.., 1996; Rancourt et al., 1996). The 
early appearance of the LI 52kd/55kd proteins is unique among the gene products transcribed 
from the MLP and is suggestive that the proteins may have functions in addition to those 
involved in assembly.
iii) DNA replication:
Replication of the adenovirus 36kbp genome begins with the formation of a preinitiation 
complex at the origins of replication located within the lOObp inverted terminal repeat 
regions. The preinitiation complex consists of 3 viral proteins encoded by the E2 transcription 
unit, namely, the precursor terminal protein (pTP), DNA polymerase (Pol), and the DNA 
binding protein (DBP). The first two are present in infected cells as a heterodimer (pTP-Pol), 
and together with DBP can sustain a low level of replication from the core region (Smart and 
Stillman, 1982; Van der Vleit, 1995). The terminal protein (TP) which is bound to the 
parental DNA via a phosphodiester bond can enhance initiation, possibly by conferring subtle 
changes on the conformation of the core structure.
DBP, which is known to destabilise the DNA helical structure (Hay et al., 1995), forms a 
multimeric protein-DNA complex which enhances the association of host protein nuclear 
factor 1 (NF1) with its own recognition site. In turn, NF1 interacts with Pol (Bosher et al., 
1992), thereby orientating pTP-Pol to the core region. The preinitiation complex is further 
stabilised by another host nuclear factor, NFIH/oct-1, which is capable of DNA bending, and 
may also bind to pTP-Pol.
The initial reactions of replication involve the distortion of the origin to permit the template 
strand to enter the Pol active site and coupling of dCMP to pTP. Once elongation has started, 
NF1 and NFIII/oct-1 dissociate (figure 1.5), and daughter molecules are synthesised as long 
as DBP and host protein NFII are present to remove topological stress. Initiation and 
elongation are ATP independent. The replication fork proceeds to the 3' inverted terminal 
repeat where the polymerase may dissociate having generated a daughter duplex and a 
ssDNA-DBP complex. In the second stage of DNA replication, displaced ssDNA-DBP 
complexes can be used for the same protein-primed initiation process if the template forms a 
panhandle structure. Alternatively, displaced strands with opposite polarity might renature to 
form a dsDNA daughter molecule.
Viral genome replication occurs in defined subnuclear structures (Hozak et al., 1993; Pombo 
et al., 1994; Besse and Puvion-Dutilleul, 1994) which develop from early replicative sites 
containing a mixture of ssDNA and dsDNA complexes, to distinct compartments which 
contain either ssDNA-DBP (viral ssDNA accumulation sites) or dsDNA complexes located to 
the fibrillogranular network. DNA replication occurs at the borders of the fibrillogranular 
network contiguous with the viral ssDNA accumulation sites. Besse and Puvion-Dutilleul 
(1994) suggest that replicating ssDNA genomes migrate to the nearest fibrillogranular site as 
soon as a portion of the genome becomes double stranded. Conversely, a non-replicating 
strand separated from dsDNA migrates to the viral ssDNA accumulation site. The mechanism 
by which viral DNA migrates is unknown, although there is evidence that pTP-DNA and TP- 
DNA can interact with nuclear matrix components at replication and transcription sites 
(Schaak etal., 1990; Fredman and Engler, 1993).
Within two hours of synthesis, viral genomes can be located in capsids (Besse and Puvion- 
Dutilleul, 1994). Fredman and Engler (1993) suggest that processing of pTP-DNA to TP- 
DNA by the viral 23kd protease is required to release TP-DNA for encapsidation. However,
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pTP-DNA is packaged within virus particles in Ad2tsl infected cells, which can replicate 
efficiently at the non-permissive temperature (Webster etal., 1994; Rancourt et al., 1995).
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Figure 1.5: General outline of the first round of Ad DNA replication. The parental TP 
containing template DNA (a) forms a mulli-prolein-DNA complex with DBP (b). A preiniliation complex (c) 
is assembled with the various replication proteins and initiation occurs by covalent coupling of a dCMP 
residue to pTP. In the presence of dNTP elongation starts by a displacement mechanism, requiring minimally 
pol and DBP. Replication can proceed from both sides of the molecule (d and e), and finally duplex daughter 
strands containing TP al one end and pTP at the other. Alternatively, if displaced strands of different polarity 
are formed (g), these can renature, to form a duplex with two TP molecules (h). In addition, if intiaslrand 
renaturation of the ITR occurs, this can lead to a panhandle structure (i). The regenerated double stranded origin 
can be used again for protein primed initiation, leading to a partially duplex intermediate (j) and finally a 
daughter molecule (f). reproduced from Van Der Vleit (1995).
Webster et al. provide evidence that TP, processed from pTP, cannot interact with Pol to 
form the heterodimer required for DNA replication initiation. It seems likely that pTP-Pol, 
pTP-DNA, and TP-DNA have distinct nuclear matrix binding properties which have a direct 
bearing on viral replication and transcription site localisation during the course of infection. 
Recent evidence (Angeletti and Engler, 1996) suggests that pTP attachment to the nuclear 
matrix can be regulated by one or more tyrosine kinase mediated phosphorylation events. The 
implications are that such events may facilitate pTP-DNA encapsidation and have a functional 
role in pTP-DNA localisation at DNA replication sites. Similarly, phosphorylation and
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dephosphorylation events ascribed to DBP during DNA replication (Russell et al., 1989) may 
facilitate ssDNA-DBP complex localisation to viral ssDNA accumulation sites.
iv) Late gene transcription and translation:
After the onset of DNA synthesis, most late proteins are translated from mRNA's originating 
from the major late transcription unit (MLTU) which extends from the major late promoter 
(MLP) at map co-ordinate 16.8 (figure 1.6a) to a termination signal close to the right end of 
the genome. Although during the early phase of infection the MLP is active at a level 
comparable to other transcription units, transcription is subject to control at the level of 
transcriptional termination and does not extend beyond map co-ordinate 75. At late times post 
infection, the transcription termination block is alleviated (Larsson et a.l., 1992) and the 
primary transcript generated can be processed into a minimum of 20 mRNA's that are 
grouped into five families (LI to L5) according to their different polyadenylation sites (poly 
(A) sites).
An important event governing the transition from early to late gene expression is viral DNA 
replication. The intermediate gene product, protein IVa2, gains efficient access to viral 
templates during replication and contributes to the late phase dependant MLP activation. In 
this respect, IVa2 is a temporal regulator, promoting late MLP activity and the generation of 
late (LI to L5) mRNA transcripts (Tribouley et al., 1994; Lutz and Kedinger, 1995). 
Accumulation of late mRNA's is also regulated at the level of poly (A) site selection. Prior to 
the onset of DNA synthesis, only LI mRNA's encoding the 52kd and 55kd phosphoproteins 
accumulate in the cytoplasm. LI pre-mRNA poly (A) sites have additional m-acting elements 
that are required for recruiting cellular 3’ end processing factors utilised for addition of the 
200 residue poly (A) tail (Dezazzo et al., 1991; Imperiale et al., 1995). Late in infection, the 
situation is reversed and the L2 and L3 poly (A) sites are used 2-3x more frequently than the 
LI poly(A) site because of a higher affinity for 3' processing factors. Additionally, Larsson 
et al. (1992) have shown that by blocking translation late in infection, only LI and L4 
mRNA's accumulate in the cytoplasm, implying that the use of the L2, L3, and L5 poly (A) 
sites require one or more late viral factors.
A further layer of regulation of gene expression is the temporal control of alternative splicing 
of mRNA transcripts. Most viral mRNA's are matured by removal of one to three introns, the
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extreme examples being mRNA for protein IX, which contains no introns, and mRNA 
encoding the fibre protein, which contains auxiliary x, y and z leaders and requires the 
removal of six introns (Alestrom et al., 1980). Most often the introns are positioned in the 5' 
or 3' non-coding portion of the pre-mRNA. For instance, expression of the LI mRNA 
family represents an example of alternative splicing in which the last intron is spliced using a 
common 5' splice site and two alternative 3' splice sites, generating mRNA's for the 
52kd/55kd (proximal 3' splice site) and Ilia (distal 3' splice site) proteins. The Ilia distal 3' 
splice site is relatively weak and does not bind cellular splicing factors as effectively as the 
proximal site. Efficient Ilia splicing requires late viral protein synthesis, possibly virus 
encoded splicing factors, or virus induced/modified cellular splicing factors (Imperiale et al., 
1995).
Regulation of the E3 splicing system is perhaps the best studied (Scaria and Wold, 1994; 
reviewed by Wold et al., 1995). The E3 region is embedded within the MLTU which allows 
for both transcriptional and post-transcriptional control of E3 mRNA. Approximately nine 
alternatively spliced mRNA are polyadenylated at one of two sites generating two families of 
mRNA’s. Transcription occurs from the E3 promoter early in infection, but is reduced at late 
stages, with E3 mRNA arising from MLP activity. These new mRNA contain the tripartite
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Figure 1.6: Organisation of the Ad2 genome. (A) schematic representation of the MLTU which 
encodes 5 families of mRNA's (Ll to L5). All mRNA's from this unit receive a common set of 5' leaders 
through splicing the tripartite leader region. (B) spliced structures of the major mRNA's expressed from the Ll 
region and their relative expression during infection (reproduced from Nordqvist et al., 1994).
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leader sequence and are as abundant as the L4 family of mRNA, thus, the E3 11.6kd protein 
is a major late protein being detected approximately 24 hours post infection.
All the late mRNA's from the MLTU have a common 201-nucleotide tripartite leader 
sequence at their 5' end, which is important for cytoplasmic stability and for selective 
transport late in infection (figure 1.6b). A variant form of this leader contains a 440- 
nucleotide i-leader exon, the splicing of which is temporally regulated during infection by the 
E4 ORF3 and E4 ORF6 proteins (Nordqvist et al., 1994; Ohman et al., 1993). E4 ORF3 
facilitated splicing of major late mRNA at early times of infection usually leads to the 
inclusion of the i-leader exon (l,2,i,3), however, the majority of mRNA's expressed late in 
infection contain the common tripartite leader (1,2,3), which is dependant on the exon 
skipping functions of E4 ORF6. Interestingly, the functions of E4 ORF3 and ORF6 are 
dependant on late viral protein synthesis, which if defective, results in late mRNA's retaining 
the i-leader exon. In addition, The E4 ORF4 inhibition of El A trans-activation of early gene 
expression, may autoregulate E4 ORF3 and ORF6 splicing events (Bondesson et al., 1996). 
Viral protein synthesis dominates synthetic activity during the late stages of infection, and 
cellular protein synthesis ceases. The events involved have been attributed to a variety of 
processes, for instance, the accumulation of viral mRNA in the cytoplasm is facilitated by the 
combined functions of the E1B 55kd and E4 ORF6 proteins which do not assist the transport 
of cellular mRNA's (Babiss et al., 1985; Pilder et al., 1986; Ornelles and Shenk, 1991), 
although recent evidence indicates that some translocation of small cellular mRNA's via 
nuclear pore complexes can occur (Smiley et al., 1994). Furthermore, the expression of the 
160 nucleotide viral associated mRNA's (VA RNA I and II) blocks the anti-viral activities 
induced by interferon (Zhang and Schneider, 1993). Interferon activates a double stranded 
RNA dependant kinase (DAI), which inactivates the essential translation factor elf2-a 
(O'Malley et al., 1988). This has the effect of blocking the initiation of protein synthesis 
during viral infection. The VA RNA's are able to prevent this process by binding to the 
kinase, blocking its activation by interferon, and so allowing the initiation of protein 
synthesis to proceed. The dephosphorylation of CAP binding protein (elf-4f), another 
essential translation factor, has been shown to correlate with shutoff of host cell protein 
synthesis (Yang et al., 1996). Synthesis of viral proteins continues because the common 
tripartite leader sequence of all viral mRNA's can promote ribosome binding late in infection.
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The virus-encoded L4 lOOkd protein is also required for efficient late viral protein synthesis 
(Riley and Flint, 1993). The protein appears to enhance late translation by binding with 
mRNA, possibly via the tripartite leader sequence, and may be involved in the selective 
export of late mRNA's to the cytoplasm.
v) Virion assembly and maturation:
Late in the infectious cycle, structural proteins are preferentially translated and rapidly 
transported to the nucleus, with a lag period of 3 to 6 minutes after release from the 
polyribosomes (D’Halluin, 1995). The uptake of proteins by the nucleus is extremely 
selective, often requiring nuclear localisation signals (reviewed by Garcia-Bustos etal., 
1991). Several adenovirus proteins, namely, fibre (Shing Hong and Engler, 1991), ElA13s 
(Lyons et al., 1987), DBP (Morin et al., 1989), pTP (Zhao and Padmanabhan, 1988) and V 
(Russell and Kemp, 1995), contain arginine and lysine rich sequences that constitute these 
signals. The nuclear transport of viral proteins lacking NLS sequences may be facilitated by 
an association with proteins that do, as is the case with Ad-Pol which is chaperoned with 
pTP.
The first step in adenovirus assembly is the formation of hexon capsomers, which requires 
the L3 encoded protein II (hexon) and the L4 lOOkd protein. The L4 lOOkd protein binds to 
hexon in stoichiometric amounts while the latter is still attached to polyribosomes. The L4 
lOOkd protein facilitates trimerisation of hexon monomers shortly after translation, then 
dissociates from the complex. Although the L4 lOOkd protein may be involved in 
transporting the hexon to the nucleus (Cepko and Sharp, 1983), there is evidence that the L3 
encoded protein, pVI, is required for this function (Morin and Boulanger, 1984). On 
reaching the nucleus, hexon capsomers appear to be able to self assemble to form groups of 
nine (GON) hexon molecules which assemble to form the 20 sides of the virion molecule, 
while penton capsomers will assemble to form the 12 vertices. There is evidence that hexon 
capsomeres can assemble to form virus-like particles, and that formation of penton base may 
be a rate limiting step in the assembly process (Boudin et al., 1979). In contrast to hexon, the 
L2 encoded penton, and L5 encoded fibre proteins oligomerise in the absence of other viral 
proteins (Karayan etal., 1994).
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After the construction of hexon shells, the assembly of virus particles proceeds through an 
ordered series of events (figure 1.7) which have been studied thoroughly using viral 
temperature sensitive mutants (blocked at different stages of assembly at the restrictive 
temperature), and by pulse-chase kinetic studies (Edvardsson et al., 1976; D'Halluin et 
al.,V¥]% and reviewed by D'Halluin, 1995). Initially, the first recognisable viral assembly 
intermediate is a light intermediate particle (buoyant density of 1.315g/cc in a CsCl 
equilibrium gradient), that contains the capsid structural components pVI, pVIII, pllla, and 
possibly IX, which confer stability to the virion structure. Although thermolabile mutants of 
pVIII (H5sub304; Liu etal., 1985), and protein IX (H5dl313; Colby and Shenk, 1981), 
have been identified, it is as yet unclear if both have any additional functional roles during the 
assembly process. Also associated with light intermediate particles are the 50kd and 39kd 
probable scaffold proteins and the L4 lOOkd protein. The light intermediate particles mature 
into heavy intermediate particles (buoyant density of 1.37g/cc) with the insertion of viral 
DNA and the removal of the 50kd and 39kd proteins.
The left end of the viral genome including the El A region has been shown to be inserted into 
the virion first, with nucleotide sequences at 200 to 400bp appealing to be essential for the 
encapsidation of the genome (Hammerskjold and Winberg, 1980). The factors involved in 
binding to the ds-acting elements have not been identified, although the IVa2 protein, which 
is present in light intermediate particles (Edvardsson et al., 1976; D'Halluin et al., 1978) 
possibly in association with the Ll 52kd/55kd proteins have been implicated (Gustin et al., 
1996), as they are both known to bind DNA. The possible role of the Ll 52kd/55kd proteins 
in packaging was suggested by the analysis of a temperature sensitive mutant (ts369), which 
accumulates incomplete particles at the restrictive temperature that cany only small segments 
of the left end of the genome (Hasson et al., 1989 and 1992). Similarly, possible roles for 
DBP and pllla in DNA packaging have been suggested by the analysis of mutants, tsl9 
(Roovers et al., 1990), and H2tsll2 (D'Halluin et al., 1982), both of which accumulate light 
intermediate particles at the restrictive temperature.
The viral DNA is condensed into a core structure by the viral proteins V, pVII and possibly 
pmu (Vayda and Flint, 1987). It is unclear whether the core proteins are encapsidated with 
the viral genome, as they are not detected in either light or heavy intermediate particles 
(D'Halluin 1995; Schmid and Hearing, 1995).
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Figure 1.7: Assembly pathway for Ad2/5. The different stages of virus assembly have been indicated 
at the top and the polypeptides only present in some structures are indicated below. Defective mutants in the 
assembly pathway are indicated at the top of the arrow at the right side. CX; cyclohexamide (reproduced from 
D'Halluin, 1995).
After DNA packaging, young virions are matured into infectious particles by the cleavage of 
structural proteins pVI, pVIII, pEHa, and the core proteins pVII, pTP, and pmu (Trembley et 
al., 1983; reviewed by Weber, 1995). There is evidence that the LI 52kd/55kd scaffold 
proteins are also cleaved during virus assembly, as probable cleavage products have been 
identified in mature virions (Hasson et al., 1992). None of these cleavages takes place in cells 
infected with the Ad2tsl temperature sensitive mutant at the non-permissive temperature. The 
mutation has been mapped to the L3 region encoding the viral 23kd protease, with a proline 
substituted for lysine at residue position 137 (Yeh-Kai et al., 1983). Viral 23kd protease 
activity has been detected in nuclei of infected cells, and inside mature virions, but not in 
Ad2tsl young virions accumulated at the non-permissive temperature (Bhatti and Weber, 
1979). The temperature sensitive protease is synthesised and transported to the nucleus to 
become associated with incomplete particles in a manner similar to the wild type protease 
(Anderson, 1990; Rancourt et al., 1995). The defect apparently resides in a failure of the 
enzyme to be activated and encapsidated. The failure to dephosphorylate protein V is another 
interesting consequence of Ad2tsl infection (Weber and Khitoo, 1983), the significance of 
which is still unclear.
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1.1.4 Progressive reorganisation of host cell structure.
The eytoskeletal and nuclear morphological changes associated with adenovirus infections of 
cultured cells are a result of complex interactions between host and viral components which 
allows for efficient production of virus particles. The cyLopathic effects that are observable by 
light microscopy, culminate in cell death and release of progeny virions. In recent years, 
information provided by electron microscopy techniques such as immunocytochemistry, 
autoradiography,m.y/ta-hybridisation and selective staining have been complementary in 
determining the structure-function relationships of cellular domains at the ultrastructural level, 
and are reviewed in this section.
i) Nuclear organisation of replication and transcription:
The nucleus is organised into a series of structural domains which includes the nucleolus, 
chromatin (in various degrees of condensation), and interchromatin regions which contain 
several characteristic structures, including perichromatin fibrils and granules, and other 
nuclear bodies including coiled bodies (Brasch and Ochs, 1992; Puvion-Dutilleul et cd., 
1995a; Hassan, 1995). In uninfected cells, active DNA synthesis occurs at ovoid bodies 
adjacent to chromatin (Hozak et al., 1993; Hassan, 1995). However, nuclei of infected cells 
progressively accumulate new induced structures as a consequence of viral replication 
(Puvion-Dutilleul and Puvion, 1995; Puvion-Dutilleul etal., 1995b; Besse and Puvion- 
Dutilleul, 1994; Pombo and Carmo-Fonseca, 1995). The earliest ultrastructural changes, 
detected at 6 to 8 h.p.i, are small irregularly shaped masses of thin fibrils that rapidly increase 
in size and become pleomorphic, appearing as crescents, rings, and spheres by 16 to 20 h.p.i 
(figure 1.8). These structures contain DBP, and are contiguous for DNA synthesis at the 
early stage. However, late in infection, at the pleomorphic stage, these structures contain the 
majority of viral ssDNA-DBP and continuous replication is displaced from these sites to the 
surrounding fibrillogranular network (peripheral replicative zone), which contains viral 
dsDNA (figure 1.9). Still later, the ssDNA-DBP accumulation sites become smaller and more 
homogenous in shape appearing as globular inclusions rather than crescents and rings (Chaly 
and Chen, 1993). These centres are eventually located at the outer edge of the viral genome 
storage site which is detected in cells after 18 to 20 h.p.i. The genome storage site is 
frequently associated with crystalline arrays of virus, and it has been suggested that DNA
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from this compartment may be incorporated into virions (Puvion-Dutilleul and Puvion, 
1990).
6-10 h infection
16-20 h infection
Figure 1.8: Intranuclear organisation of Ad2/5 replication. Shortly after die onset of viral 
replication, Ad DNA synthesis occurs at focal centres that are scattered in the nucleoplasm and excluded from 
llie nucleolus. Later, at 16-20 h.p.i, ssDNA and DBP accumulate next to llie replication sites, giving rise to 
goblet-shaped structures (reproduced from Pombo and Canno-Fonseca, 1995).
Infected cells subjected to a pulse of ^H-uridine (Puvion-Dutilleul et al., 1992) have been 
examined by electron microscopy to locate viral transcription sites. At early stages of 
infection, transcription is present at the early replicative sites, and at intermediate stages, is 
detected at peripheral replicative zones. From 17 h.p.i onwards, labelled RNA is present in 
peripheral replicative zones, interchromatin granules, virus induced compact ring structures, 
and ribosome containing areas of the cytoplasm. Pombo et al. (1994) suggest that replication 
and transcription occur together in the early replicative sites, and peripheral replicative zones, 
and that interchromatin granules and compact rings may be involved in post-transcriptional 
processing and intranuclear trafficking of viral RNA as it moves through the nucleus into the 
cytoplasmic compartment.
ii) Post-transcriptional processing and assembly centres:
In non-infected cells, splicing factors have been shown to accumulate in several distinct 
nuclear structures, including interchromatin granules, perichromatin fibrils, coiled bodies 
(Bridge et al., 1993; Bridge and Pettersson, 1995; Rebelo et al., 1996) and interchromatin 
granule-associated zones (Puvion-Dutilleul et al., 1994 and 1995a). Although the
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concentrations of splicing components in discrete nuclear compartments raises the possibility 
that they are involved in splicing, Bridge etal. (1995) suggest that some compartments may 
be important in aspects of spliceosome assembly, including recycling and storage of splicing 
factors. For instance, the clusters of interchromatin granules and their associated zones, as 
well as coiled bodies, may be involved in pre- and/or post-splicing events such as 
spliceosome assembly and/or sorting of spliced molecules and intron degradation (Ferreira et 
al., 1994; Puvion-Dutilleul etal., 1995a).
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Figure 1.9: Schematic drawing summarising the three distinct phases of ultrastructural 
modifications observed in Ad5 infected cell nuclei. At the earliest stage of nuclear transformation, 
replicative foci consist of small areas of densely packed fibrils. In the intermediate stage, the replicative foci 
are enlarged and give rise to multiple copies of two contiguous structures, the pleomorphic ssDNA 
accumulation sites and the surrounding peripheral replicative zone. In the late stage of nuclear transformation, 
the two compartments of the replicative foci decrease in size, whereas the new centrally located viral genome 
storage site appears. At this stage, clusters of interchromatin granules, which are also present in uninfected 
nuclei, are enlarged, and virus induced compact rings of unknown significance are numerous. Both structures 
are located at the periphery of the large viral inclusion body (reproduced from Puvion-Dutilleul et al., 1992).
Following adenovirus infection, the initial distribution of splicing components remains 
unchanged (Besse and Puvion-Dutilleul, 1995; Bridge etal., 1993 and 1995), however, after 
the onset of DNA synthesis small nuclear ribonuclear particles (snRNP's) are associated with 
the early replicative sites (figure 1.10) that contain DNA, RNA and ssDNA-DBP. As 
infection progresses and the ssDNA-DBP accumulation sites become pleomorphic, snRNP 
distribution appears to be confined to the peripheral replicative zones and interchromatin
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granules. Therefore, at late stages of nuclear changes, splicing components are no longer in 
the centre of the nucleus, which is occupied by the viral genome storage site (figure 1.10), 
but are localised at the border of this large inclusion body, where they form a spherical shell 
consisting of enlarged clusters of interchromatin granules and fibrillogranular networks. The 
compact ring structures, which do not contain snRNP's, are also embedded in this shell at the 
nuclear periphery.
Non-poly<A) 
viral RNA
Figure 1.10: Schematic model of a quarter nucleus at the late stage of nuclear 
transformation. The large viral genome storage site, which is not involved in the transcription and RNA 
processing steps, is surrounded by a shell consisting of four structures, three of which contain viral RNA. 
Both the peripheral replicative zone, which is also a transcription site for viral genomes, and the clusters of 
interchromatin granules, in which viral RNA is present, contain spliceosome components and poly(A)+ RNA. 
The virus induced compact rings contain non-polyadenylated viral RNA, which could correspond to unused 
portions of the viral transcripts. The viral ssDNA accumulation sites, which are devoid of RNA, are not 
involved in the synthesis and processing of viral transcripts.
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Through the specific detection of viral RNA transcripts and poly(A) RNA molecules (viral 
and cellular), Puvion-Dutilleul et al. (1994) have proposed that the peripheral replicative zone
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is the precise site of viral genome transcription and the main site of viral RNA splicing. 
Additionally, the interchromatin granules participate in post-splicing events, and may 
contribute to the regulation of the amount of individual mRNA in the cytoplasm at defined 
periods of time. The virus induced compact ring structures containing viral RNA (but not 
poly(A) RNA) are probably not involved in splicing events, but contain non-used portions of 
primary late transcripts resulting from differential poly(A) site selection at the post­
transcriptional level.
These authors also observed the disappearance of coiled bodies and interchromatin granule- 
associated zones at intermediate stages of nuclear transformation. These sites are likely to be 
concerned with spliceosome maturation and/or storage/recycling of snRNP's, but additionally 
are highly enriched in p80-coilin, an 8Okd phosphoprotein of unknown function (Puvion- 
Dutilleul et al., 1995a; Rebelo et al., 1996). The finding that coiled bodies are very labile 
structures that require ongoing protein synthesis is suggestive that adenovirus induced 
inhibition of cellular protein synthesis may, in part, cause the disassembly of these sites, and 
consequently affect splicing events late in infection.
Coiled bodies are known to be associated with other structural domains, the most prominent 
being the nucleolus which is actively involved in the biogenesis of pre-ribosome’s and the 
transport of poly(A) RNA from the nucleus to the cytoplasm (Carmo-Fonseca et al., 1993; 
Bridge and Pettersson, 1995; Schneiter et al., 1995). The inhibition of cellular protein 
synthesis by adenovirus infection has been shown to result in the inhibition of ribosomal 
RNA production and cause the redistribution of nucleolar antigens (Castiglia and Flint, 1983; 
Bridge et al., 1995). Additionally, fibrillarin, a structural component of coiled bodies and 
nucleoli, has also been shown to be redistributed to the proximity of ssDNA-DBP 
accumulation sites and latterly to the peripheral replicative zones late in infection (Puvion- 
Dutilleul and Christensen, 1993). Studies utilising deletion mutants of p80-coilin (Bohmann 
et al., 1995) have demonstrated that these effects may be specifically related to p80-coilin 
which appears to have a role in maintaining nucleolar structure and function. Recent studies 
(Schul et al., 1996) have also shown coiled bodies to be intimately associated with cleavage 
bodies and PML (promyelocytic leukaemia) bodies within uninfected cells (figure 1.11). 
These authors suggest that 3' cleavage factors, required for 3' processing and 
polyadenylation of pre-mRNA, undergo transcriptional dependent recycling in cleavage
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bodies, and that components required for splicing factor recycling may be involved in this 
process. Their findings have also led them to propose that cleavage bodies are closely 
associated with sites of RNA synthesis, and although coiled bodies and PML bodies are 
outside these sites, they may be involved in processing of specific RNA's.
The PML protein was first identified as part of a fusion protein with retinoic acid receptor-a 
(RARa), which results from a chromosomal translocation associated with acute 
promyelocytic leukaemia (APL). The PML protein contains a cysteine-rich motif, known as 
the RING finger, that is commonly found in a family of proteins involved in RNA 
transcriptional control and processing (Koken et al., 1994; Borden et al., 1995; Puvion- 
Dutilleul et al., 1995b). The latter authors have shown PML to concentrate in PML bodies 
and interchromatin granule-associated zones in uninfected cells, however during adenovirus 
infection, the protein is located in virus-induced clear amorphous inclusions (figure 1.12). 
These structures are initially small, and irregularly shaped, but as infection progresses they 
become larger, more spherical, and abundant, usually surrounded by virus particles.
Figure 1.11: Schematic representation of the proposed organisation of a trio of cleavage 
body, coiled body and PML body on an active gene. The cleavage body is in contact with the 
entire gene or just with the downstream part containing the cleavage site. The other two bodies do not contain 
DNA or newly transcribed RNA, yet are associated with the specific locus (reproduced from Schul et al., 
1996).
In addition to its presence in inclusions, PML is also detected within virus-induced protein 
crystals that are known to contain at least one viral structural protein, namely, the hexon. The 
origin of clear amorphous inclusions and protein crystals is unclear, although recent studies
have indicated that the E1B 55kd and E4 ORF3/ORF6 proteins are responsible for the 
redistribution of PML protein and PML body components during the course of infection 
(Carvalho etal., 1995; Doucas etal., 1996). Doucas etal. (1996) have shown the E1B 55kd 
protein to localise transiently with PML bodies early in infection (5 to 8 h.p.i) and complex 
with the E4 ORF6 protein. The E4 ORF3/ORF6 proteins appear to induce the morphological 
changes that culminate in the formation of the PML containing fibrillar tract, although 
evidence suggests that the E4 ORF3 protein, by itself, is able to promote this reorganisation, 
and remains localised to the tracts throughout the later stages of infection. The E1B 55kd/E4 
ORF6 protein complexes have a more diffuse nucleoplasmic distribution, which probably 
correlates to viral replicative zones (Ornelles and Shenk, 1991). Doucas et al. have proposed 
that the morphological changes associated with the E4 ORF3/ORF6 proteins may facilitate the 
movement of regulated host factors from PML bodies to viral replication and transcription 
sites. The sequestration of PML protein into virus-induced clear amorphous inclusions 
(fibrillar' tracts) may be required for its inactivation, as recent evidence demonstrates a direct 
involvement of PML in interferon anti-viral effects (Puvion-Dutilleul et al., 1995b; 
Grotzinger etal., 1996).
Nuclear reorganisation is considered to have reached the late phase when crystalline arrays of
I
virus particles are distributed in the electron-translucent regions of the nucleoplasm (Chaly 
and Chen, 1993; Lutz et al., 1996). Associated with virion containing centres are the viral 
genome storage sites, clear amorphous inclusions, and protein crystals (figure 1.12). The LI 
52kd/55kd proteins have been shown to be associated with virion particles in assembly 
centres and to two other domains, termed, loading centres, and densely stained structures 
(Hasson et al., 1992). These domains may correlate to the electron-dense amorphous 
inclusions described by Lutz et al., which have been shown to contain protein IVa2 (figure 
1.12). These electron-dense structures have the appearance of altered nucleoli (Zhongue et 
al., 1986) and are anchored to the nuclear lamina by matrix filaments. Using embedment free 
electron microscopy, these authors have shown that by 28 h.p.i the filaments connecting 
amorphous and granular vims centres are decorated with capsids and mature virions, which 
suggests that they may be involved in transport of capsid intermediates, and mature virions. 
The granulated regions contain capsids and may be the sites of capsid assembly and storage, 
whilst the electron-dense amorphous inclusions may be the sites of DNA packaging into
30
immature virions. After 48 h.p.i, lysed nuclei still contain remnants of the nuclear-virus 
related structures, and many virions arc still attached to the nuclear matrix filaments. In 
addition, virions are also attached to intermediate filaments of the host cell cytoplasm.
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Figure 1.12: Ad-induced alterations of cell nuclei during infection. The main structural
alterations appealing during infection are schematically represented and named. Protein IVa2 was shown to
localise to structures indicated with stars (reproduced from Lutz el al., 1996).
iii) Disruption of intermediate filaments:
The cytoskeleton is composed of microtubules, microfilaments, and intermediate filaments 
which form an interconnected network of fibrils that altogether, impart structural integrity to 
the cell. The intermediate filament (IF) family of proteins includes vimentin, and the 
eytokeratins (reviewed by Goldman etal., 1986). In addition, the nuclear lamins, the main 
components of the peripheral nuclear lamina (Georgatos et al., 1994), are also members of 
the IF family, and have a regulatory role in determining the morphology of the nuclear 
envelope.
Disruption of the vimentin system occurs within 30 minutes of virus uptake (Belin and 
Boulanger, 1987), and depends on the adenovirus induced activation of a cellular protease,
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the activity of which is required for efficient transcytoplasmic migration of virion components 
to the nuclear envelope. Later in infection, from 14 h.p.i onwards, adenovirus induces a 
distinct sequence of eytoskeletal rearrangements that occur continuously during the course of 
infection (Staufenbiel et al., 1986). For instance, the extended vimentin system has been 
shown to collapse into the perinuclear region of infected cells. A similar’ pattern of disruption 
is also observed in E1B 19kd transfected cells (White and Cipriani, 1989). Of interest is the 
disassembly of cytokeratin 18 (K18) late in infection (20 h.p.i onwards), to form spheroid 
globules and cytoplasmic clumps (Chen etal., 1993). This alteration is due, at least in part, to 
the activity of the L3 23kd protease which cleaves the cytokeratin 18 protein, removing its N- 
terminal head domain, and thereby blocking its ability to form fibres. The disruption of the IF 
system, and the nuclear matrix (Zhongue et al., 1986), might make the cell more susceptible 
to rupture, and facilitate the release of progeny virions. The inhibition of cellular protein 
synthesis prevents restoration of the eytoskeletal structure (Zhang and Schneider, 1994) and 
therefore may promote these events.
1.1.5 The L3 23kd protease:
Adenoviruses, like many viruses, encode an endoproteinase that is essential for virus 
maturation and infectivity. The enzyme is synthesised late in infection and is required for the 
proteolytic cleavage of at least six viral proteins, namely, pVI, pVII, pVIII, pllla, pTP, pmu, 
and possibly the LI 52kd scaffold protein (reviewed by Weber, 1995; Russell and Kemp, 
1995). Synthetic peptides have been used in vitro to determine the consensus cleavage site as 
being (M,L,I)XGG’X and (M,L,I)XGXG (Webster etal., 1989; Anderson, 1990). The 
GENBANK/EMBL nucleotide databanks have been screened for adenovirus protease 
substrate proteins (reviewed by Weber, 1995) and putative cleavage sites in homologous 
regions compiled (Table 1.2). None of these cleavages occur in cells infected with the Ad2tsl 
mutant, at the non-permissive temperature, resulting in the production of non-infectious virus 
particles devoid of protease activity (Weber, 1976; Rancourt et al., 1995).
Inhibitory profiles (Webster etal., 1989; Anderson, 1990; Tihanyi et al., 1993; McGrath et 
al., 1996) and mutagenesis studies (Grierson et al., 1994; Rancourt et al., 1994) have 
classified the enzyme as a cysteine protease that is active as a monomer and which does not 
require proteolytic activation. However, the Ad2 and Ad2tsl recombinant enzymes have little
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Virus Protein6 Cleavage site PI Peptide cleaved0
in vitro in vivo
H2C pVII (197) MFGG AKKR 24 Yes Yes
pVIII (227) IGGA GRSS 157 — Yes
pVIII (227) LAGG FRHR 111 Yes —
pVI (250) MSGG AFSW 33 Yes Yes
pVI (250) IVGL GVQS 239 Yes
11-kDa (79) MAGH GLTG 26 - —
LTGG MRRA 31 Yes
MRGG ILPL 50 - Yes
pTP (668) MRGF GVTR 172 Yes -
MGGR GRHL 180 Yes -
LGGG VPTQ 314 No —
MTGG VFQL 346 No
pllia (585) LGGS GNPF 570 — __
L1 52-kDa (415) LAGT GSGD 351 - -
H12 pVI (265)d LNGG AFNW 33 Yes
pVI (265)° IVGL GVKS 254 - Yes
11-kDa (72)d LTGN GRFR 27 - Yes
11-kDa (72)d MKGG VLPF 42 - Yes
pVII (188)d MYGG AKTR 23 Yes
pllia (582)d LGGS GNPF 565 Yes
pTP (606)’ LQGY GSTH 140 —
LRGG VFEL 289 - —
pVIII (233)d IRGK GIQL 138 - Yes
LGGS GRSS 163 Yes
L1 52-kDa (373)'’ LTGA GTED 328 - -
H40' pVI (267) LNGG AFSW 33
pVI (267, IVGL GVKS 256
pVIII (233, LAGG ARHV 111 —
pVII (185) MYGG AKRR 23 - —
pTP (643, LRGF GSTR 172 - —
pTP (643) LSGS GMQG 318 - —
pTP{643) MQGG VFEL 323 - —
L1 52-kDa (380) LTGT GTDA 336 - —
11-kDa (70) MAGS GRRR 27 - —
11-kDa (70) IKGG FLPA 40 —
Ilia (576) LGGT GAAS 556 - -
H41 pVIII (233)” LAGG SRHV 111
pVlh IVGL GVKS - - -
CAN1 pVII (132)' LFGG AKQK 23 - -
MAVI pVI’ IMGL GLQP - - -
Table 1.2: Adenovirus substrate proteins and putative cleavage sites.
activity compared with that in disrupted wild type virions (Webster et al, 1993; McGrath et 
al., 1996), and requires activation through the addition of an 11 residue peptide, 
GVQSLKRRRCF, that is the C-terminal cleavage product of pVI (Webster and Kemp, 1993; 
Mangel et al., 1993; Rancourt et al., 1995). The activating peptide (pVI-ct) is highly 
conserved among other serotypes (Weber, 1995) and a similar peptide derived from Ad 12 
pVI, GVKSLKRRRCY, has also been shown to activate the Ad2 enzyme (Friemuth and 
Anderson, 1993). Additionally, protease’s from a wide range of serotypes have been shown 
to cleave Ad2 precursor proteins when incubated with Ad2tsl virions (Houde and Weber, 
1990). Recently, Rancourt etal. (1995) determined that full infectivity is restored in Ad2tsl 
infected cells after the addition of activating peptide late in infection. The authors suggest that
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the protease defective phenotype is, at least in part, due to specific interactions involving pVI 
that are required for protease packaging Zz? vivo.
Webster et al. (1993) proposed that activation of the enzyme occurs via a disulphide bond 
interchange between the oxidised (dimeric) form of pVI-ct and a conserved cysteine residue 
of the viral protease. Mutagenesis studies (Grierson etal., 1994; Jones et al., 1996; Rancourt 
et al., 1996) have indicated that an interaction between the highly conserved Cysl04 residue 
of the 23kd protease (figure 1.13) and pVI-ct can occur, and have identified the active site 
triad to be composed of the highly conserved His54, Glu71, and Cysl22. Jones et al. (1996) 
have indicated that a conformational change induced by pVI-ct binding can enhance the 
availability of the Cys 122 nucleophile for catalysis.
Recently, confirmation of the proposed mechanism of activation has come from the atomic 
structure of the Ad2 23kd protease co-crystallised with pVI-ct (Ding et al., 1996). The active 
site triad appears to have a 3-dimensional arrangement similar to that of papain (figure 1.14), 
although the order of active site residues on the linear polypeptide differs between both 
enzymes. In addition, the activating peptide has been shown to interact with two non­
contiguous regions of the protease, with the N-terminal 3 residues of pVI-ct interacting with 
6-strand S7 and residues 4 to 10 interacting with S5 residues 104 to 109. The authors 
suggest that a peptide corresponding to residues 4 to 11 of pVI-ct could be an enzyme 
inhibitor, and therefore a potential anti-viral agent. Cabrita et al. (1997) have also indicated 
that the N- and C-terminal regions of pVI-ct are essential for productive interaction, indicating 
that the removal of the N-terminal glycine and valine residues does not affect peptide binding 
but does abolish activation.
Redox modulation has a profound effect on recombinant Ad2 and Ad2tsl enzyme activity, 
with several isoforms resulting from intra- and inter-chain disulphide bridge formation being 
detected (Keyvani-Amineh et al., 1996). Of interest is the observation that recombinant 
Ad2tsl, but not Ad2, enzyme activity is stimulated by low concentrations of oxidising agent. 
The Ad2tsl proline to leucine substitution (P137L) has been shown to induce a slight 
structural change in an externally disposed loop of the recombinant protease that may offset 
the geometry of cysteine residues involved in disulphide bond formation (Keyvani-Amineh et 
al., 1995). The addition of oxidising agent may overcome this defect and promote pVI-ct 
binding. Isoforms of 23kd protease have been isolated from infected cells late in infection,
C-term H7
C-term
His
H2
N-term
HlCys-122
Glu-71
Activating peptide
H5
Cys-104
Figure 1.14: Atomic structure of the Ad2 23kd protease co-crystalised with pVI-ct. The complex is 
ovoid with a-helices labelled Hl through to H7 and B-strands SI through to S7 from the N-terminus to C- 
terminus. pVI-ct is the nearest B-strand in the figure. The heterodimer is ovoid with three a-helices forming 
the blunt end. In the central region are three a-helices which interact with a single B-sheet. A seventh helix 
is at the pointed end. The cofactor becomes the sixth B-strand in the central B-sheet. forming a disulphide 
bond and several hydrogen bonds. Two small B-strands cross near the bottom of the central helix. Side 
chains are shown only for the active site residues Cys-122. His-54. and Glu-71. Reproduced from Ding et 
al. (1996),
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and from wild type virus particles (Keyvani-Amineh etal., 1996; Greber et al., 1996). Native 
enzyme isolated from cytoplasmic extracts of cells, and virus particles, have been shown to 
be oxidised, while nuclear isoforms, which are presumed to be active, are reduced. Greber et 
al. (1996) have proposed that when newly assembled viruses are released from the lysing 
cell, the viral protease encounters the oxidising extracellular environment and is inactivated by 
intra-chain disulphide bond formation. Conversely, when the virus enters the more reducing 
environment of the endosome, early in infection, the inactivating disulphide bond is reduced, 
and the protease is reactivated.
It is still unclear whether activation is an absolute requirement for enzyme activity when the 
substrate is a protein instead of a peptide. The purified enzyme alone has been shown to 
cleave actin, ovalbumin, and fibrin in vitro (Tihanyi et al., 1993). Additionally, Webster et al. 
(1993) have shown that co-infection of insect cells with recombinant baculovirus expressing 
pTP and 23kd protease results in processing of pTP to an intermediate, iTP, but not to mature 
TP. The authors speculated that other mechanisms of activation may occur, and additional 
evidence also supports this. Several reports have proposed that viral DNA may be involved in 
the catalytic mechanism (Mangel et al., 1993 and 1996), although Webster et al. (1994) have 
suggested that viral DNA may only serve to stabilise the protease in vitro, and possibly 
enhance the interaction of protease and substrates in vivo. Recently, the peptide VEGGS, has 
been shown to mimic the activity of pVI-ct by inducing a similar conformational change 
(Diouri et al., 1996). The sequence of the peptide resembles the conserved cleavage site 
(M,L,I)XGG'X, although the authors noted that the serine residue was not cleaved. 
Surprisingly, although no adenovirus proteins contain the VEGGS motif, like pVI-ct, 
VEGGS incorporation into Ad2tsl infected cells results in the recovery of infectious 
particles.
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1.2 General themes in virus assembly and maturation.
1.2.1 Herpesviruses.
i) Herpes simplex virus (HSV) assembly:
The herpesvirus family is composed of Herpes simplex (fever blister), Herpes zoster 
(Chickenpox and shingles), Cytomegalovirus (salivary gland virus) and Epstein-Barr virus 
which, like adenoviruses, are dsDNA (13Okbp) viruses that replicate in the cell nucleus. The 
DNA genome is contained inside an icosahedral capsid (125nm in diameter) that is separated 
from the virion envelope by an amorphous complex of virus-encoded proteins called the 
tegument (reviewed by Roizman and Sears, 1990) The envelope contains a number of 
glycoproteins which facilitate the attachment of virions to susceptible cells. After attachment, 
the viral envelope glycoprotein B induces its fusion with the cellular plasma membrane, 
permitting the nucleocapsid to enter directly into the cytoplasm. In the cytoplasm the capsid 
migrates to a nuclear pore, where the viral DNA is released into the nucleus and initiates viral 
multiplication. Like polyomavirus/SV40 and adenoviruses, there is a programme of early 
transcription which produces proteins required for the replication of the viral genome and 
subsequent late gene expression.
Assembly of virions also takes place in the nucleus and three types of capsid, designated A, 
B and C (in order of increasing sedimentation distance in sucrose gradients) can be isolated 
from HSV-1 infected cells (Gao etal., 1994; Robertson etal., 1996). Type C capsids contain 
the viral genome and are able to mature into infectious virions when associated with tegument 
proteins arranged at the inner nuclear membrane. Types A and B capsids lack DNA, although 
type A capsids are very similar to type C capsids in protein composition. Type B capsids 
differ in that they contain an additional polypeptide termed VP22a. In addition to VP22a, 
which is believed to be a scaffold protein that is removed after DNA encapsidation, B capsids 
are also composed of at least seven other proteins, namely, VP5, VP19c, VP21, VP23, 
VP24, VP26 and the recently reported UL26 gene product (Patel etal., 1995). The 162 
capsomers that make up the outer shell are composed of 150 hexons and 12 pentons which 
are predominantly composed of VP5 protein. The three other proteins that make up the outer 
shell are VP19c, VP23, which together form triplexes which connect capsomers in groups of
three (Zhou et al., 1994) and VP26, which is found at the distal tips of the hexons only 
(Booy etal., 1994).
The core of the B capsid is composed of three proteins, VP21, VP24 (products of the UL26 
gene) and VP22a (product of the UL26.5 gene). The UL26 transcript encodes the 635 
residue serine protease which undergoes autoproteolytic processing at two sites to generate 
VP21, VP24 and the 25 amino-acid C-terminal peptide (Preston et al., 1994; Matusick- 
Kumar et al., 1995; Thomsen et al., 1995). VP24 comprises the first 247 amino acids of the 
UL26 protein and is the region of the protein that contains proteolytic activity. The protease 
also cleaves the product of the UL26.5 gene (Which shares the same C-terminal cleavage site 
as the UL26 gene product) to generate VP22a and the 25 residue C-terminal peptide. 
Although capsid structures are observed in the absence of functional protease (Gao et al., 
1995) the major capsid protein VP5 does not adopt the correct conformation and viral DNA is 
not encapsidated. It has been proposed that the 25 residue C-terminal peptide is involved in 
the formation of sealed capsids and may directly interact with VP5 (Robertson et al., 1996).
ii) The human cytomegalovirus (hCMV) protease:
The hCMV UL80 gene encodes the full length 80kd protease and its substrate which, like the 
HSV-1 UL26 protein and BVRF2 protein of Epstein-Barr virus (Donaghy and Jupp, 1994), 
is autocatalytically cleaved at two internal sites generating a fully active 28kd serine protease. 
In addition, the 28kd CMV protease can proteolytically cleave itself at two internal sites 
located within its own catalytic domain (Baum et al., 1996a; Margosiak et al., 1996). The 
CMV 28kd protease is inhibited by serine-specific reagents and also by cysteine-specific 
compounds (Baum et al., 1996a and b) the latter of which induce the formation of specific 
intramolecular disulphides by a thiol-disulphide exchange reaction. It has been proposed that 
conserved cysteines have potential roles in the formation of homodimers which are believed 
to be the active form of the enzyme (Margosiak et al., 1996; Baum et al., 1996b). Recently 
the atomic structure of both the monomeric and dimeric forms of the protease have been 
determined (Tong et al., 1996; Qui et al., 1996; Shiek et al., 1996), and although the dimer 
interface is not in the immediate vicinity of the active site, dimerisation may have a profound 
effect on the conformation of the active site region.
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It has been suggested that during viral infection, the regulation of protease activity by intra­
molecular disulphide bond formation may maintain the enzyme in an inactive state until 
required. Although the CMV protease is a serine protease which does not require a cofactor, 
its mechanism of activation is very similar to the Ad2 L3 23kd protease in that the enzyme is 
redox-regulated. It is possible that the UL80 precursor is stable only in the cytoplasm of 
infected cells, and once exposed to the reducing environment of the developing viral capsid, 
the protease is activated. Like the hCMV and HSV-1 protease’s, the retrovirus HIV-1, HIV- 
2, and RSV protease’s (section 1.2.3iii) dimerise to form a catalytically active species with 
one active site per dimer. This dimerisalion plays an important role in the regulation of viral 
replication (Krausslich, 1995) and is achieved by high concentrations of protease in the 
capsid.
iii) Reorganisation of nuclear bodies:
The HSV-1 immediate early protein, VMW110, is a general trans-activator which is required 
for fully efficient viral gene expression and reactivation from latency (Everett and Maul, 
1994; Maul ef al., 1995). At early times of infection, VMW 110 localises to PML bodies and, 
like the adenovirus E4 ORF3 protein causes redistribution of PML. Both PML and VMW 110 
have the RING finger motif, and initially it was thought that both proteins had similar 
functions in vivo (Everett et al., 1995a). However, it appears that the motif is required for 
modification of the PML containing nuclear bodies, suggesting, that the RING finger has a 
functional role in complex interactions between the components of the nuclear domain 
(Everett etal., 1995b). Although the mechanism of VMW 110 action is unknown, the protein 
has been shown to complex with a 135kd ubiquitin-specific protease, which may facilitate the 
release of PML body components (Everett et al, 1997). Interestingly, the CMV IE1 major 
protein (Kelly et al., 1995), the EBNA-5 nuclear antigen of Epstein-Barr virus (Szekely et 
al., 1996) and the SV40 large T-antigen (Carvalho et al., 1995) are also localised to PML 
bodies early in infection, but the PML protein is only redistributed during CMV infection. 
Puvion-Dutilleul et al. (1995c) have shown that HSV-1 infection, like adenovirus infection 
(section 1.1.4ii), induces the formation of translucent structures composed of finally granular 
material (which may be analogous to clear amorphous inclusions) which are located at the 
nuclear border and contain the redistributed PML, SP100, and p80-coilin antigens.
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These structures appear late in infection, are localised with viral capsids, and contain high 
concentrations of capsid proteins. The authors suggest that these structures may have a 
potential role in virus assembly, possibly as storage sites of over-synthesised viral capsid 
proteins and that sequestration of cellular proteins into these virus induced structures may be 
required for the shutoff of host cell metabolism which occurs in HSV-1 infected cells.
1.2.2 Polyomavirus/SV40 assembly.
The structurally similar polyomavirus and SV40 are members of the Parvovirus family of 
dsDNA viruses. These viruses have a 5kbp genome which is complexed with cellular 
histones (often referred to as the minichromosome) inside a non-enveloped icosahedral capsid 
of 50nm in diameter (reviewed by Echhart, 1990). The small genome of SV40 codes for only 
a limited number of nonstructural proteins (reviewed by Deppert and Schirmbeck, 1995), and 
with the exception of the helicase activity of the large T-antigen, all the functions of these 
proteins are regulatory, serving to modulate cellular functions for the needs of viral 
replication and assembly. For small genomes, most functions regulating assembly must 
involve cellular pathways recruited by the virus, which are facilitated by various activities of 
proteins made early in infection. For instance, the large T-antigen of SV40/polyomavirus, 
like the El A protein of adenovirus, interacts with the cellular Rb protein, serving to enhance 
DNA replication (Hendrix and Garcea, 1994).
DNA replication has been shown to be subcompartmentalised with cellular chromatin being 
involved in initiation processes and elongation/termination of SV40 replication occurring at 
the nuclear matrix (reviewed by Deppert and Schirmbeck, 1995). This subnuclear partitioning 
also occurs during virion assembly, with capsid proteins assembling around 
minichromosomes associated with cellular chromatin. The capsid proteins, termed, VP1, 
VP2, and VP3, are all derived from an alternatively spliced single transcript and are post­
translationally modified (Salunke et al., 1986). All the late proteins contain nuclear targeting 
signals (Garcia-Bustos et al., 1991), however, VP1 protein has been shown to promote the 
nuclear accumulation of VP2 and VP3. Protein VP1 is the major component of the virus, and 
spontaneously assembles into pentomers, 72 of which form the icosahedral capsid. Although 
VP2 and VP3 proteins are not required for assembly, they associate with the 
minichromosome and interact with the capsid shell, and have therefore been implicated in
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genome packaging. VP1 has been expressed in E.coli, and has been shown to assemble into 
capsids in vitro (Liddington et al., 1991). Unlike the late stage of adenovirus capsid 
assembly, SV40 virion assembly does not involve proteolytic processing of capsid 
components, but instead, VP1 appears to pass through a series of conformational states. 
Bond switching between penta- and hexa-valent positions in the icosahedral lattice is an 
inherent property of VP1. Liddington et al. (1991) have identified 3 types of intercapsomeric 
bonds and suggest that bonding contacts probably act as control mechanisms for assembly.
1.2.3 Proteinases of RNA viruses.
The replication of many animal and plant viruses is dependant on the action of specific 
protease’s which serve a variety of functions including the separation of structural and 
nonstructural proteins, generation of specific enzymes (RNA polymerases), and the co­
ordinated assembly, and maturation of the virion. Proteolytic processing is common in the 
positive strand RNA viruses and retroviruses (reviewed by Krauslich and Wimmer, 1988; 
Hellen et al., 1989), and usually involves the cleavage of large polyproteins into functional 
units. Proteolysis of viral proteins also occurs during the replication of negative strand RNA 
viruses (such as Ortho- and Paramyxoviruses), although these cleavages are catalysed by 
cellular protease’s and are confined to viral glycoprotein precursors (Kawakara et al., 1992). 
Some of the well characterised positive strand RNA viruses and retrovirus systems are 
reviewed in this section.
i) Picornaviruses:
Picornaviridae are a family of small icosahedral viruses that cause a number of important 
disease syndromes. The family is currently divided into four genera: Rhinoviruses (the 
common cold), Enteroviruses (poliovirus), Cardioviruses (encephalomyocarditis) and 
Aphtoviruses (foot and mouth disease). All have a positive sense single-stranded monopartite 
genome which contains a single long open reading frame that is translated to yield a large 
polyprotein of 200 to 300kd (Kay and Dunn, 1990). The processing of the polyprotein 
occurs in three stages and involves the separation of the capsid precursor from the growing 
chain (primary cleavage), then processing of the structural and nonstructural precursor
43
proteins (secondary cleavage) and finally the maturation cleavage of the capsid components 
(Krauslich and Wimmer, 1988).
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Figure 1.15: Gene organisation and polyprotein processing of poliovirus. The coding region 
has been divided into three regions (Pl, P2 and P3), corresponding to major cleavage products of the 
polyprotein. Polypeptides are presented as wavy lines. Open circles indicate glycine residues except for VP2, 
where it is a serine, and filled circles denote blocked N-termini (reproduced from Krhusslich and Wimmer, 
1988).
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The first cleavage within the poliovirus poly protein (figure 1.15) occurs while it is still 
nascent on the ribosome, and is an autocatalytic process mediated by the 2A component of the 
polyprotein. Its cleavage results in the separation of the structural region (Pl) that consists 
only of capsid proteins. Most of the cleavages which subsequently take place within the 
respective capsid and nonstructural protein precursors are catalysed by the viral 3C protease. 
Of the two poliovirus protease’s, the 3C enzyme has been investigated in more detail than the 
2A protease. However, the 2A protease is known to cleave the Tyr-Gly bond linking Pl and 
P2 in vitro, and is therefore active as a mature protein as well as an intrinsic component of the 
polyprotein itself. The polyprotein contains a further nine Tyr-Gly bonds, yet only one of 
these (in the 3D polymerase region) appears to be cleaved by the enzyme, which suggests that 
additional determinants can influence whether cleavage occurs. The second 2A protease 
cleavage is not essential for virus replication, but is thought to provide a means of regulating 
the activities of the 3C protease and the 3D polymerase (Skem and Liebig, 1994).
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Eight of the 11 cleavages of the poliovirus polyprotein are catalysed by the 3C protease, 
either alone or in association with the 3D polymerase. Although all the cleavage sites are Gln- 
Gly bonds, the separation of the capsid proteins VPO, VP1, and VP3 are carried out by 3CD 
and not 3C alone. It has been proposed that elements in 3D are required to bind to the capsid 
protein precursor and so increase the affinity of 3C for its structural substrates. The 6 
remaining Gln-Gly sites that link the nonstructural proteins are readily cleaved by the 3C 
protease, and Hellen et al. (1988) have suggested that the different affinities of the 3C 
protease for its various substrates may be important in the regulation of the lytic cycle. The 
final processing event in poliovirus replication is the cleavage of the structural protein VPO 
(for which no protease has been identified) to generate VP4 and VP2, which takes place after 
the assembly of virus particles.
Proteolytic events catalysed by the 2A and 3C enzymes also leads to changes in cell structure 
and function. For instance, poliovirus 2A protease activity has been shown to facilitate the 
reduction in cellular DNA synthesis, transcription, and translation when expressed in COS-1 
cells (Skern and Liebig, 1994). The reduction in translation appears to be due to the limited 
specific proteolysis of eukaryotic translation initiation factor elf4. In addition, foot and mouth 
disease virus (FMDV) has been shown to cleave histone H3 in Baby Hamster Kidney cells, 
and the poliovirus 3C enzyme to cleave the activated form of transcription factor TFIIIC in 
HeLa cells, thus inactivating the protein and consequently facilitating the shutoff of host cell 
transcription. Poliovirus 3C also mediates the cleavage of microtubule associated protein 4 
which leads to a collapse of microtubules late in infection (Joachim et al., 1995).
All picornaviruses encode active and closely related 3C protease’s, but there is little similarity 
between the sequences of enzymatically active 2A protease’s of rhino- and enteroviruses and 
their counterparts in cardioviruses. The 2A protease’s of cardioviruses and apthoviruses 
consist of 135 to 145 and 16 amino acids respectively and are considered to be unrelated, 
although they have evolved different mechanisms for primary cleavage. Inhibitor studies 
(reviewed by Krauslich and Wimmer,1988; Nicklin, 1988) indicate that picomaviral 3C and 
2A protease’s constitute a class of cysteine protease’s distinct from the papain superfamily. It 
appears that the 3C enzyme is structurally similar to the chymotrypsin like serine protease’s, 
whereas the 2A protease resembles the smaller bacterial serine protease’s.
There is a surprising degree of similarity between 3C and other nonstructural proteins of 
picornaviruses and proteins encoded by cowpea mosaic virus and tobacco etch virus, which 
are members of the comovirus, and potyvirus groups of plant viruses respectively (Verchat 
and Carrington, 1995). Comoviruses have a genome consisting of two positive sense RNA 
strands which separately encode polyproteins for capsid and nonstructural proteins which 
eliminates the requirement for a 2A-like protease. However, the 24kd 3C-like protease can 
cleave all the sites within both polyproteins in vitro, and interestingly requires a cofactor for 
processing of the capsid precursor, although it is not a viral polymerase as is the case for 
poliovirus. The 48kd 3C-like protease of tobacco etch virus mediates its own autocatalytic 
cleavage from a single large polyprotein at Gln-Gly bonds. This cysteine protease, termed 
NIA, cleaves the viral polyprotein at 5 other sites, whereas the two other protease’s (one of 
which is a cysteine protease termed HCpro) mediate the remaining cleavage events.
ii) Hepatitis C virus.
Hepatitis C virus (HCV) is the major etiological agent of human parentally transmitted non-A, 
non-B hepatitis where chronic infection may lead to the development of liver cirrhosis, and 
hepatocellular carcinoma (reviewed by Houghton, 1996). The HCV virion contains a 
positive-strand RNA genome (9.4kbp) that has a single large open reading frame encoding a 
polyprotein of 3010 to 3033 amino acid residues. The genetic organisation of HCV is similar 
to that of Flavi- and Pestivruses and has been classified as a separate genus of the 
Flaviviridae family (reviewed by Van Doom, 1994).
At least 10 cleavage products are generated from the poly protein precursor and they are 
arranged in the order: NH2-CORE-El-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b-COOH 
(Bartenschlager etal., 1995). Core, a basic RNA-binding protein, is assumed to be the major 
constituent of the viral nucleocapsid, El and E2 are most likely virion envelope 
glycoproteins, and NS2 and NS5b are nonstructural proteins (probably involved in RNA 
replication). Although host cell signal peptidases located in the lumen of the endoplasmic 
reticulum are responsible for maturation of the structural proteins (Butkiewicz et al., 1996), at 
least two virus encoded protease’s are involved in processing of the nonstructural (NS) 
proteins. A zinc-dependant metalloprotease encompassing the NS2 region and the N-terminal 
one-third of NS3 (the NS2-3 protease) is required for cleavage between NS2 and NS3.
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Processing of NS3/4a, NS4a/4b, NS4b/5a, and NS5a/5b sites is mediated by a trypsin-like 
serine protease which is also encoded by the N-terminal one-third of NS3, but functioning 
independantly of NS2-3 (Bartenschlager et al., 1995; Koch et al., 1996). It has been shown 
that NS4a enhances the cleavage at the NS5a/5b site, and is absolutely required for cleavage 
at the NS4b/5a site. NS4a is cleaved off from NS3 by intramolecular cleavage at the NS3/4a 
site and has been shown to enhance NS3 activity in c/s and in trans (Koch et al., 1996). The 
central 12 amino acid residues, CVVIVGRIVLSK, of the 54 residue polypeptide are 
important for cofactor activity (Butkiewicz et al., 1996; Love et al., 1996), although 
sequences at the NS4a N-terminus improve the activation function, possibly by stabilising the 
NS3/4a interaction.
How NS4a exerts the activation function is unknown, although one possibility is that binding 
of NS4a changes the conformation within NS3, making the structure more ideal for substrate 
binding and/or catalysis. Koch et al. (1996) have suggested that the hydrophobic NS4a may 
also be required for localisation of NS3 to membranes of the endoplasmic reticulum, thereby 
increasing the local concentration of the protease in close proximity to the membrane 
associated polyprotein substrate. Closely related flaviviruses such as yellow fever vims and 
dengue vims also have a requirement for a protease cofactor, although processing of their NS 
proteins are mediated by a NS3/NS2b heterodimer (Amberg et al., 1994).
iii) Retroviruses.
Retroviridae are a large family of enveloped viruses that contain a single stranded genome that 
replicates via an obligatory DNA intermediate. After the initial events which leads to virus 
uncoating, the retroviral genomic RNA is reverse transcribed by the virion associated, virus 
encoded RNA-dependant DNA polymerase (reverse transcriptase). This process results in the 
synthesis of virus-specific dsDNA intermediates that integrate into the host chromosomal 
DNA to form a provirus (reviewed by Krausslich and Wimmer, 1988). The proviral DNA is 
then transcribed by cellular RNA polymerase II into the genomic 35S mRNA which can be 
spliced to yield subgenomic mRNA's.
The retrovirus genome consists of three major genetic elements referred to as gag, pol, and 
env. The gag (group-specific antigen) region encodes the capsid (CA), matrix (MA), and 
nucleocapsid (NC) proteins, and is translated as a precursor from 35S mRNA. Current
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evidence indicates that gag plays a fundamental role in the assembly of virions, and even in 
the absence of other viral proteins can assemble to form virus like particles (Krausslich et al., 
1995). The pol region encodes the viral replicative enzymes, namely, reverse transcriptase, 
integrase, and in most instances, the viral protease, which are also translated from 35S 
mRNA as part of a gag-pol fusion protein. Synthesis of the gag-pol polyprotein in human 
immunodeficiency virus type 1 (HIV-1), and rous sarcoma virus (RSV) infection, is achieved 
by ribosomal frame-shifting at one or two sites at the end of, or within, the gag gene (Yu et 
al., 1995). The infrequency of frame-shifting leads to an overproduction of structural 
proteins compared to replicative enzymes. The env gene encodes a polyprotein that is cleaved 
by cellular protease’s in transport vesicles to yield glycoproteins of the viral envelope.
Figure 1.16: Schematic representation of HIV-1 protease activation. Polyprotein 
concentration-facilitated dimerisation during HIV-1 budding (reproduced from Tomasseli and Heinrikson, 
1994).
The gag and gag-pol polyproteins are not cleaved immediately after synthesis but instead are 
transported to the plasma membrane, a process facilitated by the cotranslational probably 
concentrates and aligns the polypeptides (figure 1.16), thereby promoting inter-molecular
interactions that may result in some self-assembly of gag molecules and dimerisation of 
protease domains (Tomasselli and Heinrikson, 1994; Davis etal., 1995).
Cleavage of polyproteins occurs largely after the release of virions from cells and may require 
an intra-molecular event in which two gag-pol polyproteins dimerise to cleave at their N- and 
C-termini, or as an inter-molecular event, in which two such dimers cleave each other. HIV 
protease activity is dependent on dimerisation of monomeric subunits present in gag-pol 
polyproteins, thereby preventing premature activation prior to virus budding. When the 
protease is inactivated, or in the presence of HIV protease inhibitors, non-infectious viral 
particles are produced which display a distended spherical capsid structure, identical to that 
resulting from expression of gag alone, rather than the condensed cone shaped electron-dense 
core that is typical of mature particles (Quillent etal., 1996). Additionally, gag processing is 
reduced if gag-pol is truncated in distal regions of pol. This suggests that regions within the 
reverse transcriptase and integrase domains are essential in determining the overall 
conformation of the gag-pol precursor, which in effect modifies the ability of the protease 
domains to dimerise or cleave itself out of the polyprotein. Once released, the viral protease is 
confined to the budding particle, and thus initiates a cascade of proteolytic events resulting in 
maturation of vims particles.
The gag precursor (55kd) in HIV-1 is cleaved into smaller products that include the matrix 
protein (17kd), capsid protein (24kd), nucleocapsid protein (9kd), and a 6kd proline rich 
protein (P6) derived from the C-terminus of gag (Dorfman et al., 1994; Huang et al., 1995). 
The P6 domain appears to be required for the incorporation of the HIV-1 vpr accessory 
protein into virus particles (Wu etal., 1994), but has also been reported to have a functional 
role in virus particle production at late stages in the budding process ( Huang et al., 1995). 
These authors have suggested that P6 can directly enhance or suppress protease activity, 
possibly by altering the conformation of the gag precursor, thereby altering protease mediated 
gag processing. Besides polyprotein precursors and mature end products, intermediate 
processing products are transiently present in the maturation process because of sequential 
cleavage of polyproteins. CA and NC, and also NC and P6, are separated by short spacer 
peptides of 14 and 10 amino acid residues, termed, SP1 and SP2 respectively (Krausslich et 
al., 1995). The latter authors have suggested that initial cleavage of the gag precursor occurs 
at the C-terminus of SP1 to yield an MA-CA-SP1 intermediate, which is subsequently
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processed to CA-SP1. The presence of SP1 on cleavage intermediates infers that an ordered 
regulation of polyprotein processing occurs.
Activity of the HIV protease is not restricted to proteolytic processing of gag and gag-pol. 
The enzyme has been reported to specifically cleave the HIV-1 nef accessory protein within 
maturing virion particles (Welker et al., 1996). In addition, a number of studies of HIV 
protease cleavage of non-viral proteins suggest that the enzyme could have devastating effects 
on infected cells if it were activated outwith the virion panicle. Several studies have shown 
that the intermediate filaments (IF's) vimentin, desmosin, and glial fibrillary acidic proteins 
are cleaved in vitro by purified HIV-1 protease, and also that microinjection of the enzyme 
into human stem fibroblasts results in the collapse of the vimentin network (reviewed by 
Tomasselli and Heinrikson, 1994). The HIV-1 protease is also able to cleave microtubule 
associated proteins 1 and 2 in vitro and that the cleavage interferes with microtubule 
assembly. Several groups have speculated that HIV-1 protease may have a functional role in 
the pathogenesis associated with retroviral infection, which is in part supported by the finding 
that the protease is active in infected host cells. It remains to be determined how the enzyme is 
activated in infected cells as homodimer formation is facilitated by the increase in 
concentration of gag-pol polyproteins during the budding process.
Retroviral protease’s have been classified as aspartyl type protease’s due to the presence of 
the active site triad Asp-Thr-Gly, inhibition by pepstatin A, and sequence homologies with 
other enzymes of this class (reviewed by Krausslich and Wimmer, 1988; Tomasselli and 
Heinrikson, 1994). Although the retroviral enzymes are related to pepsin, renin, and other 
members of the aspartyl protease family, the requirement to form homodimers is unique to 
them. Whereas pepsin and renin are composed of approximately 350 amino acid residues, the 
retroviral protease monomer varies from 99 to 123 residues, giving a dimer of 198 to 246 
residues in total, with a triad from each monomer contributing to the active site.
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1.3 Subcellular localisation of viral antigens.
As mentioned previously, the aims of this project involve the further examination of virus- 
encoded proteins at the ultrastructural level. To obtain meaningful results from 
immunocytochemical studies, the production and use of well characterised antibodies of 
defined specificities is required. The methods most commonly used are reviewed in this 
section. For a more complete discussion on aspects of the immune system and 
immunocytochemistry, the following reviews and texts are recommended: Harlow and Lane 
(1988), and Griffiths (1993).
1.3.1 Monoclonal antibody production and characterisation.
Because of the polyclonal nature of the immune response, immunisation of an animal with a 
single protein antigen will give rise to an antiserum containing a mixture of antibodies with 
varying affinities that are directed against a variety of epitopes. Therefore, ideally it would be 
advantageous to select a single B lymphocyte, secreting an antibody of interest, and allow it 
to grow up as a clone of cells in culture, from which antibodies can be selected as required. 
As B cells have only a limited life span in culture, continuous production of monoclonal 
antibodies requires a means of immortalising these cells. The methodology for doing this was 
provided in 1975 by Kohler and Milstein. They showed that B lymphocytes, if induced to 
fuse with a continuously growing myeloma cell (lymphoid tumour cell), acquired the ability 
to grow indefinitely in culture, whilst continuing to secrete antibody.
The cells used for producing hybridoma cell lines are usually of mouse origin, with B cells 
being most commonly obtained from the spleen of the donor mouse. In order to maximise the 
chances of obtaining antibodies of the desired specificity, the spleen cell population of the 
donor mouse is enriched for B cells specific for the antigen during the weeks prior to 
collection of spleen cells. Alternatively, in vitro immunisation is also possible. In this case 
spleen cells are collected from an non-immunised mouse and cultured (under defined 
conditions) in the presence of antigen. This results in the proliferation of antigen specific B 
cells which negates some of the problems of immunological tolerance or suppression. 
However, a disadvantage is that this method gives rise to predominantly IgM antibodies 
which are generally less desirable than IgG's derived from m vivo immunisation.
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Several mouse myeloma cell lines have been employed for monoclonal antibody production, 
most being derived from MOPC 21 plasmacytoma's of the Balb/c mouse strain. These 
myelomas have been chosen because of their inability to grow in selective medium containing 
Hypoxanthine, Aminopterin, and Thymidine (HAT) medium. The myelomas are deficient in 
the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT) and consequently 
are resistant to the drug 8 azaguanine. HGPRT is a key enzyme in the salvage of purines and 
will utilise exogenously supplied hypoxanthine to produce inosinic acid, the common purine 
nucleotide precursor. Thus a cell blocked in purine biosynthesis will nevertheless be able to 
survive if supplied with hypoxanthine, provided that the HGPRT is functional. Inhibition of 
de novo purine biosynthesis may be achieved with the drug aminopterin. Aminopterin is a 
potent inhibitor of the enzyme dihydrofolate reductase (DHFR) which catalyses the reduction 
of dihydrofolate to tetrahydrofolate (FH4). FH4, in turn, is an essential cofactor in the 
biosynthesis of both purines and thymidine. To survive in the presence of aminopterin, a 
normal cell needs to be provided with a source of purines (in the form of hypoxanthine) and 
with thymidine, which can be utilised via the enzyme thymidine kinase (TK). Therefore, a 
normal cell will survive in HAT medium, while a cell deficient in HGPRT or TK will not. 
Fusion of spleen cells with myelomas is most frequently achieved using polyethylene glycol 
as the fusogen. Following fusion, the cells are transferred into HAT medium which selects 
for the hybridoma cells. The unfused myelomas are killed by HAT medium, while the spleen 
cells have only a very limited growth potential in culture. Identification of hybridomas 
secreting the desired antibody is achieved by plating the cells in limited dilution’s and 
allowing the cells to grow to near confluence. The testing procedure depends on the nature of 
the antigen, although typically some form of radioimmunoassay, immunoblotting, or 
immunofluorescence microscopy is used. Cells secreting the antibody of interest are 
separated from other non-secreting cells (or cells secreting irrelevant antibodies) in culture, by 
limited dilution cloning, or plating at low density in agarose. If necessary, monoclonal 
antibodies of interest can be epitope mapped using a variety of techniques that can include 
limited proteolysis, and deletion mutagenesis of protein antigens, although methods selected 
are primarily determined by the nature of the antigen.
It is noteworthy that a recent innovation in antibody production has come from the ability to 
clone and express immunoglobulin genes in non-lymphoid eukaryotic cells and prokaryotic
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systems (Rosa etal., 1989). Perhaps the simplest method of producing antibodies by 
expression in these systems is to micro-inject mRNA isolated from the parent hybridoma into 
target cells of interest. However, a major obstacle to efficient production of recombinant 
immunoglobulins is that they are constructed from two chains encoded by separate genes.
1.3.2 Immunocytochemistry
Immunofluorescence microscopy can provide important information regarding the subcellular 
localisation of antigens of interest. However, the various electron microscopy techniques 
now commonly used can provide additional information, at the ultrastructural level, which is 
often required. For instance, the high resolution localisation of viral DNA replication in Ad 
infected cells to border domains between ssDNA-DBP accumulation sites and the peripheral 
replicative zone (Besse and Puvion-Dutilleul, 1994), would be less apparent using 
immunofluorescence microscopy (Pombo et al., 1994). To obtain high resolution data, the 
structural organisation of cells must be preserved without introducing artefacts which may 
interfere with interpretation of results.
The first part of fine structure preservation is the fixation step, which is critical in determining 
how closely the image in the electron microscope resembles the in vivo structure. The aim of 
fixation is to 'freeze' cell organisation in a particular time frame, so that every molecule 
remains in its original location during visualisation. The only fixative procedure which can 
achieve this is cryo-fixation (followed by cryo-sectioning), although for immunolabelling 
procedures this technique is not applicable. An exception is the freeze-substitution approach 
in which cells must be exposed to chemical solvents to protect the structural integrity of the 
cell throughout immunolabelling procedures. Hence, for immunocytochemistry, and enzyme 
cytochemistry, chemical fixation is the only method available. However, chemical fixation 
can lead to the loss of epitopes (such as occurs with osmium tetroxide), and volume and 
shape changes which lead to structural distortions within the cell. In addition, steric 
hindrance, and chemical alteration of epitopes can also occur through fixative-induced cross­
links. Therefore a compromise between preserving the antigens of interest, and organelle 
structure, with maintaining immunoreactivity is required if meaningful results are to be 
obtained.
Embedding media also affect the structural organisation of the cell and have a profound effect 
on immunoreactivity. Resin-free embedding has been used successfully with Ad infected 
cells (Zhongue et al., 1986) and is probably the most suitable method for immunolabelling 
studies. However, a major disadvantage with this method is the difficulty in thin-sectioning, 
which can ultimately affect the structural preservation of the cell. Therefore most 
immunocytochemical protocols involve embedding in either hydrophilic acrylic resins 
(Puvion-Dutilleul and Puvion, 1995), or the more hydrophobic epoxy resins (Chaly and 
Chen, 1993; Greber et al., 1993), both of which are generally considered to result in 
diminished immunoreactivity. This is a major disadvantage of the epoxy resins especially. 
Fixed cells must be completely dehydrated in protein denaturing solvents before resin 
infiltration, and then the resin can only be polymerised by heating above 50°C. Although the 
acrylic resins are not water-miscible, they are designed so that they combine at least some 
degree of hydrophilicity with good sectioning properties. Additionally, acrylic resins can be 
polymerised at low temperatures, and interestingly have been used for immunofluorescence 
microscopy studies (Jackson and Blythe, 1993).
Immunolabelling reactions can be performed pre- or post-embedding, with each method 
having distinct advantages and disadvantages. For instance, pre-embedding procedures 
require permeabilisation of membranes to allow penetration of antibody to cellular 
compartments. The detergents and solvents used can inevitably destroy some fine structure, 
and lead to extraction of antigens. After the antibody reactions the cells are treated with 
fixative (usually osmium tetroxide), dehydrated, and conventionally embedded in epoxy 
resin. The most widely used pre-embedding procedure is the immunoperoxidase technique 
using horseradish peroxidase (HRP), conjugated to a secondary antibody. This method is 
considered attractive because the HRP effectively amplifies the primary immune reaction by 
catalytically oxidising proportionately large amounts of its substrate. Additionally, a further 
amplification can be obtained by using antibodies against HRP in the peroxidase anti­
peroxidase (PAP) technique (reviewed by Griffiths, 1993).
The use of antibodies on thin sections has a wide field of application, although a disadvantage 
is that only antigenic sites which are accessible at the surface of thin sections are detected. 
However, in the absence of permeabilisation steps, and with the use of gold particles as 
markers, the post-embedding technique allows the precise identification of labelled structures
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which are generally well preserved. The post-embedding technique also allows the 
simultaneous detection of several antigens, provided that the primary antibodies are raised 
from different animals and that the gold particles bound to the secondary antibodies are of 
different sizes. In addition, this procedure can also be combined with specific staining of 
proteins and DNA (Puvion-Dutilleul and Puvion, 1995). For instance, among the protein 
stains which reveal subsets within the total viral and cellular proteins are the periodic acid- 
schiff (PAS)-like reaction for glycoproteins, and the silver staining method which reveals 
acidic proteins. However, the bismuth staining method is of interest due to the exclusive 
staining of highly phosphorylated proteins and has the advantage of being compatible with 
the post-embedding technique. Immunodetection, in conjunction with selective staining of 
proteins and DNA, has been used successfully in studies examining the nature of virus- 
induced intranuclear structures (Puvion-Dutilleul and Puvion, 1995; Puvion-Dutilleul et al., 
1995a and b), however, there are no rules governing which immunocytochemical protocol 
will provide the most useful information regarding a specific antigen of interest, and often, 
several parameters mentioned in this section must be altered.
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1.4 Aims of the project.
Although the Ad2 23kd protease is believed to be activated within the 'young' virion, several 
reports have suggested that the viral protease has cleavage activity prior to activation by the 
pVI-ct peptide, or the pVI protein from which it is derived. For instance, the Ll-52kd 
scaffolding protein is cleaved at an early stage in virus assembly and prior to the cleavage of 
other viral proteins (Hasson et al, 1992), and eytokeratins K7 and K18 are cleaved exterior to 
the virus (Chen etf al, 1993), whilst protease activation presumably takes place within the 
newly assembled virion. This suggested that other mechanisms of regulation might affect 
viral protease activity within lytically infected cells.
The aim of the project was to generate a panel of monoclonal antibodies specific to the Ad2 
23kd protease, which after characterisation, could be used to determine the subcellular 
distribution of the viral protease within Ad2 and Ad2tsl infected HeLa cells.
The second objective of this project was to determine the epitopes of monoclonal antibodies 
which could be used to study the effect of ligand binding on the conformation of the viral
enzyme.
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2 Methods and Materials
2.1 Expression and Purification of Recombinant Ad2 23kd 
Protease.
2.1.1 The GST gene fusion system.
The glutathione s-transferase (GST) fusion system introduced by Smith and Johnson (1988) 
consists of the pGEX series of plasmids that contain the GST gene from Shis to soma 
japonicum. The 26kd GST protein forms an affinity tail on the protein products of genes 
inserted into the multiple cloning site (MCS). The pGEX plasmids also feature a tac promoter 
that enables inducible high-level expression of fusion proteins, and the Lac 19 gene which 
ensures that any E.coli strain can be used. Fusion proteins are recovered from bacterial 
lysates using glutathione-containing affinity matrices, and eluted under mild, non-denaturing 
conditions (5mM reduced glutathione). Once purified, the protein of interest can be cleaved 
away from GST using site specific protease’s that recognise sequences between GST and the 
MCS.
The plasmid pGEX23k was previously constructed using the vector pGEX-2T (Webster and 
Kemp, 1993) and transformed into Escherichia coli JM101 cells. A single colony was picked 
from a selective agar plate and used to inoculate 5ml of Luria Broth (LB) containing 
100p.g/ml Ampicillin (Amp) and left for six hours at 37 °C with shaking. A fraction of the 
starter culture was added to 250ml of LB-Amp and grown until cells had reached an 
absorbance of between 0.5 and 0.8 at 600nm. The expression of recombinant fusion protein 
was induced by the addition of freshly prepared 0.1 mM Isopropyl-8-thiogalactopyranoside 
(IPTG) from a 0.1M stock. After a period of four to six hours (at 37°C), cells were harvested 
by centrifugation at 10000 rpm (JA-14 rotor, Beckman centrifuge J2-21) for 5 minutes at 
4°C, and the pellet washed with ice-cold STE buffer (ImM EDTA; 150mM NaCl; lOmM 
Tris/HCl, pH 8.0). After a second centrifugation, the pellet was stored at -20°C.
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2.1.2 Purification of fusion proteins from E.coli.
Thawed cell pellets were resuspended in 6ml of STE buffer containing 100 pg/ml lysozyme 
and incubated on ice for 15 minutes at 37°C. Lysis was achieved by the addition of 1.5% 
Sarkosyl, and after 3x 10 second sonication bursts on ice (Sanyo Soniprep 150), the lysate 
was clarified by centrifugation at 10000 rpm (JA-14 rotor, Beckman centrifuge J2-21) for 5 
minutes at 4°C. Supernatants were adjusted to 2 or 4% Triton X-100 (Frangioni and Neel, 
1992), vortexed, and applied to a 1 ml column of pre-equilibrated (PBS) Glutathione 
Sepharose-4B beads (Sigma), at a flow rate of 0.5ml/min. Unbound protein was washed 
through the column by applying lOx column volume of wash buffer (150mM NaCl; 75mM 
Hepes, pH 7.4) or PBS, before addition of elution buffer (lOmM reduced glutathione; 
150mM NaCl; 75mM HEPES, pH7.4). Collected fractions were examined by SDS-PAGE 
and/or Western blotting (methods 2.2.2 and 2.2.3) and stored at -20°C.
2.1.3 Expression using the pETllc vector in E.coli.
The pET series of vectors are examples of T7 expression systems that take advantage of the 
highly specific nature of the T7 RNA polymerase. The plasmids used for cloning and 
expression of cDNA's are based on the multi-copy plasmid pBR322, and carry a T7 
promoter followed by a unique cloning site. For efficient expression, vectors must be 
transformed into an E.coli strain that expresses the T7 RNA polymerase, such as DH1 (DE3) 
and BL21 (DE3). The bacteriophage DE3 present in these strains is a lambda derivative that 
has been engineered to contain the gene for the T7 polymerase under the control of the Lac 
UV5 promoter. It also carries the Lac I gene so that the T7 polymerase gene, normally 
switched off, can be activated by IPTG.
Plasmid pT7AD23K6 (Grierson et al., 1994) was transformed into E.coli BL21(DE3) cells. 
Starter cultures were grown for six hours at 37°C, and 1ml used to inoculate 250ml of M9 
medium. The minimal medium was prepared by mixing 12.5ml of 20x M9 (370mM NH4CI; 
68mM KH2PO4; 845mM Na2HPO4), 5ml of 20% (w/v) glucose, 0.25ml of 1M MgSO4, 
250pl of lOOpg/ml Amp and made up to 250ml with ddH20 (Novagen Technical Bulletin). 
All components were stenle filtered (Acrodisc 0.2pm). Cultures were grown until an optical 
density of between 0.5 and 0.8 was observed at 600nm, and expression induced by the 
addition of IPTG to a final concentration of 0.6mM. After six hours at 37°C, cells were
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harvested as described in methods 2.1.1, except that cell pellets were resuspended in 
Suspension buffer (5mM EDTA; 4% glycerol; 50mM Tris/HCl, pH 8.0). Pellets were stored 
at -20°C.
2.1.4 Preparation of bacterial lysates for FPLC.
Thawed cell pellets were resuspended in 6ml suspension buffer containing lOOpg/ml 
lysozyme for 15 minutes at 37°C. Cells were freeze/thawed three times in liquid nitrogen 
before the addition of lOOpl of 1M MgSO4 and 100pi of DNAase I (2mg/ml stock). After an 
incubation of 15 minutes at 37°C, lysates were centrifuged for 5 minutes at 15000rpm (JA-20 
rotor, Beckman centrifuge J2-21). Clarified lysates were filtered (Acrodisc 0.2pm) before 
applying to DEAE-Sepharose column (methods 2.1.7).
2.1.5 Expression of recombinant 23kd protease in Sf9 cells.
i) Insect cell culture:
Spodoptera frugiperda cells (Sf9) were maintained in suspension cultures at 28°C in TC-100 
medium (Gibco-BRL) supplemented with 10% Foetal Calf Serum (FCS) and 50pg/ml 
Gentamycin (Gibco-BRL). For routine maintenance, cells were passaged every 2 to 3 days 
(at a cell count of 2x10^ cells per ml), and 80% of the culture was discarded and replaced 
with the same volume of TC-100/FCS.
ii) Sf9 infection with recombinant virus:
Recombinant baculovirus containing the plasmid pVL23K (derived from the transfer vector 
pVL1393) were constructed and purified (Webster, 1992). Suspension cultures (500ml) of 
Sf9 cells were grown to a density of 8x10^ cells per ml. Cells were pelleted by centrifugation 
at 2500rpm for 5 minutes (IEC-Centra 3), and resuspended in 15ml of a 10^ p.f.u./ml stock 
of recombinant vims (kindly donated by Dr. A. Webster, University of St. Andrews). TC-100 
medium was added to a volume of 50ml and cells were infected for one to two hours at 28°C, 
before TC-100/10%FCS was added to give a final volume of 500ml. Infection was allowed 
to proceed for sixty hours at 28°C. Infected cells were collected by centrifugation at 2500rpm 
for 15 minutes and washed in PBS. Pellets were stored at -20°C or processed immediately.
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2.1.6 Purification of 23kd protease from Sf9 cells.
The washed cell pellet from infected Sf9 cells was suspended in 5ml of ice-cold 50mM 
Tris/HCL, pH 8.0 and homogenised on ice with twenty strokes of a tight fitting pestle (type 
B) in a Dounce Homogeniser. The nuclei were sedimented for 5 minutes at low speed in a 
microfuge and the cytoplasmic extract was clarified by centrifugation for 20 minutes at 
30000g (Beckman TL-100 Ultracentrifuge) at 4°C.
2.1.7 Fast Protein Liquid Chromatography (FPLC).
i) Anion exchange (DEAE-Sepharose):
Clarified supernatants (5 to 10ml) were filtered and applied to a DEAE-Sepharose column 
(Pharmacia), previously equilibrated with vacuum filtered (Anachem 0.2pm) 50mM 
Tris/HCL, pH 8.0 (buffer A) for one hour (at lml/min). After eluting the 23kd protease with 
buffer A, remaining proteins were eluted with filtered buffer B (1M NaCl; 50mM Tris/HCl, 
pH 8.0). The elution profile was monitored at 280nm and 1ml fractions collected. Fractions 
were either stored at -20°C or analysed (methods 2.2) and pooled for further purification. 
DEAE-Sepharose columns were stored in 0.02% (w/v) sodium azide.
ii) Cation exchange (Mono-S and CM-Sepharose):
Pooled fractions (approximately 20ml) from DEAE-Sepharose separations were applied to a 
CM-Sepharose and/or Mono-S column (Pharmacia), pre-equilibrated with buffer A (for 30 
minutes) at lml/min. Retained 23kd protease was eluted by increasing the salt concentration 
to 150mM with buffer B. The elution profile was monitored at 280nm and 1ml fractions 
collected. Fractions were stored at -20°C and analysed as described in methods 2.2.
iii) Gel-filtration (Superdex-75):
For the separation of isomeric forms of the 23kd protease, 200pl of concentrated protein 
(minimum of 1 mg/ml) was applied to a Superdex-75 column (Pharmacia), pre-equilibrated 
with elution buffer (150mM NaCl; 50mM Tris/HCL, pH 8.0) for two hours at a flow rate of 
0.5ml/min. The elution profile was monitored at 280nm and 0.5ml fractions collected. 
Fractions were stored at -20°C.
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2.1.8 Concentration of purified protein (ultrafiltration).
Fractions of purified protein were pooled, and concentrated either at high pressure (10ml 
Amicon chamber) or by centrifugation (Centricon). In both cases the molecular weight cut off 
of membranes was lOkd. The amicon chamber was fitted with a filtron disc membrane, 
which was pre-equilibrated with ddH20. Amicon ultrafiltration was performed on ice using a 
magnetic stirrer, concentrating protein solutions into a final volume of 1ml. Centricon 
ultrafiltration was achieved by centrifugation at 3000rpm (IEC Centra-R), at 4°C, until 
protein solutions were of 0.5ml final volume.
2.2 Assessment of protein purification.
2.2.1 Determination of total protein concentration.
Quantification of total protein concentration was done using the microassay procedure as 
described in the BioRad protein assay manual. A standard curve was prepared with a series 
of concentrations of Soybean Trypsin Inhibitor (SBTI) ranging from 1.0 to 20pg/ml. 
Standards of 0.8ml, and samples diluted 1/100 were placed in test tubes, to which a dye 
reagent concentrate (obtained from BioRad) was added to give a final volume of 10ml. 
Samples were mixed by gentle inversion, and after 5 minutes the absorbance at 595nm 
measured against a reagent control. The concentration of protein samples was determined 
from a calibration curve of SBTI standards.
2.2.2 SDS-Polyacrylamide electrophoresis (SDS-Page).
BioRad mini gel equipment was used in accordance with manufacturers instructions. SDS- 
PAGE recipes are listed in table 2.1. After the addition of TEMED and freshly prepared 
ammonium persulphate to the separating gel, the mixture was poured between the assembled 
glass plates.
The mixture was overlaid with approximately 0.5ml water saturated butanol and allowed to 
polymerise before the removal of the butanol overlay and washing with 70% ethanol. After 
the addition of the stacking gel, 10 or 15 well combs were placed between the plates. After 
polymerisation, these were removed and the wells washed with water.
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Table 2.1: SDS-PAGE recipes, volumes in ml.
Separating gels Stacking gel
Reagents 10% 15% 20% 3.2%
40% (w/v) Acrylamide 5.625 8.44 11.25 1.275
2% (w/v) N, N' metliylenebisacrylamide 1.400 0.975 0.468 0.70
10% (w/v) SDS 0.225 0.225 0.225 0.10
1M Tris/HCL (pH 8.7) 8.40 6.40 - -
2M Tris/HCL (pH 8.7) - - 4.20 -
1M Tris/HCL (pH 6.9) - - - 1.25
Water 4.35 6.46 8.57 6.70
10% (w/v) ammonium persulphate 0.125 0.125 0.125 0.05
TEMED 0.015 0.015 0.015 0.02
Running buffer (Laemmli): lOx Tris/glycine (25mM Tris; 190mM glycine; 0.1% (w/v) SDS; ddH20).
Samples were treated with loading buffer (5% (v/v) 6-mercaptoethanol; 2% (w/v) SDS; 2.5% 
(v/v) glycerol; 0.001% (w/v) Bromophenol blue; 50mM Tris/HCL, pH 7.5), boiled for 2 
minutes, and cooled prior to gel loading. Gels were electrophoresed at a constant voltage 
(100 volts) until the samples reached the separating gel, thereafter, the voltage was increased 
to 180 volts. After the dye front migrated to within 1cm from the bottom of the plates, the 
apparatus was disassembled, and gels prepared for Western blotting (methods 2.2.3), or 
Coomassie blue stained (0.2% (w/v) Coomassie brilliant blue R250; 50% methanol; 10% 
acetic acid) for 15 minutes, then destained (2% methanol; 10% acetic acid), after which gels 
were dried onto 3MM Whatman filter paper using a BioRad 583 vacuum gel dryer (heated to 
80°C), or sealed in airtight plastic bags. For silver staining of Coomassie stained gels, the 
gels were first rinsed in 30% ethanol (3x 20min), then washed in water (2x 15min), before 
being soaked in sodium dithionite (0.25g/l) for 1 minute (with shaking). Gels were then 
washed (2x lmin), and immersed in 0.2% silver nitrate in ImM formaldehyde for 30
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minutes. Gels were again washed with water (1 minute) then immersed in 6% (w/v) sodium 
carbonate)/6mM formaldehyde/20|lM sodium dithionite until bands developed. Development 
was stopped by addition of 3.5% acetic acid and gels then rinsed extensively in water (4x 
30min). Gels were stored in 20% ethanol.
2.2.3 Western Blotting.
After separation by SDS-PAGE, protein samples were electroblotted to a Hybond PVDF 
membrane (Amersham,UK) using a semi-dry blotter (Pharmacia LKB Multiphor II). Eight 
pieces of 3MM Whatman filter paper, and the PVDF membrane, were cut to gel size. PVDF 
was pre-soaked in methanol for 2 minutes, and all components were equilibrated for 15 
minutes in transfer buffer (48mM Tris; 39mM glycine; 20% methanol; 0.00375% SDS). The 
blotting sandwich was prepared by placing 4 pieces of filter paper on top of the anode plate, 
then the PVDF membrane, gel, and finally 4 more layers of filter paper (air bubbles removed 
at each stage). The cathode plate was then placed on top and a constant current of 
approximately 50mA/gel was applied. After one hour, the PVDF membrane was removed 
and either stored at -20°C in a sealed plastic bag, or incubated for one hour at room 
temperature, or overnight at 4°C, in Blocking buffer (5% (w/v) dried milk powder; 0.1% 
(v/v) Tween-20; PBS). After blocking, the membrane was incubated with primary antibody 
(either rabbit polyclonal antiserum or cell culture supernatants containing relevant monoclonal 
antibodies), for 30 minutes in blocking buffer at the required antibody titre and with gentle 
rocking. After a series of washes in blocking buffer (3x 10 minutes), the membrane was 
incubated with a 1/5000 dilution of either anti-rabbit Ig, or anti-mouse Ig horseradish 
peroxidase linked whole antibody (Amersham,UK), for 30 minutes in blocking buffer. The 
membrane was washed in blocking buffer (3x 10 minutes) and finally in 0.1% Tween- 
20/PBS for 15 minutes. The blot was immersed in a 1:1 mixture of two ECL reagents 
(Amersham,UK) for 3 minutes, and placed between two acetate sheets. Finally, the 
membrane was exposed to an X-ray film (Fuji-RX) for defined periods of time before being 
processed in a Kodak M35 X-OMAT processor.
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2.2.4 Densitometric assay of protein concentration.
An SDS-Page gel containing SBTI standards (ranging from 1.0 to 20pg/ml), and a known 
dilution of sample protein were stained and destained. The gel image was then digitised using 
a Mirror 800 Scanner, and using the NIH Image 1.54 Program (for Macintosh) the lanes 
were marked and plotted. The relevant peaks of each lane were integrated and the areas 
displayed. With the areas corresponding to the standards, protein concentration of the sample 
was read directly from the SBTI calibration curve.
2.2.5 Estimation of enzyme activity by capillary electrophoresis.
i) Peptide assay for recombinant protease:
To determine the activity of purified 23kd protease, lOptl of solution containing the enzyme 
was incubated with 10pl of activating peptide (GVQSLKRRRCF) which was aliquoted from 
a lmg/ml stock kept at -20°C, and 25 pi of freshly prepared assay buffer (lOmM EDTA; ImM 
B-mercaptoethanol; 50mM Tris/HCL, pH 8.0) for 5 minutes at room temperature (in 0.5ml 
siliconised eppendorf tubes). Synthetic substrate (LSGAGFSW) was added (5pl from a 
2mg/ml stock) and the assay was allowed to proceed for one hour at 37°C. At defined time 
points, lOpil aliquots were transferred to eppendorf tubes containing lOpl CE buffer 
(BioRad), and 80pl ddH2O (filtered using 0.2pm Acrodisc) and either analysed immediately 
by capillary electrophoresis or stored at -20°C. For biological activity assays of monoclonal 
antibodies (Mabs) against the Ad2 23kd protease, the above synthetic substrate was 
substituted with the acetylated synthetic substrate (Ac-LRGAGRSR) due to non-specific 
digestion by cellular aminopeptidases in cell culture supernatants.
ii) Capillary electrophoresis:
All samples were thawed and filtered (Amicon micropure.22) prior to capillary 
electrophoresis. The BioRad Biofocus 3000 Capillary Electrophoresis System was initiated 
15 to 30 minutes before assays were examined. Water (HPLC grade), capillary wash 
(BioRad) and CE (capillary electrophoresis) buffer were filtered before use, and were 
replaced regularly.
The Instrument was used in accordance with the manufacturers instructions. In general, when 
examining digestion of LSGAGFSW, the CZE (capillary zone electrophoresis) method was
64
used, and runs were typically of 15 minutes duration. For the acetylated substrate, runs were 
of 5 minutes duration. Using the Biofocus 3000 Integrator program, the area of peaks within 
spectra were calculated giving relative concentrations of substrate and products.
2.3 Monoclonal Antibody Production.
Some of the methods described in this section are derived from Antibodies: A laboratory 
manual (Harlow and Lane, 1988).
2.3.1 Immunisations and test bleeds.
For initial immunisations, purified 23kd protease (methods 2.1.3,4,7 and 8) in 100pl PBS, 
was mixed with an equal volume of Freunds complete adjuvant (Sigma), followed by a series 
of 15 second sonication bursts, with 2 minute incubations on ice, until droplets of emulsion 
placed on water did not disperse. Incomplete Freunds adjuvant was used in subsequent 
immunisations.
Ten male Balb/c strain mice (six weeks old) were injected with 50|ig of 23kd protease (in a 
total volume of lOOjul) by the intraperitoneal route, using a 0.5ml syringe with a 23-gauge 
needle, and marked at the base of the tail with permanent marker for future identification. 
This procedure was repeated at 14 and 35 days post initial immunisation.
Test bleeds were done 24 and 45 days after the initial immunisation. Isolated mice were 
heated under an infrared lamp for a few minutes to increase blood flow to the tail, which was 
then 'nicked' two inches from the base (using a sterile scalpel) across the tail vein. Several 
drops of blood were collected and incubated for one hour at 37°C, stored overnight at 4°C, 
then centrifuged at lOOOOrpm for 10 minutes (MSE microcentaur microfuge). The serum was 
removed from the cell pellets and centrifuged once more (lOOOOrpm/lOmin) before being 
tested (methods 2.2.3 and 2.3.2).
Mice were kept and used in accordance with Home Office guidelines.
65
2.3.2 Screening for positive antibody response.
Nitrocellulose sheets (Amersham,UK), pre-equilibrated in PBS, were immersed in solutions 
of 20 to 50pg/ml 23kd protease (purified from Sf9 cells) for two hours with gentle agitation. 
After washing 3 times in PBS (10 minutes each), the sheets were immersed in blocking 
buffer (5% (w/v) dried milk powder; 0.1% (v/v) Tween-20; PBS) for two hours, or 
overnight at 4°C. For long term storage, sheets were covered in plastic wrap and kept at 
-20°C.
A single nitrocellulose sheet was placed over a Teraski plate (Sterilin) which had lOpl 
aliquots of cell culture supernatant and/or rabbit polyclonal antiserum per well. Another 
Teraski plate was placed on top, and the sandwich was clamped with crocodile clips (sides of 
Teraski plates were cut and smoothed). The sandwich was inverted, tapped lightly to ensure 
air bubbles were released from the nitrocellulose surface, and placed in a humid chamber. 
After 30 minutes, the nitrocellulose sheet was released from the plates and rinsed quickly 3 
times in PBS, and washed extensively for a further 30 minutes in PBS. Nitrocellulose sheets 
were incubated with anti-mouse and anti-rabbit Ig horseradish peroxidase whole antibody for 
30 minutes in blocking buffer. Dot blots were developed using ECL reagents (methods 
2.2.3) after extensive washing in PBS and 0.1% Tween-20/PBS. When screening cell 
culture supernatants, polyclonal antiserum R11 (raised against the N-terminal region of the 
Ad2 23kd protease), diluted 1/5000, was aliquoted into specific wells of teraski plates to aid 
identification of positive responses by correct orientation.
2.3.2 Preparation of tissue culture plates with macrophages.
Balb/c mice were killed by anaesthesia and swabbed with 70% ethanol. Warmed G-MEM 
(5ml/mouse) was injected into the peritoneal cavity using a 23-gauge needle, and the 
abdominal region was massaged for 2 to 3 minutes. After re-sterilisation, the peritoneal cavity 
was pierced on the right side, just below the liver, using a 19-gauge needle, and 4 to 5ml of 
peritoneal exudate was allowed to drip into a 10ml centrifuge tube. Macrophages were 
centrifuged at 1200rpm for 10 minutes and resuspended in G-MEM supplemented with 
Hypoxanthine-Aminopterin-Thymidine (HAT) hybridoma grade (Sigma), and 10% FCS (for 
cell fusion’s only), or G-MEM/10%FCS (for cell resuscitation and maintenance). A single 
mouse would yield enough macrophages for three 96 well plates (lOOpl/well), or two 24 well
plates (0.5ml/well), which were placed in an incubator set at 37°C/5% CO2 and left 
overnight.
2.3.4 Hybridoma production:
i) Counting myeloma and hybridoma cells:
When an exact cell count was required, a drop of cell suspension was applied to a 
hemocytometer (Neubauer counting chamber) and examined using an Olympus CK2 phase 
contrast microscope. Thereafter:
numbei of cells counted/nuraber of squares counted x 104 = number of cells/ml.
ii) Preparing myeloma cells for fusion:
Myeloma cells (SP2/0) were resuscitated from liquid nitrogen storage (methods 2.3.5) two 
weeks before cell fusion and maintained in G-MEM/10%FCS at 37°C/5% CO2, passing 
every 3 to 4 days into new 75cm^ flats (Sterilin, UK). The day before cell fusion, cells were 
split into fresh G-MEM/10%FCS at a density of 5x10$ cells/ml in 75cm^ flats.
iii) Intravenous boost before cell fusion:
Three days before cell fusion’s, immunised mice (best responders) were given a final boost 
of purified 23kd protease (50pg in PBS) without adjuvant. Mice were isolated, warmed 
using an infrared lamp, and placed into a restraining chamber. After swabbing the tail with 
70% ethanol, 0.2ml of solution was injected into the tail vein approximately 2cm from the 
base using 0.5ml syringe fitted with a 26-gauge needle.
iv) Preparing splenocytes for fusion:
Two mice were killed by anaesthesia. Using sterilised scalpels and forceps the abdominal 
cavities were cut open and spleens removed. Both were placed in a 100mm tissue culture dish 
containing 10ml of pre-wanned G-MEM (without FCS), and contaminating tissue removed. 
Cells were teased through fine wire gauze using forceps and 1ml syringes fitted with 19- 
gauge needles (cell clumps were disrupted by repeated pipetting). The lysate was transferred
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to a centrifuge tube and left for 3 minutes for particulate matter to settle. The supernatant was 
removed from the cell debris and added to a fresh centrifuge tube (concentration of cells was 
8x10^ cells/ml).
v) Cell fusion:
Supernatants from splenocyte preparations were centrifuged at 1200rpm for 10 minutes, and 
pellets were resuspended in 5ml of NH4CI to lyse the red blood cells. After 10 minutes, 
suspensions were centrifuged as before and resuspended in 10ml of pre-warmed G-MEM. 
Myeloma cells and splenocytes were washed twice (1200rpm/10min) and combined to give a 
ratio of 5 splenocytes to 1 myeloma cell, then pelleted. During the washing steps, a vial of 
0.5g polyethylene glycol (PEG) of hybridoma grade (Sigma) was melted at 50°C and 
transferred to 37°C after the addition of 0.5ml G-MEM. The PEG solution was added 
dropwise over a period of a minute to the cell pellet (in a water bath at 37°C) while 
resuspending the cells by continual mixing with a Pasteur pipette. After mixing for an 
additional minute, 10ml of G-MEM was added over a period of 3 minutes (1ml in the first 
minute) to the cell mixture, which was then pelleted (1200rpm/10min), and resuspended in 
10ml of G-MEM/10%FCS(HAT). from the 10ml stock, dilution’s of 1/5 and 1/10 in G- 
MEM/10%FCS(HAT) were aliquoted (100p.l) into twenty 96 well plates containing 
macrophages. After one to two weeks, the media was changed to G-MEM/10%FCS(HT) and 
individual wells screened for positive clones (methods 2.3.2) when cells were approximately 
70% confluent.
vi) Single cell cloning:
After a positive well was identified, cells were transferred to a 24 well plate containing 
macrophages (the original 96 well plate was maintained in the event of contamination). After 
several days the cells were resuspended when approximately 90% confluent, and lOpl 
serially diluted in G-MEM/10%FCS(HT) as neat, 1/5, 1/25, and 1/125, before aliquoting 
(100|il) into two 96 well plates containing macrophages. The plates were left for a further 3 
days (undisturbed) and examined using an Olympus CK2 microscope for single cells, or 
clusters of cells derived from a single clone. If it was unclear that cell clusters were derived 
from a single clone, then those wells were re-subcloned.
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Wells marked as being single cell clone positives, were allowed to grow to 70% confluence 
before being screened (methods 2.3.2) for antibody production. Positive clones were 
gradually weaned off HT supplement over a period of two weeks, and were maintained in G- 
MEM/10%FCS in 24 well plates.
2.3.5 Long term storage of cell lines.
Dimethyl sulphoxide (DMSO) was of hybridoma grade and purchased from Sigma as 5ml 
ampoules (stored at room temperature).
i) Freezing positive clones:
Cell lines screened positive for antibody production were expanded into 6 well plates. At 
90% confluence, cells were resuspended by repeated pipetting and centrifuged 
(1200rpm/10min). Media was removed by aspiration, and the pellet gently resuspended in 
pre-chilled freezing mix (10% DMSO; 30% FCS; G-MEM) and quickly placed on ice in 
screw top vials, then stored at -70°C. After 24 hours, the vials were placed in liquid nitrogen.
ii) Recovering cells from liquid nitrogen storage:
Frozen vials were removed from liquid nitrogen storage and quickly thawed at 37°C. 
Immediately the vials were sterilised with 70% ethanol and the cell suspension added to 10ml 
G-MEM. After centrifugation (1200rpm/10min), the cell pellet was resuspended in 0.5ml G- 
MEM/10%FCS, and dilution’s aliquoted (lOOpl) into 24 well plates containing macrophages.
2.3.6 Cell culture maintenance and supernatant storage.
Monoclonal cell lines were maintained in 24 well plates, and passaged every 2 to 3 days into 
fresh G-MEM/10%FCS. Those of interest were expanded into 6 well plates and finally into 
75cm2 flats. In some instances the media was changed to protein free hybridoma media 
(Gibco-BRL) gradually over a period of two weeks as not to shock the cells. Cell lines were 
kept at 37°C/5%CO2.
Cell culture supernatants from 75cm^ flats that were 90% confluent were centrifuged for 10 
minutes at 3000rpm (IEC Centra-R) and filtered (Acrodisc 0.2pm). The pH was adjusted by
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adding 1/20 volume of 1M Tris/HCl (pH 8.0). Sodium azide was added to 0.02%, and 
supernatants were stored at -20°C.
2.3.7 Isotyping monoclonal antibodies.
The Serotec isotyping kit was used for classing and subclassing monoclonal antibodies from 
cell culture supernatants. Vials of freeze-dried anti-mouse IgGl, IgG2a, IgG2b, IgG3, IgA 
and IgM (positive and negative controls were also provided) were reconstituted into 96 well 
plates containing recommended dilutions (neat, 1/10 and 1/50) of cell culture supernatants. 
Plates were left for an hour, at room temperature, and agglutination determined as being 
positive for a particular isotype.
2.3.8 Monoclonal antibody purification.
The choice of purification method depends on a number of variables which include the class 
and subclass of antibodies, their intended use, and source for purification. During the course 
of this study it was not deemed necessary to generate ascitic fluids as a source of concentrated 
antibody for purification. Instead hybridoma cell lines were cultured in either protein free 
media or 10% NCS/G-MEM, with the method of antibody purification being dependant on 
the media type used. For instance, 500ml hybridoma cell cultures (maintained in protein free 
media) were sterile filtered, adjusted to pH 8.8 (using 2M Tris/HCl, pH 8.8) and applied to a 
pre-equilibrated (50mM Tris/HCl, pH8.8) 5ml Mono-Q column (Pharmacia) at a flow rate of 
0.5ml/min (overnight at 4°C). Monoclonal antibodies were eluted by increasing the salt 
concentration using 1M NaCl/50mM Tris-HCl (pH8.0) and appropriate fractions were 
assessed by SDS-PAGE and stored at 4°C or 20°C.
Small scale antibody preparations (50ml or less in protein free media) were the primary 
source of antibodies used in biological assays. These were concentrated by amicon 
ultrafiltration to a final volume of 2ml then injected into a pre-equilibrated DEAE-sepharose 
ion exchange column (section 2.1.7). Although a nominal amount of antibody was retained 
by the matrix (and later eluted with 150mM NaCl/50mM Tris-HCl, pH 8.0), the majority of 
antibody solution was collected in the flow through fractions. Alternatively, by raising the pH 
of the antibody solution (pH 8.5), antibodies were retained by the matrix and eluted as 
described above.
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Antibodies were purified from cell cultures maintained in 10% NCS/G-MEM using protein- 
A/G columns by methods described in Harlow and Lane (1988). Because mouse antibodies 
of the IgGl subclass do not have a high affinity for protein-A, the salt concentration of the 
antibody solution was raised (3m NaCl final concentration) to increase the strength of 
hydrophobic bonds that are the basis for the interactions. In addition, cell culture supernatants 
were adjusted to pH 8.9 (through addition of 1/10 volume of 1M Sodium Borate, pH 8.9). 
Antibody solutions were applied to a 1ml protein-A (or protein-G) Sepharose 4B column 
(Sigma), then beads were washed with 10 volumes each of 3M NaCl/50mM Sodium Borate 
(pH8.9), and 3M NaCl/lOmM Sodium Borate (pH 8.9) before elution with lOOmM glycine 
(pH 3.0) into eppendorf tubes containing 50pl of 1M Tris/HCl (pH 8.0).
2.4 Epitope Mapping: Limited proteolysis and chemical cleavage.
2.4.1 Proteolytic cleavage of 23kd protease.
Aliquots of purified recombinant 23kd protease (methods 2.1.3/4/7 and 8) at a concentration 
of 0.8mg/ml, were stored at -20°C in 150mM NaCl/50mM Tris-JCL, pH 8.0. Trypsin, 
Chymotrypsin, and Endoproteinase Glu-C (Staphylococcus aureus V8) were all HPLC pure 
(Sigma) and stored as freeze-dried powder. Stock solutions of trypsin (lOmg/ml in ImM 
HCL), chymotrypsin and endoproteinase Glu-C (5mg/ml in ddH2O), were prepared fresh 
prior to limited proteolysis experiments (Carrey, 1990). The ratio of proteolytic enzymes to 
23kd protease ranged from 1/100 to 1/1000 (w/w), at either 25°C or 37°C. Proteolysis was 
allowed to proceed for one hour, during which samples were removed at defined time points 
and stored at -70°C, before being examined by SDS-Page and Western blotting.
2.4.2 Chemical cleavage using Cyanogen Bromide (CNBr).
CNBr (purchased from Sigma) was weighed in a fume hood, and 100 Molar fold excess (in 
10M acetonitrile) over methionines was added to purified 23kd protease (0.8mg/ml) pre­
treated with 0.1M B-mercaptoethanol for two hours at 37°C. The mixture was flushed with 
nitrogen gas, sealed and incubated for 24 hours in the dark (in a fume hood). After chemical 
cleavage, 10 volumes of ddH2O was added to remove excess CNBr, frozen at -70°C
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overnight and freeze-dried for 24 hours. The lyophilised powder was resuspended in 200|il 
ddH2O and aliquots analysed by SDS-Page and Western blotting.
2.4.3 Multiscreen blots of cleavage products.
SDS-Page gels were prepared with a two well comb. Samples to be examined were loaded 
into the elongated well (200pl), and pre-stained or low molecular weight markers into the 
first well (20pl). Gels were electroblotted, then blocked for one hour or overnight at 4°C 
(methods 2.2.3). Blots were placed into a BioRad Protean II Multiscreen apparatus in 
accordance with the manufacturers recommendations. Cell culture supernatants derived from 
monoclonal cell lines of interest, were diluted according to titre (1/100 to 1/1000) in 1ml 
blocking buffer and loaded into the multiscreen (usually lanes 5 to 20). The apparatus was 
tilted during loading to prevent the accumulation of air bubbles in the lanes. After 30 minutes 
incubation, lanes were flushed twice with blocking buffer, the blot removed, and washed for 
30 minutes (3x lOmin) in blocking buffer. Addition of secondary antibody and developing 
are described in methods 2.2.3.
2.4.4 Protein sequencing.
i) SDS-PAGE:
A 12.5% separating gel was prepared by mixing 1.66ml of 30% acrylamide/0.8% piperazine 
diacrylamide (PDA) with 1.33ml ddH2O, and 1ml of 4x gel buffer (0.4% SDS; 1.5M 
Tris/HCl, pH 8.8), then degassed for 10 minutes. To polymerise the gel, 2pl of TEMED and 
15pl of 10% ammonium persulphate were added before pouring between the glass plates in a 
BioRad minigel apparatus. The gel was overlaid with water saturated butyl-alcohol, which 
was replaced after one hour with lx gel buffer, covered with cling film overnight at 4°C. 
Stacking gel was prepared by mixing 0.99ml of 30% acrylamide/0.8% PDA, 1.5ml of 4x gel 
buffer, and 3.5ml ddH2O, degassed, then polymerised by the addition of 2pl TEMED and 
15pl of 10% ammonium persulphate. The gel was left for 3 to 4 hours at room temperature 
after insertion of the comb.
The lower reservoir of the gel apparatus was filled with electrophoresis buffer (75mM Tris; 
O.58M Glycine; 0.1% (w/v) SDS), the upper with lx upper electrode buffer (0.4% (w/v) 
SDS; 125mM Tris/HCl, pH 6.8) plus 0.75ml of lOmM glutathione per 150ml of upper
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buffer. The gel was pre-run with 10|il sample buffer mix (1.25ml upper electrode buffer, 
25% glycerol; 0.6mM B- mercaptoethanol; 0.02% bromophenol blue) for one hour at 
15mA/gel. The gel tank was washed out, and the lower reservoir filled with electrophoresis 
buffer , whilst the upper reservoir was filled with 150ml electrophoresis buffer containing 
150|ll of lOOmM sodium thioglycolate. Samples were loaded with sample buffer and a 
constant current of 15mA/gel maintained until the dye front was 1cm from the bottom of the 
gel.
ii) Western blotting:
After protein separation by SDS-Page, proteins were electroblotted onto a problot membrane 
(Applied Biosystems) using a BioRad mini trans-blot cell. The membrane was cut to gel size 
and soaked in methanol for 3 minutes. The membrane, two pieces of Whatman 3MM filter 
paper, gel, and fibre pads were soaked in transfer buffer (lOmM CAPS, pH 11.0; 10% 
methanol) for 10 minutes. This was repeated several times to eliminate glycine from the 
electrophoresis buffer. A blotting sandwich was prepared by layering the gel on top of filter 
paper and fibre pad then placing the membrane on top of the gel. Filter paper and fibre pad 
were placed on top of the membrane, and the sandwich clamped within a holder which was 
placed into the buffer tank. Transfer buffer and cooling block were inserted into the tank and 
the apparatus was set at a constant current of 300mA for two hours (cooling block was 
changed after one hour). The membrane was stained (0.1% amido black; 40% methanol; 1% 
acetic acid) for 1 minute, then destained with 40% methanol/1% acetic acid overnight.
iii) Sequencer analysis.
Bands of interest were cut out of the membrane and proteins sequenced using a Procise 
Protein Sequencer coupled with an Applied Biosystems HPLC apparatus. Western blots in 
parallel with amido black staining aided localisation of protein bands of interest.
2.5 Epitope Mapping: Deletion mutants of the 23kd protease.
Many of the techniques described in this section are based on methods outlined by Sambrook 
etal. (1989).
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2.5.1. Vector pGEXcPK and oligonucleotide primer design.
Expression vector pGEXcPK was constructed by Hanke et al. (1994) by inserting the PK tag 
linker into the EcoRl site of the pGEX-2T polylinker, abolishing the linker 3'- end EcoRl 
site, so that genes of interest can be cloned between BamHl and EcoRl.
Oligonucleotide primers were designed with BamHl (GGATCC) and EcoRl (GAATTC) 
sites in reading frame with the PK tag, Figure 2.1. The numbering of deletion mutants refers 
to the first and the last amino acids from the 23kd protease that will be expressed as a deletion 
mutant clone. Oligonucleotide primers are listed below:
1: 5,/GCT<GGATCC;AT(qGGdTCCkGrIjGAG|bAG1GAA?t 3’
2: 5' GGGAATTCAGTGTACGCCCCCAGTCTC 3'
3: 5’ GGGGGAAGGAATTCTGGCGCTACGGCGCAGG 3*
4: 5' ATCCATGGGAATTCGGGGCCAGTTGGCAAAGGC 3'
5: 5’ GTGACAAAAAGGAATTCCGCTCCTAATCTGCG 3’
6: 5' CTGCGCCGTGGATCCATTGCTTCTTCCCCCG 3'
7: 5’ GCGAGACTGGATCCGTACACTGGATGGCC 3'
8: 5' GTACCTGGGGAATTCTAAGCATGGAGTTGGG 3’
9: 5’ GCGGAAGTAGGGAATTCGGCGCTCCAGGAAG 3'
Using the amplifier software package (Macintosh) a simulation of PCR reactions was 
performed using Ad2 genome as a template. Primers were predicted to bind without 
mismatches, and were synthesised on a Beckman 1000 DNA Synthesiser. Synthesised 
primers were resuspended in 200pl HPLC grade water, and concentrations determined by 
measuring the absorbance at 260nm of a sample diluted 1/100 with water (with one 
absorbance unit being equivalent top 50pg/ml single stranded DNA, and the average 
molecular weight of one base being 330 daltons).
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l->
1 atg ggc tcc agt gag cag gaa ctg aaa gcc att gtc aaa gat ctt ggt tgt ggg cca tat
1 Met gly ser ser glu gin glu leu lys ala ile val lys asp leu gly cys gly pro tyr
61 ttt ttg ggc acc tat gac aag cgc ttt cca ggc ttt gtt tct cca cac aag etc gcc tgc
21 phe leu gly thr tyr asp lys arg phe pro gly phe val ser pro his lys leu ala cys 
7->
121 gcc ata gtc aat aeg gcc ggt cgc gag act ggg ggc gta cac tgg atg gcc ttt gcc tgg
41 ala ile val asn thr ala gly arg glu thr gly gly val his tip met ala phe ala trp 
<-2
181 aac ccg cgc tea aaa aca tgc tac etc ttt gag ccc ttt ggc ttt tct gac caa ega etc
61 asn pro arg ser lys thr cys tyr leu phe glu pro phe gly phe ser asp gin arg leu 
6->
241 aag cag gtt tac cag ttt gag tac gag tea etc ctg cgc cgt age gcc att get tct tcc
81 lys gin val tyr gin phe glu tyr glu ser leu leu arg arg ser ala ile ala ser ser 
<-3
301 ccc gac cgc tgt ata aeg ctg gaa aag tcc acc caa age gtg cag ggg ccc aac teg gcc
101 pro asp arg cys ile thr leu glu lys ser thr gin ser val gin gly pro asn ser ala
361 gcc tgt gga eta ttc tgc tgc atg ttt etc cac gcc ttt gcc aac tgg ccc caa act ccc
121 ala cys gly leu phe cys cys met phe leu his ala phe ala asn tip pro gin thr pro 
<-4
421 atg gat cac aac ccc acc atg aac ctt att acc ggg gta ccc aac tcc atg ctt aac agt
141 met asp his asn pro thr met asn leu ile thr gly val pro asn ser met leu asn ser 
<-8
481 ccc cag gta cag ccc acc ctg cgt cgc aac cag gaa cag etc lac age ttc ctg gag cgc
161 pro gin val gin pro thr leu arg arg asn gin glu gin leu tyr ser phe leu glu arg 
<-9
541 cac teg ccc tac ttc cgc age cac agt geg cag att agg age gcc act tct ttt tgt cac
181 his ser pro tyr phe arg ser his ser ala gin ile arg ser ala thr ser phe cys his 
<-5
601 ttg aaa aac atg
201 leu lys asn met
Figure 2.1: Oligonucleotide primers used to amplify regions of the Ad2 23kd protease 
gene. Regions of the 23kd protease gene corresponding to synthesised primers are underlined. The first and 
last amino acids of expressed deletion mutants are highlighted.
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2.5.2 Polymerase chain reaction (PCR).
For deletion mutagenesis, synthetic oligonucleotides were used to amplify regions of the Ad2 
23kd protease gene in a polymerase chain reaction (Saiki et al., 1985). The products were 
amplified using Ad2 DNA (kindly provided by Ian Leith, University of St.Andrews) as a 
template. The polymerase used was Venttm (New England Biolabs) together with a lOx 
concentration reaction buffer. The reactions were earned out in a final volume of IOOjlxI:
lx reaction buffer.
200qM each of dGTP, dATP, dTTP and dCTP (Pharmacia).
1 pi of DNA template.
280ng each of 5' (upstream) and 3' (downstream) primers.
1.5 Units Vent1111 polymerase.
The reactions were overlaid with 50pl of sterilised white paraffin to prevent evaporation, and 
placed in a programmable heating block (Techne Dry-Block PHC-1). The conditions used for 
PCR reactions were:
Cycle 1 (melting) 94°C for 1.5 minutes 
Cycle 2 (annealing) 55°C for 1.5 minutes 
Cycle 3 (elongation) 72°C for 2 minutes
Repeated 30 times and held at 72°C for 9.9 minutes.
The reaction mixture was removed from under the paraffin overlay to a fresh tube and mixed 
with 50pl phenol:chloroform:isoamylacohol (Amresco,UK), at a ratio of 25:24:1, pre-mixed 
and buffered between pH 6.5 and 6.9. The mixture was then vortexed for 20 seconds, and 
centrifuged at 13000g (bench top microfuge) for 5 minutes. The aqueous top phase was 
carefully removed to a fresh tube and 3ftl of Lithium Chloride (10M stock), and 220|il 
absolute alcohol was added. The mixture was kept at -20°C for 20 minutes and the 
precipitated DNA pelleted by centrifugation at 13000g for 10 minutes. After discarding the
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supernatant, the pellet was vacuum dried (Howe Gyrovap GT) for 10 minutes and 
resuspended in lOpl of ddH2O. DNA was stored at -20°C.
2.5.3 Restriction digests of PCR products and vector DNA.
In a typical reaction, ljig of vector DNA (pGEXcPK) was added to lpl of lOx multicore 
buffer (Promega) and l|ll each of BamHl and EcoRl (Promega) and the reaction allowed to 
proceed for 1.5 hours at 37°C. Usually about 500ng of PCR amplified DNA was obtained, 
which was mixed with lid each of BamHl and EcoRl with 5pl multicore buffer in a total 
volume of 50pl. Digestion occurred over two hours at 37°C.
2.5.4 Agarose gel electrophoresis and purification of restricted DNA.
DNA samples were separated by agarose gel electrophoresis using a Pharmacia DNA 100 gel 
rig in accordance with manufacturers instructions. Agarose gels of 1 to 2% (restricted DNA 
of 0.2kb or less were loaded onto 2% gels) were prepared by dissolving lg of agarose 
(Sigma) in 70ml ddH2O, boiled, and added to 10ml of lOx TAE buffer (150mM EDTA; 3M 
Tris/acetic acid, pH 8.0), 20ml ddH2O, and lOOpl of 0.5mg/ml ethidium bromide. Gels 
were cooled slightly before pouring, and care taken to ensure that 2% gels did not have 
trapped air bubbles that would interfere with DNA migration. Appropriate combs were added 
and the gel allowed to set (usually one hour). DNA samples were mixed with 2.5pl of 5x 
DNA loading buffer (0.05% bromophenol blue; 40% glycerol; 50mM EDTA; 60mM 
Tris/acetic acid, pH 8.0) and loaded into the wells. A DNA standard lkb DNA ladder (Gibco- 
BRL) was used throughout. Gels were electrophoresed at lOOv constant voltage until the dye 
front had migrated to 2/3 the gel length. The DNA band were examined on a UV (365nm). 
Vector and amplified restricted DNA of the predicted size, were excised from gels using a 
sterile scalpel and transferred to a 1.5ml eppendorf tube. Gel slices could be stored at -20°C 
or DNA extracted using a Qiagen DNA extraction kit in accordance with the manufacturers 
instructions. Pellets were air dried for 10 minutes and DNA eluted with 20ll1 ddH2O. DNA
was stored at -20°C.
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2.5.5 Ligation of vector and insert DNA.
The ligation of purified insert and vector DNA was achieved using T4 DNA ligase 
(Promega). The ligation mixtures comprised of 1 pi vector DNA and 5ptl insert in a total 
volume of 20pl, containing 2pl lOx ligase buffer and lpl T4 DNA ligase. The ligation 
reactions were allowed to proceed for four hours at room temperature, and control ligations 
of vector DNA alone were done in parallel. Although no attempt was made to quantify the 
molar ratio of insert to vector DNA, these procedures proved to be adequate. After four 
hours, lOpil of the ligation mixture was used to transform competent E.coli (XL1 Blue), 
ligated DNA was not stored.
2.5.6 Preparation of competent bacterial cells.
A 0.5ml aliquot of overnight culture of XL 1 blue cells was inoculated into 50ml LB medium. 
This was incubated at 37°C (with shaking) until the culture reached an optical density of 
approximately 0.3 at 600nm. The culture was centrifuged at 3000rpm for 10 minutes (IEC 
Centra-R) at 4°C. Cell pellets were resuspended in 5ml of sterile ice-cold 0.1M MgCl2, and 
centrifuged as before. Cell pellets were resuspended in 2ml of sterile ice-cold 0.1M CaCl2- 
The preparations were left on ice for at least 30 minutes before being used in transformations. 
XLlblue cell stocks were maintained on agar plates containing lOOpg/ml tetracycline (Tet), at 
4°C.
2.5.7 Transformation of competent bacteria.
Competent XLlblue cells (200p.l aliquots) were kept chilled on ice, and lOptl of ligation mix 
(methods 2.5.5) or Ipl of purified plasmid (methods 2.5.9) were added. After 30 minutes 
(on ice) the samples were heat shocked in a water bath set at 42“C, for 90 seconds, and then 
immediately placed on ice for a further 5 to 10 minutes. Transformed cells and non- 
transformed competent cell controls were spread onto Amp/Tet agar plates using a sterilised 
glass rod, left for 15 minutes, and finally incubated overnight at 37°C.
2.5.8 Preparation of agar plates.
Molten LB/agar was kept at 55°C until equilibrated at this temperature. Ampicillin and 
Tetracycline were added to a final concentration of O.lmg/ml, and the agar poured into sterile
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petri-dishes (approximately 20ml/dish). After flaming the surface of the agar to remove 
bubbles, plates were left for one hour to solidify and used the same day.
2.5.9 Small scale plasmid preparation (miniprep).
The method used throughout is outlined in the Qiagen plasmid handbook. Single colonies 
from selected agar plates were used to inoculate 3ml of LB/Amp medium, then grown 
overnight at 37°C. Cells were pelleted (bench top microfuge), and resuspended in buffer Pl 
(lOmM EDTA; Tris/HCl, pH 8.0) containing lOOpg/ml A (Qiagen), and 0.3ml of buffer P2 
(200mM NaOH; 1% (w/v) SDS), then incubated at room temperature for 5 minutes. Ice- 
chilled buffer P3 (3M Potassium acetate, pH 5.5) was added (0.3ml), then cell lysates were 
mixed gently and incubated on ice. After 10 minutes, lysates were centrifuged at 13000g 
(microfuge) for 15 minutes. The DNA was precipitated from the supernatant by adding 0.8 
volumes of isopropanol, and centrifuged for 15 minutes at 130000g. DNA was washed twice 
with 70% ethanol and redissolved in 40pl ddH2O.
To check for potential clones, 2|il of DNA was incubated with BamHl, EcoRl, and 
multicore buffer (IjllI each) in a total volume of 10pl, and left for 1.5 hours at 37°C. Digests 
were examined by agarose gel electrophoresis, and positive clones used for expression of 
deletion mutants.
2.5.10 Expression and purification of deletion mutants.
Deletion mutant plasmids were transformed into E.coli BL21 (DE3) cells. A single colony 
was picked from a selective agar plate and used to inoculate 5ml LB/Amp medium, and 
grown overnight at 37°C. From the starter culture, 1ml was used to inoculate 250ml of 
LB/Amp and grown until an optical density of between 0.5 and 0.8 was observed at 600nm. 
Expression of deletion mutants was induced by the addition of IPTG at a final concentration 
of O.lmM. After six hours, cells were harvested by centrifugation (lOOOOrpm/lOmin), and 
washed once in STE buffer (section 2.1.1), then pelleted as before (methods 2.1.2). Pellets 
were stored at -20°C.
Thawed pellets were resuspended in 3ml STE buffer with Pefabloc (Boehringer Mannheim), 
added to a final concentration of 4mM, and supplemented with lysozyme (lOOpg/ml). The 
pellets were incubated on ice for 15 minutes. Triton X-100 was added (1% final
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concentration), then lysates sonicated (3x 15 second bursts/2min on ice), and centrifuged at 
15000g (JA-17 rotor, Beckman J2-21 centrifuge) for 5 minutes, at 4°C. Supernatant fractions 
were added to 0.5ml glutathione Sepharose-4B beads (pre-swollen in PBS) and incubated in 
10ml plastic tubes, on ice, mixing periodically. After 30 minutes, the mixture was pelleted by 
centrifugation (1000g/2min) and supernatant aspirated off the beads. The glutathione 
Sepharose beads were washed 10 times with ice-cold PBS. Fusion proteins were eluted with 
lOmM reduced glutathione/PBS, and examined by Western blotting with appropriate 
monoclonal antibodies.
2.6 Epitope mapping: Overlapping peptides.
2.6.1. Design of overlapping peptides.
Synthesised peptides which extend over two regions of the Ad2 23kd protease (R48 to P101, 
and F133 to S19) are listed below:
1 (57/71) FAWNPRSKTCYLFE-S
2 (67/81) CYLFEPFGFSDQRLK-S
3 (77/91) DQRLKQVYQFEYESL-S
4 (87/101) EYESLLRRSAIASSP-S
6 (87/95) EYESLLRRS
7 (82/90) QVYQFEYES
8 (133/146) FANWPQIPMDHNPT-S
9 (142/156) DHNPTMNLITGVPNS-S
10 (151/164) TGVPNSMLNSPQVQ-S
11 (161/176) PQVQPTLRRNQEQLYS
12 (183/194) PYFRSHSAQIRS
13 (176/187) SFLERHSPYFRS
14 (171/182) QEQLYSFLERHS
15 (175/189) YSFLERHSPYFRSHS
All peptides were synthesised on serine linked Pepsyn resin, although in some instances the 
serine was not native to the Ad2 23kd protease (-S). The start and finish amino-acids indicate
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the position of these residues in the intact protein. Peptide 5 (region 1) was previously 
synthesised (Webster, 1992) and has the sequence; RETGGVWHMAFAWN (48/61). 
Overlapping peptides synthesised on cellulose support (SPOTs test; Genosys) were designed 
as follows:
For region 1 (R63 to 1105) all peptides were of 13 residues in length, shifted by 2 amino 
acids i.e.;
RSKTCYLFEPFGF
KTCYLFEPFGFDQ
...................etc.
For region 2 (D102 to K202) peptides of 13 residues in length, overlapping by 5 amino-acids 
were synthesised i.e.;
DRCITLIKSTQSV
STQSVQGPNSAAC
............... etc.
2.6.2 Peptide synthesis.
The method used is essentially the same as that described by Webster (1992). All peptides 
were synthesised by solid phase fluorenyl methoxy carbonyl (Fmoc) polyamide chemistry. 
The Fmoc penta fluorophenyl derivatives of amino acids and Fmoc-L-Ser(But)-Pepsyn resin 
were purchased from Millipore. Plastic columns (1.5ml) and 10pm pore filters were obtained 
from Mobitec. Dimethylformamide (DMF), glacial acetic acid, acetonitrile, and trifluoracetic 
acid (TFA) were all HPLC grade from Rathburn. Piperidine was purchased from Applied 
Biosystems. Ethanedithiol, anisole, tertiary amyl alcohol, and 1-hydroxybenzotriazole 
(HOBT) were obtained from Aldrich. DMF was routinely tested for dimethylamine using 
fluorodinitrobenzene (FDNB) from Sigma, as descibed by Webster (1992). The apparatus 
used for synthesising peptides consisted of a plastic box with 5 columns with filters and a 
outlet for applying vacuum by reduced pressure.
Resin (75mg) was resuspended in 1ml DMF and transferred to a column and sucked dry 
using the vacuum line in a fume hood. Columns were washed three times with DMF (vacuum 
being applied each time), then filled with piperidine (20% in DMF), Dried, and filled again,
but allowing to percolate through (approximately 15 minutes). Amino-acids (30-40mg) were 
dissolved in 300pl DMF and lOOpl HOBT (1.3g/10ml DMF), vortexed, and added to the 
column, after it had been washed 4 times with DMF to remove any residual piperidine. The 
whole apparatus was placed in an incubator (25°C) and left for 1 to 1.5 hours. This 
procedure was repeated until all amino-acids had been added.
The resin was deprotected and washed sequentially with DMF, t-amyl alcohol, glacial acetic 
acid,t-amyl alcohol (2x 0.5ml each) then ether (4x 0.5ml). An eppendorf tube was placed 
underneath each column, and 200pl cleavage reagent added (TFA containing a total of 5% of 
the appropriate scavengers such as anisole, or phenol if peptides contained arginines). Tubes 
were left for one to two hours or overnight if arginine was present, then TFA was vacuum 
filtered into the eppendorf tube, and resin washed with TFA. A stream of nitrogen gas was 
used to evaporate TFA, and 500pl of ether was added to precipitate peptides. Peptides were 
finally washed 5x with ether, then redissolved in water and freeze-dried.
2.6.3 Peptide purification using High Performance Liquid Chromatography 
(HPLC).
HPLC grade S-acetonitrile, TFA, and water were obtained from Rathburn. A Gilson HPLC 
connected to an Apple II computer with pre-set gradient programs was used throughout. 
Freeze-dried peptides were weighed, dissolved in 1ml 0.1% TFA/water, then filtered 
(0.2pm Acrodisc). An RsiL Cl8 HL column (5pm sylane particles packed into a total column 
volume of 4.15ml), was washed with 100% acetonitrile/0.1% TFA for 25 minutes, then 
equilibrated for 15 minutes with 0.1% TFA/water. Sample (1ml) was injected, and a 
continuous gradient applied (0 to 50% acetonitrile in 25 minutes), and 1ml fractions collected 
after 10 minutes (approximately 20% acetonitrile). The elution profile was monitored at 
226nm, and purified peptides analysed by capillary electrophoresis. Aliquots of HPLC 
fractions (lOpl) were added to lOpl CE buffer and 80pl filtered water then examined using 
the CZE method (methods 2.2.5). In addition, peptides were also sequenced (methods 
2.2.4). Purified peptides were stored at -20°C.
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2.6.4. Determination of epitopes by competitive ELISA.
Immulon micro titer plates (Dynatech ltd) were coated with lOOpl of 1% glutaraldehyde (in 
PBS) and left overnight at 4°C. Plates were washed 3 times with PBS, and lOOpl of purified 
23kd protease (methods 2.1) were added to a final concentration of 5pg/well in PBS, then 
left overnight at 4°C. Plates were rinsed with 150jll1 wash buffer (0.5% (w/v) dried milk; 
0.1% (v/v) Tween-20; PBS) three times and incubated in blocking buffer (5% (w/v) dried 
milk; PBS) for 3 hours at 37°C, or overnight at 4°C. ELISA plates were again rinsed with 
wash buffer 3 times. In a separate 96 well plate, a doubling dilution series of cell culture 
supernatant was added to an equal volume of peptide solution (100(Ltg/ml in PBS) and 
incubated for one hour at 37°C. Antibody/peptide solutions were transferred to corresponding 
wells on the 23kd protease coated ELISA plate and left for an additional hour at 37°C. ELISA 
plates were rinsed 3 times (150pl each) with wash buffer, and lOOpl of secondary antibody 
(anti-mouse Ig horseradish peroxidase linked whole antibody, Amersham), diluted 1/5000 
with wash buffer, was added to each well. Incubations were at 37°C for 30 minutes, then 
plates were rinsed extensively with wash buffer, and finally with PBS alone. Peptide 
inhibition of antibody binding to 23kd protease was detected by the addition of 3,3',5’,5- 
Tetramethylbenzidine (TMB) liquid substrate system (Sigma). TMB was added at 50|il/well 
and colour development read at 655nm after a one hour incubation at 37°C (in darkness).
2.6.5 Overlapping peptides bound to cellulose (SPOTs test).
Overlapping peptides synthesised on cellulose membranes by fluorenyl carbonyl (Fmoc) 
chemistry (Genosys,UK), were used for epitope mapping in accordance with manufacturers 
instructions.
Membranes were rinsed in methanol (HPLC grade, Rathburn) for 3 minutes, then incubated 
in 20mls of TBS (25mM Tris, pH 8.0; 144mM NaCl) for 10 minutes. Concentrated blocking 
buffer (supplied by Genosys) diluted 1/10 with T-TBS (0.1% (v/v) Tween-20; TBS, pH 
8.0) was added, and membranes blocked overnight at 4°C. After blocking, membranes were 
washed 3 times (15 minutes each) in T-TBS, and monoclonal antibody solution added at a 
dilution of 1/200 in T-TBS. After a 3 hour incubation, membranes were washed 3 times as 
described above. The cellulose membranes were incubated with secondary antibody (anti­
mouse Ig horseradish peroxidase linked whole antibody) diluted 1/5000 in T-TBS, for 30
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minutes, with gentle agitation, followed by 3 washes in T-TBS and finally in TBS alone. The 
blots were developed as described in methods 2.2.3.
Cellulose membranes were re-probed with several monoclonal antibody supernatants. 
Regeneration of membranes was achieved by washing in 20ml ddH2O, then 20ml DMF, and 
finally 20ml ddH2O for 10 minutes each. Regeneration buffer A (8M Urea; 1% SDS; 
ddH2O) was added for 10 minutes, followed by an incubation in regeneration buffer B (50% 
ethanol; 10% acetic acid; ddH2O) for 10 minutes. Methanol was added for 10 minutes, and 
the SPOTs procedure described above repeated in full, for new antibody solutions.
2.7 Adenovirus (type 2) infection of HeLa cells.
2.7.1 HeLa monolayer and spinner cell culture maintenance.
Monolayer HeLa cells (generously provided by Prof.J.Lamb, University of St.Andrews, and 
originally purchased from Imperial Labs) were maintained in 75cm^ flats (Sterilin) with 
25ml G-MEM/10%NCS, at 37°C/5%CO2. Cells were passaged every 3 days by washing the 
cell monolayer with trypsin/EDTA (5ml) and overlaying the monolayer with 2ml 
trypsin/EDTA. After approximately 2 minutes, 8ml of G-MEM/10%NCS was added and the 
flat gently tapped to release cells into suspension. Generally, 1/5 or 1/10 dilutions of cell 
suspension were seeded into new 75cm^ flats. HeLa spinner cells were maintained in S- 
MEM/10%NCS at 37°C. When the cells reached a density of 5x10^ cells/ml they were 
passaged to give a cell concentration of 2x10^ cells/ml.
Periodically cell stocks were examined for mycoplasma contamination (methods 2.8.2).
2.7.2 Preparation of wild type Ad2 virus stocks.
i) Infection of HeLa spinner cells:
HeLa spinner cell cultures (6 litres) were grown to a density of 3x10$ cells/ml, then 
centrifuged for 30 minutes at 3000rpm in a Mistral 6L centrifuge. Cell pellets were 
resuspended in 250ml of S-MEM and 1ml of Ad2 arcton extract added. After 2 hours at 
37°C, S-MEM/2%NCS was added to a final volume of 6 litres. Cells were harvested at 72 
hours post infection (h.p.i) by centrifugation (as before), the cell pellet was washed with 
PBS, and resuspended in 48ml of lOmM Tris/HCl, pH 7.0. Cell suspension (12ml) and
40ml of trichloro-trifluoro-ethane (arcton) were added to 4x 50ml sterile centrifuge tubes and 
shaken for 30 minutes at 4°C using a mechanical shaker. Extracts were centrifuged at 800g 
(IEC-Centra 3R) and the aqueous layer removed then clarified by centrifugation at lOOOOg for 
30 minutes (JA-17 rotor, Beckman J2-21 centrifuge). Fractions were aliquoted (1ml) and 
stored at -70°C. Titre of virus stocks were determined by plaque assay.
ii) Plaque assay:
HeLa monolayer cells were grown to 90% confluence in 50mm^ petri dishes (sterilin). Media 
was aspirated from the cell monolayer and replaced with 0.1ml of serially diluted vims stock 
(range of 10"? to 10“i0 used) and incubated for one hour at 37°C/5%CO2- Duplicate assays 
were performed for all dilutions, and uninfected controls were included. When the incubation 
was completed, 4ml of agar overlay (20ml 2.5% (w/v) Noble agar; 20ml 5x G-MEM(- 
glutamine); 10ml tryptose phosphate broth (2.95g/100ml); 9ml sodium bicarbonate 
(2.25g/100ml); 2ml NCS; 2ml 1M MgCl; 2ml glutamine (2.9g/100ml); 100 Units each of 
Penicillin and Streptomycin; ultrapure water to 100ml), cooled to 42°C, was added gently to 
the side of the petri dish (Precious and Russell, 1991). After the overlay had set, dishes were 
placed at 37°C/5%CO2 for 4 days then 2ml of agar overlay was added. Cells were fixed after 
a further 4 days by adding 10% (v/v) formal saline and left overnight. After removing the 
agar overlay, monolayers were stained with 0.1% crystal violet solution for 20 minutes to 
observe plaques.
2.7.3. Ad2 infection of HeLa monolayer cells:
HeLa monolayer cells grown in 75cm^ flats were infected with Ad2 wild type virus stock, or 
Ad2tsl mutant virus (kindly donated by Ailsa Webster and Ian Leith, University of 
St-Andrews) at approximately 10 p.f.u/cell. When cells were approximately 70% confluent, 
media was aspirated off, and cell monolayers washed with pre-warmed G-MEM. HeLa cells 
were incubated with virus (in 5ml G-MEM) for one hour at 37°C/5%CO2. The virus solution 
was replaced with 25ml G-MEM/2%NCS and left at 37°C/5%CO2 until harvesting at defined 
time points. Ad2tsl infected cells were incubated at 39°C (non-permissive) or 33°C 
(permissive) temperatures.
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HeLa monolayer cells for immunocytochemical studies were grown on Henley-Wessex 
multispot slides in G-MEM/10%NCS ( 3 slides/lOOmm^ dish) and infected as described 
above. Cells were grown on slides for a minimum period of 24 hours before infection.
2.7.4. Preparation of nuclear and cytoplasmic extracts.
All protease inhibitors were obtained from Sigma (except PefablocSC which was purchased 
from Boehringer Mannheim), and stored at -20°C. Lysis buffers were stored at 4°C and 
protease inhibitors added when required. .
i) From HeLa monolayer cells:
At fixed times post infection, HeLa monolayer cells were washed with ice-cold PBS, and 
removed from 75cm2 flats (using a rubber cell scraper) into 1ml PBS/flat. Cells were 
centrifuged at 6000rpm for 2 minutes at 4°C (Eppendorf centrifuge S402), and the pellet 
washed in 0.5ml PBS, then re-centrifuged and stored at -70°C. Addition of lOOpl lysis 
buffer (50mM sodium flouride; 5mM tetra sodium pyro-phosphate; ImM sodium 
ortho vanadate; lOmM B-glycerophosphate; 0.5% NP40; 2mM EDTA; 20mM Na2HPO4; 
ddH2O) containing protease inhibitors (ImM Leupeptin; ImM Pepstatin; lOOmM Pefabloc; 
ImM Bestatin; ImM TPCK), then centrifugation at 14000rpm for 10 minutes at 4°C, yielded 
cytoplasmic extracts (supernatant fraction) which were stored at -70°C. Nucleoplasmic 
extracts from pellets were obtained by adding 5M NaCl to lysis buffer to give a final salt 
concentration of 425mM. Lysates were incubated on ice for 20 minutes, then centrifuged at 
14000rpm for 15 minutes at 4°C. The supernatant was stored at -70°C.
ii) Hypotonic lysis of spinner cells:
HeLa spinner cells (2 litres) were centrifuged at 1500g (Mistral 6L centrifuge) for 15 
minutes, washed in PBS, and pelleted. The pellet was resuspended in 5ml hypotonic lysis 
buffer (lOmM Hepes/NaOH, pH 7.9; lOmM KC1; 1.5mM MgCl2) containing protease 
inhibitors (see above), and left on ice for 10 minutes to allow cells to swell. The cells were 
lysed by 15 strokes in a glass Dounce homogeniser (type B pestle). Large particulate matter, 
including nuclei, were sedimented at lOOOg for 10 minutes at 4°C. The supernatant was 
centrifuged at lOOOOOg for 30 minutes at 4°C (Beckman TL-100 Ultracentrifuge) to give the
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soluble cytoplasmic extract (also referred to as the SI00 extract). Nuclei were lysed by 
adding high salt buffer (20mM Hepes/NaOH, pH 7.9; 420mM NaCl; 25% glycerol; 1.5mM 
MgCl2; 0.2mM EDTA) containing protease inhibitors, followed by 15 strokes of the Dounce 
homogeniser. In some instances, 0.5% NP40 was added to nucleoplasmic fractions to 
disrupt lipids (Stow and Hay, 1993). Lysates were centrifuged at lOOOOOg for 30 minutes 
(4°C) and the supernatant stored at -70°C.
2.7.5 Fixation of Hela monolayer cells for immunocytochemistry.
Glutaraldehyde (25% aqueous stock stored at -20°C) and osmium tetroxide (2% aqueous 
stock stored at room temperature) were purchased from Sigma. Paraformaldehyde was 
obtained from BDH and 40% Formaldehyde from May and Baber ltd. Sheep serum was 
obtained from the Scottish Antibody Production Unit (SAPU).
Infected and uninfected cells grown on glass slides were washed three times with PBS to 
remove any traces of media prior to fixation. For light microscopy, cells were incubated with 
fixative (5% (v/v) formaldehyde; 2% (w/v) sucrose; 1% (v/v) sheep serum) for 10 minutes. 
In some instances, 4% paraformaldehyde solutions were prepared by adding 8 grams to 
100ml ddH2O, and heating in a fume hood until dissolved. After cooling, 100ml of 2x PBS 
was added. Paraformaldehyde solutions were prepared as required.
For electron microscopy, the above fixatives were used in addition to 1% (v/v) 
glutaraldehyde/PBS, pH 7.4. Mixtures of fixative solutions, such as 2.05% PfG (2% (w/v) 
paraformaldehyde; 0.05% glutaraldehyde; PBS, pH 7.4) were prepared as required 
(Griffiths, 1995). The duration of fixation ranged from 10 to 60 minutes for all fixatives 
used. Fixed monolayer cells to be treated with 1% (v/v) osmium tetroxide/80mM cacodylate 
buffer, pH 7.3, were first washed with 80mM cacodylate buffer alone (3x 15minutes) and 
then post-fixed with buffered osmium tetroxide for a further 30 minutes.
Fixed cells were washed 3 times with blocking buffer (1% (v/v) sheep serum; PBS, pH 7.4) 
and stored in blocking buffer containing 0.02% Sodium azide, at 4°C for a maximum period 
of one week.
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2.8 Immunocytochemistry.
Methods used in light microscopy studies are derived from Antibodies: a laboratory manual 
(Harlow and Lane, 1988), and Immunocytochemistry: a practical approach (Monaghan and 
Robertson, 1993). The latter book was also a source of methods used during electron 
microscopy studies, in addition to Fine structure immunocytochemistry (Griffiths, 1993), 
which was a valued source of technical information.
2.8.1 Source and preparation of primary antibodies.
Monoclonal antibodies against cytokeratin peptide 18 (clone K5.B17.2) and vimentin (clone 
V9) were purchased from Sigma and used at a 1/40 dilution in PBS. Dr.A.Webster and 
Professor.R.T.Hay (StAndrews University) kindly provided monoclonal antibodies 44E1, 
11F11, and 3D11B1, specific for the Ad2 preterminal protein (pTP). Cell culture 
supernatants for these monoclonal antibodies, those against the Ad2 23kd protease (methods 
2.2) and the promyelocytic leukaemia protein (PML), clone 5E10 (Stuurman et al. , 1992), 
were filtered (0.2pm Acrodisc) then used at dilution’s ranging from 1/2 to 1/10. 
Dr.D.A.Mathews and Professor.W.C. Russell (University of StAndrews) kindly donated 
rabbit polyclonal antiserum against the Ad2 V, pVI, and DNA binding protein (DBP). In 
addition, Prof.W.C.Russell generously donated aliquots of monoclonal antibodies 
recognising the Ad2 pVII, and DBP proteins. Dr.A.I.Lamond (University of Dundee) 
provided both monoclonal (SP10) and polyclonal (204/4) antibody solutions specific to p80 
coilin. Stuart Annan (University of St.Andrews) donated polyclonal antiserum specific to the 
Ad2 pVIII protein.
Polyclonal antiserum against viral antigens were extensively pre-absorbed onto uninfected 
HeLa cell monolayers, and individual titres determined for both light and electron microscopy 
studies. HeLa cells were grown in 25cm^ flats and fixed when 90% confluent. Cell 
monolayers were permeabilised (10% (w/v) sucrose; 0.5% (v/v) NP40; 1% (v/v) sheep 
serum) for 5 minutes, then washed three times (5min each) with 1% sheep serum/PBS. 
Antiserum (lOOpl) of appropriate dilutions (1/500 to 1/5000) were added to the cell 
monolayers and incubated for one hour with gentle rocking. This procedure was repeated
three times. Pre-absorbed antiserum were filtered and stored at 4°C with 0.02% sodium 
azide, or kept at -20°C. Antiserum against cellular proteins were titred only.
2.8.2 Immunofluorescence.
Fixed HeLa monolayer cells were permeabilised (10% (w/v) sucrose; 1% (v/v) sheep serum; 
0.5% (v/v) NP40; PBS) for 5 minutes then incubated in blocking buffer (1% sheep 
serum/PBS) three times (5 minutes each). The glass slides were dried around the wells using 
a P100 pipette tip wrapped in Medi-Wipe tissue, taking care to avoid the wells. Primary 
antibodies were added (lOgl/well), and left in a humid chamber for one hour at room 
temperature. Microscope slides were quickly rinsed with PBS, permeabilised, then washed 
and dried as described above. Texas Red conjugated affinipure donkey anti-rabbit IgG, and 
Fluoroscein conjugated affinipure donkey anti-mouse IgG secondary antibodies (Jackson 
Immunoresearch) were added (lOptl) at recommended dilutions (1/50 to 1/200), and 
incubated for one hour in a humid chamber (protected from light). Finally, slides were rinsed 
with PBS (3x lOmin) in darkness, then dried around the edges. Citifluor (Chemical 
Laboratories, University of Kent) was added dropwise between the wells, then coverslips 
were gently applied onto the microscope slide. Often coverslips were sealed onto slides with 
nail varnish to prevent cell monolayers being disturbed when using oil immersion. 
Fluorescence was examined using a Nikon Microphot-FXA microscope with either 20x,40x, 
or lOOx (oil immersion) objectives at emission spectra of 525nm for fluorescein, and 620nm 
for Texas red. Cell fluorescence was photographed with an automatic exposure onto Ilford 
HPS 400 film. In addition, a BioRad Confocal Laser Microscope was used in colocalisation 
studies using a lOOx oil immersion objective.
Periodically cells were examined for mycoplasma contamination, when adding second 
antibodies, the DNA-intercalating agent 4', 6-diamidino-2-phenylindole (DAPI) was added (a 
dilution of 1/1000 from a stock of lOOpg/ml in PBS) directly with second antibody solutions.
2.8.3 Preparation of fixed cells for electron microscopy.
i) Embedment:
Fixed HeLa cell monolayers on Henley-Wessex slides were washed in 80mM cacodylate 
buffer for 15 minutes (3 times). Cells were dehydrated gradually in 50, 70, 80, and 90%
88
89
ethanol for 10 minutes each, then finally dehydrated in 100% ethanol 3 times (20min each), 
and left overnight in 100% ethanol. The araldite epoxy resin used (MY753) is not miscible 
with ethanol, therefore glass slides were left in 100% propylene oxide (3x 20min). Prior to 
infiltration of resin, the embedding medium was prepared by combining 19ml epoxy resin 
(MY753), 21ml of the hardener, dodecyl succinic anhydride (DDSA), and 0.6ml of the 
plasticiser, dibutyl phthalate, in a fume hood. After mixing the components thoroughly, 
1.2ml of resin accelerator, benzyl dimethylamine (BDMA) was added. All components were 
obtained from Agar Scientific. Resin infiltration was performed gradually by adding 2 parts 
propylene oxide to 1 part resin for one hour, then 1 part propylene oxide to 2 parts resin for a 
further hour. Gelatine capsules were placed over wells and 100% resin added. Cells were 
embedded for 48 hours, and cured at 60°C in an oven within the fume hood. Embedded 
slides were dipped into liquid nitrogen briefly, and gelatine capsules snapped off.
ii) Thin sections:
Resin blocks were trimmed to a four sided pyramid, then cut using an ultramicrotome 
(Reichart Ultracut S) fitted with a diamond knife, to give sections of 50 to 70nm thickness. 
Thin sections were applied to hexagon 100-mesh copper grids (Agar Scientific), pre-coated 
with 1% pioloform in chloroform. Grids (with sections) were carbon coated using a Balzers 
coating machine (BA3), at high voltage and vacuum. Sections were then ready for 
immunolabelling or contrasting.
2.8.4 Immunolabelling thin sections:
Grids were immersed section down on drops of blocking buffer (5% (v/v) sheep serum; 
0.1% (w/v) gelatine; 0.05% (v/v) Tween-20; PBS) for 30 minutes, then incubated on drops 
of 0.02M glycine for a further 10 minutes to block free aldehyde groups (Griffiths, 1993). 
Grids were then placed on 5ml of wash buffer (1% (v/v) sheep serum; 0.1% (w/v) gelatine; 
0.05% (v/v) NP40; PBS) for 15 minutes on an orbital shaker, then transferred to 100p.l 
drops of primary antibody on parafilm for one hour. After 3x 15 minute incubations in wash 
buffer (gently on an orbital shaker), thin sections were incubated with 1/20 dilutions of 6nm 
colloidal gold-affinipure goat anti-rabbit IgG, and 12nm colloidal gold-affinipure goat anti­
mouse IgG, on parafilm at room temperature for one hour. Immunolabelled sections were
incubated (3x 15min) with wash buffer, PBS (3x 15min), then for one minute with ddH2O 
on an orbital shaker (5ml each). Finally, grids were placed on drops of 2.5% glutaraldehyde 
for 1 minute to fix immunogold labelling, and stored overnight in ddH2O with 0.02% 
sodium azide.
2.8.5 Contrasting thin sections.
Uranyl acetate (0.2g dissolved in 70% ethanol) and lead citrate (1.76g trisodium citrate and 
1.33g lead nitrate dissolved in 30ml ddH2O, then 8ml IN NaOH pus ddH2O to 50ml) were 
centrifuged for 10 minutes at lOOOOrpm (MSE benchtop centrifuge) and stored in foil at 4°C. 
Inverted grids were added to uranyl acetate drops on dental wax. Meanwhile, NaOH pellets 
were placed on filter paper within a petri dish and clean dental wax placed in the centre of the 
dish. Drops of lead solution were applied to the dental wax. After uranyl acetate staining, 
grids were washed in ddH2O 3 times, then dried with tissue paper and transferred to the lead 
citrate solution. After 5 minutes, the grids were dipped in 0.02N NaOH twice, ddH2O 3 
times, and dried as before.
2.8.6 Transmission electron microscopy.
Contrasted thin sections were examined using a Phillips EM 301 Microscope at 80kv. The 
camera film used was Agfa Scientia EM film. For any particular antigen, a minimum of 5 
grids were examined (prepared at different periods during the study). For viral antigens, 
primary antibodies were incubated with uninfected cell thin sections as a control for non­
specific reactions. Secondary antibodies were incubated with thin sections not treated with 
primary antibodies. Controls were done throughout the whole study as stringent monitoring 
of background levels of gold particles, and artifactual structures arising from thin section 
preparation was essential. The magnification of thin sections necessary to detect immunogold 
labelling varied with the type of fixation used, but 34,000x was sufficient for most purposes.
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2.9 Processing of viral and cellular proteins
2.9.1 Immunoprecipitation of 23kd protease from cell extracts.
i) Covalently coupling monoclonal antibodies to Dynabeads:
Dynabeads M-450 rat anti-mouse IgGl (Dynal,UK) were used in accordance with 
manufacturers instructions. Beads were resuspended in the supplied vial for 1 minute by 
vortexing, then the required volume was aliquoted into a 0.5ml Eppendorf tube and separated 
from stock solution by applying to the Dynal MPC-E/E-1 magnetic particle concentrator. 
Beads were washed several times with 0.1% bovine serum albumin (BSA)/PBS.
For direct antigen capture, 10^ dynabeads were added to crude cell culture supernatants 
(approximately 1.5pg of antibodies in total) and incubated at room temperature for 30 
minutes with continuous slow rotation, followed by several washes (3x 15min) in 
0.1%BSA/PBS. Crosslinking of bound antibody to beads was achieved firstly by washing in 
0.2M triethanolamine, pH 9.0, and resupending in 10ml of this buffer. Solid dimethyl 
pimelidate dihydrochloride (DMP) was added (52mg) to the bead suspension to a final 
concentration of 20mM, and incubated at room temperature for 45 minutes with rotational 
mixing. The reaction was stopped by concentrating the beads in the MPC and resuspending 
several times in 0.2M triethanolamine, pH 9.0. After two hours, all non-covalently coupled 
antibody was removed by stringent washing in 1% Triton X-100 /PBS. Beads were finally 
washed with PBS (3x 15min) and stored at 4°C.
ii) Antigen capture from cell lysates:
Nuclear and cytoplasmic extracts (methods 2.7.4) were pre-cleared by mixing lysates and 
uncoated dynabeads for one hour, with continual rotation, at 4°C. Dynabeads were removed 
from cell lysates using the MPC. Pre-cleared lysates were added to antibody coated beads and 
incubated for one hour as described above. To lOOpl of lysate supernatant, approximately 
10? beads were added. The beads were washed 4x 15minutes with 0.1%BSA/PBS, and 
bound protein eluted from the beads either by resuspending the washed pellet in SDS-PAGE 
loading buffer, then boiling for 3 minutes, and applying to the MPC, or resuspending in
92
lOOjil O.5M acetic acid then vortexing for 15 seconds, and applying to the MPC. Eluted 
protein was examined by Western blotting.
2.9.2 Preparation of polyclonal antiserum against the Ad2 Ll-52kd protein.
i) Peptide synthesis and coupling to carrier protein:
The peptide GDYEPPRRRARMYL corresponding to residues 47 to 59 of the Ad2 Ll-52kd 
protein, was synthesised from the carboxyl terminus as described in methods 2.6.2, using F- 
moc-L-Cys(Trt)PEG-PS. The peptide was purified by reverse phase HPLC (methods 2.6.3). 
The peptide was coupled to Human Serum Albumin (HSA) using N-succinimidyl-3-(pyridyl 
dithio)-propionate (SPDP) which couples the amino groups to the cysteinyl residue of the 
peptide. HSA (lOmg) was dissolved in 1ml of 0.1M NaCl/O.lM sodium phosphate, pH 7.5, 
and then 225|il of 20mM SPDP in ethanol was added dropwise over 5 minutes. The solution 
was stirred for a further 30 minutes at room temperature before the free SPDP was removed 
using the fast desalting HR10/10 column (pre-equilibrated with 0.1M NaCl/O.lM sodium 
phosphate, pH7.5). Fractions containing HSA were pooled and mixed with 3mg peptide (3x 
molar excess of peptide to activated groups). The conjugated peptide was dialysed against 
PBS at 4°C overnight.
ii) Immunisations and test bleeds:
Emulsion for immunisation was prepared by mixing 0.75ml of peptide conjugated HSA 
(0.5mg/mlPBS) with 1ml of Freunds complete adjuvant and repeatedly sonicating (15 second 
bursts) with intermittent cooling on ice (2min each). An emulsion was known to be stable 
when droplets did not disperse on water. A Dutch rabbit was injected subcutaneously with 
lml emulsion (approximately 200gg of peptide/HSA) at 4 sites on the back. A booster 
injection (same concentration of conjugate) was given two weeks later, with incomplete 
Freunds adjuvant (again subcutaneously). A test bleed (5ml) from the rabbits ears was taken 
7 days after the second injection. The sera was allowed to clot for one hour, placed at 4°C 
overnight, then centrifuged at lOOOOg for 10 minutes (benchtop microfuge), and stored in 
0.5ml aliquots at -20°C.
Rabbits were kept and maintained in accordance with Home Office guidelines.
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iii) Assessment of antiserum (direct ELISA):
The direct ELISA method is essentially the same as the competitive ELISA protocol described 
in methods 2.6.4. Unconjugated peptide was incubated with microtiter plates which had been 
treated with 1% glutaraldehyde (or carbonate buffer, pH 9.0) at a concentration of 10|±g/well 
(150pl/well final volume). Microtiter plates were left overnight at 4°C, then washed 3 times 
with PBS (200pl/well). Non-specific binding was blocked by adding 150(il of 10% (w/v) 
dried milk/PBS to each well, and incubating for 3 hours at 37°C (or overnight at 4°C), before 
washing with 3x 200pl of wash buffer (1% (w/v) dried milk; 0.5% (v/v) Tween-20; PBS). A 
doubling dilution series of rabbit antiserum in wash buffer was prepared in a separate plate 
and then 50pl from each well was transferred to the peptide coated plate, which was then 
incubated at 37 °C for one hour. The plate was rinsed extensively with 200pl wash buffer (4x 
15min) then second antibody (anti-rabbit Ig horseradish peroxidase linked whole antibody, 
Amersham), diluted 1/5000 in wash buffer was added to each well (lOOpl). After 30 
minutes, plates were incubated 4 times with 200pl wash buffer (15min each), and TMB 
added as described in methods 2.6.4.
Another method of screening antiserum, dot-blots (methods 2.3.2), was used to screen 
antiserum to the Ad2 Ll-52kd protein. Pre-equilibrated PVDF sheets were incubated with 
non conjugated peptide solutions (lmg/ml in PBS), blocked and washed as described in 
methods 2.3.2. A doubling dilution series of polyclonal antiserum was used.
2.9.3 Cleavage of p80 coilin and pVIII.
i) In vitro transcription/translation systems:
The TNT coupled reticulocyte lysate system (Promega) was used in accordance with 
manufacturers instructions. The plasmid pBS751.2A (coilin cDNA in pBSSK-) was kindly 
donated by Dr.A.I.Lamond (Dundee University). The plasmid contains a T3 TNA 
polymerase promoter upstream of the coilin start codon. Plasmids for the wild type Ad2 23kd 
protease (pT7AD23K6), tsl mutant (p250A, originally from Carl Anderson; Brookhaven, 
New York), and Ad2 pVIII (in pRSETA, from Stuart Annan; University of StAndrews) all 
have T7 RNA polymerase promoter sites. All DNA templates were prepared using the 
QIAprep spin plasmid kit (Qiagen,UK) and stored at -20°C. The TNT lysate system reagents 
were stored at -70°C, rapidly thawed prior to use, and kept on ice throughout. Rabbit
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reticulocyte lysates were not used if thawed twice.35 S-methionine was obtained from 
Amersham, stored at -70°C and used in accordance with radiation safety guidelines.
A typical invitro transcription/translation reaction was as follows:
TNT rabbit reticulolysate 25pl
TNT reaction buffer 2ptl
TNT RNA polymerase (T3 or T7) 1 pi
Amino-acid mixture minus methionine (ImM) lptl
35S-methionine (lOOOci/mmol) at lOmci/ml 4pl
RNAsin ribonuclease inhibitor (40U/ml) 1 pi
DNA templates (0.5 to l.Opg/gl) 2jll1
ddH2O 34pl
All components were mixed in a siliconised 0.5ml eppendorf tube (Sigma) then incubated at 
30°C for 90 minutes. Reaction mixtures were stored at -70°C if not used immediately. Non- 
DNA, and control DNA reaction mixtures were included throughout.
ii) Assays with recombinant Ad2 23kd protease:
Aliquots (lOpl) of purified protease (50pg/ml) were incubated with lOpl of activating peptide 
(lmg/ml stock in ddH2O) and assay buffer (25gl) in siliconised Eppendorf tubes. TNT lysate 
reaction mixtures (lOpl) of wild type and tsl mutant 23kd protease were treated identically. 
Digestion reactions were started by the addition of pVIII or p80 coilin TNT lysate mixtures, 
and the reaction allowed to proceed for two hours at 37°C ( aliquots extracted at defined time 
points). Reactions were stopped by transferring aliquots to -70°C. All proteins were 
immunoprecipitated before loading onto 15% SDS-Page.
iii) Immunoprecipitation using polyclonal antisera:
Polyclonal antibodies against pVIII and p80 coilin were covalently coupled to Protein-A 
sepharose (Sigma) prior to immunoprecipitations, using methods described by Harlow and 
Lane (1988).
Protein-A Sepharose beads (250mg) were pre-swollen in 1ml PBS for one hour. An aliquot 
(lOOpl) of beads was incubated with 5 to 10|ll of polyclonal antisera, then incubated for two 
hours at room temperature, with gentle rotation. The mixture was centrifuged briefly
(Microcentaur microfuge), washed twice with 10ml 0.2M borate buffer, and resuspended in 
the same buffer. DMP was added to a final concentration of 20mM, and the mixture was 
gently rotated for 45 minutes at room temperature. Beads were pelleted by centrifugation and 
resuspended in lml 0.2M ethanolamine, pH 9.0, rotated gently for two hours (washing in the 
same buffer periodically), then finally washed with 1% Triton X-100/PBS (3x lOmin) to 
remove unbound material. Crosslinked antibody/protein A Sepharose beads were stored at 
4°C in PBS.
TNT lysate reactions (and reaction digests) were pre-cleared with protein-A Sepharose beads 
(10pl of original stock) for one hour at 4°C, with rotation. Protein-A Sepharose beads were 
separated from the pre-cleared lysates by centrifugation through micropure-22 filters 
(Amicon) at lOOOg for lminute (Microcentaur microfuge). Antibody coupled protein-A beads 
were washed (4x 15min) in blocking buffer (0.1%BSA/PBS) then added to pre-cleared 
lysates and incubated for one hour at 4°C with gentle rotation. Beads were washed with 
blocking buffer (4x 15min) and PBS alone (15min), pelleted, and resuspended in SDS-Page 
loading buffer. Samples were boiled for 3minutes, and examined by 15% SDS-Page. Gels 
were stained/destained then dried (methods 2.2.2) and taped into a Fujix BAS IP cassette, a 
phospo-imager screen placed on top, then left overnight. Radiolabelled proteins were detected 
using the Fujix BAS 1000 Phosphorimager.
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3 Results and Discussion
3.1 Monoclonal antibody production.
3.1.1 Purification of recombinant 23kd protease from E.coli.
Webster (1992) cloned the Ad2 23kd protease gene into pGEX-2T and transformed E.coli 
JM101 cells with the pGEX23k construct. The author showed the level of GST-23kd fusion 
protein expression to be very high (approximately 20mg per litre of cell culture), although the 
majority of fusion protein appeared as insoluble inclusion bodies, making purification by 
affinity chromatography very difficult. Additionally, it was noted that a significant amount of 
proteolytic degradation had occurred, and that E.coli protease’s may have been responsible. 
Due to the high level of fusion protein expression, this system was reassessed for the 
purpose of obtaining enough recombinant 23kd protease for immunising Balb/c mice (section 
3.1.2). The methodology of GST-23kd expression and purification is outlined in section 2.1, 
although initially, instead of sarkosyl addition, Triton X-100 was added to a final 
concentration of 1% prior to sonication. SDS-PAGE and Western blotting analysis revealed 
that much of the GST-23kd fusion protein (apparent molecular weight of 47kd) remained in 
the insoluble fraction of bacterial lysates. However, intact fusion protein and a 28kd co­
purified degradation product were isolated from the soluble fraction of bacterial lysates 
(figures 3.1a and b). Additionally, both the intact and degraded forms of the GST-23kd 
fusion protein were cleaved after a 30 min incubation with lOOng of thrombin (Sigma) in 
cleavage buffer (150mM NaCl; 2.5mM CaCl2; 0.1% B-mercaptoethanol; 50mM Tris-HCl, 
pH 8.0) at 25°C (using the methods described by Guan and Dixon (1991)).
It is not uncommon for fusion proteins to appear as insoluble inclusion bodies (reviewed by 
Marston, 1986; Sassenfeld, 1990) and many purification protocols make use of solubilisation 
and refolding steps to increase the yield of expressed proteins. Frangioni and Neel (1993) 
adapted the GST purification system to solubilise fusion proteins from crude bacterial lysates. 
These authors utilised the alkyl anionic detergent sarkosyl (N-laurylsarcosine) to solubilise 
GST fusion proteins, and showed that subsequent treatment with nonionic detergent (Triton 
X-100) enhanced solubilised fusion protein affinity to glutathione-agarose. Similarly, the 
GST-23kd fusion protein was solubilised with a final concentration of 1.5% sarkosyl (from a 
10% stock in STE buffer) being optimum (figure 3.1c). For sarkosyl sequestration, a final
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10% stock in STE buffer) being optimum (figure 3.1c). For sarkosyl sequestration, a final 
concentration of 4% Triton X-100 (from a 10% stock in STE buffer) was required. Sarkosyl 
concentrations greater than 1.5% decreased fusion protein affinity for glutathione-Sepharose, 
despite increasing the concentration of Triton X-100 proportionately.
15% 0.75% 0.5% 0.25% 0% HSA
sarkosyl concentration (v/v)
Figure 3.1: Expression of the Ad2 23kd protease as a fusion protein with GST. Samples of 
purified fusion protein were examined using 15% SDS-PAGE and either stained with Coomassie blue (part A) 
or electroblotted and probed with polyclonal antiserum Rll (raised against the N-terminal 15 amino acid 
residues of the Ad2 23kd protease, Webster (1992)) at a 1/5000 dilution (parts B and C). The samples were 
IPTG induced JM101 cells transformed with plasmids pGEX-2T (for GST protein alone) and pGEX23k (GST- 
23kd fusion protein). The methodology of purification is described in section 2.1. Part A: Human serum 
albumin (lane 1), purified recombinant 23kd protease (lane 2), purified GST protein (lane 3), purified GST- 
23kd (lane 4), and GST-23kd (soluble fraction from cell lysates) (lane 5). Part B: Human serum albumin (lane 
1), purified recombinant 23kd protease (lane 2), Purified GST-23kd after incubation with thrombin (lane 3), 
and purified GST-23kd (lane 4). Part C: Western blot showing effect of increasing sarkosyl concentrations on 
GST-23kd purification.
Addition of Phenylmethanesulphonyl fluoride (PMSF) to a final concentration of ImM (from 
a 50mM stock in methanol) did not prevent proteolytic degradation of GST-23kd fusion
degradation was also evident when GST-23kd fusion protein was expressed in E.coli BL21 
(DE3) cells. These cells are deficient in the Ion protease, and ompT outer membrane protease 
(Rosenberg et al., 1987). Nakano et al. (1988) noted that E.coli strains such as AD202 which 
are deficient in ompT protease, exhibit a reduction in proteolytic degradation of fusion 
proteins.
The pET expression system was also assessed for large scale production of recombinant 
23kd protease required for monoclonal antibody production. A four, hour induction of E.coli 
BL21 (DE3) cells transformed with pT7AD23k6 (the Ad2 23kd protease gene cloned into 
pET l l-C) has been shown to yield approximately lmg of soluble 23kd protease per litre of 
M9 media (Webster, 1992; Grierson et al., 1994). The methodology of expression and 
purification outlined in section 2.1 is essentially the same as that described by these authors. 
After a 6 hour induction, cells from 1 litre cultures were pelleted, then disrupted by addition 
of lysozyme and freeze/thawed (frozen for 10 minutes in liquid nitrogen then incubated at 
37°C for 15 minutes). Following DNAase 1 treatment and centrifugation, clarified 
supernatant was applied to a DEAE-Sepharose anion exchange column, and the elution 
profile monitored (figure 3.2a). SDS-PAGE and Western blotting analysis revealed that flow 
through fractions 19 to 35 (inclusive) contained 23kd protease, which when pooled, was 
applied to either a CM-Sepharose or Mono-S cation exchange column. Following elution 
(section 2.7.Iii), recombinant protein was detected by SDS-PAGE and/or Western blotting 
(figures 3.2b and c).
Three proteins co-purified with the 23kd protease have apparent molecular weights of 35kd, 
18kd, and 14kd. The 35kd E.coli protein was partially removed when pooled DEAE- 
Sepharose flow through was applied to a ssDNA-Sepharose column, eluting with 200mM 
NaCl (figure 3.2d).
However, a significant reduction in overall yield of 23kd protease was evident when using 
the ssDNA-Sepharose column. In contrast, the Mono-S column has a binding capacity of 
20mg per ml of matrix. This served as a useful concentration step, with an estimated 3.75mg 
of recombinant protein (derived from 5x one litre cultures) being eluted into a final volume of 
5ml (figure 3.3). This in turn was concentrated further by lyophilisation. Because of possible 
harmful effects of Trisma base and high salt concentration on Balb/c mice, the freeze-dried
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Figure 3.2: Purification of expressed 23kd protease from E.coli lysates.
23kd protease was purified from IPTG induced BL21 (DE3) cells transformed with the plasmid 
pT7AD23k6 using the methods described in section 2.1.The elution profile from the 
DEAE-Sepharose column is shown in part A with a Coomassie blue stained 15% 
Polyacrylamide gel (ii) and Western blot (iii) of pooled fractions (19 to 35 inclusive) 
superimposed with prestained Mr markers (i). The pooled eluate was injected into either the 
CM-Sepharose (B), Mono-S (C), or ssDNA-Sepharose (D) columns. Coomassie blue stained 
15% Polyacrylamide gels showing eluted fractions containing 23kd protease are included with 
respective elution profiles. Absorbance at 280nm (---), and percentage of buffer B (--).
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powder was resuspended in 1ml of 0.1M ammonium bicarbonate buffer and applied to a pre­
equilibrated (same buffer) fast-desalting HR 10/10 column (Pharmacia). Eluted fractions were 
pooled then lyophilised. After the addition of 1ml PBS, it was evident that the majority of 
recombinant 23kd protease was rendered insoluble through desalting/freeze-drying. This final 
concentration step was replaced with Amicon ultrafiltration (section 2.1.8), with Mono-S 
eluate gradually concentrated into 1ml PBS.
0.03 0.06 0.125 0.25 0.5 1.0
SBTI standards (pg)
figure 3.3: Final yield of purified 23kd protease. Coomassie blue stained 15% Polyacrylamide gel 
of SBTI standards and a lOpl sample of pooled Mono-S fractions containing 23kd protease. Prestained 
molecular weight markers were also included.
3.1.2 Immunisations and test bleeds.
Five mice received an estimated 50pg of soluble 23kd protease which was known to be 
enzymatically active (figure 3.4a), whilst another five mice received a mixture of 35pg 
soluble and 15pg insoluble 23kd protease throughout the immunisation regime. Western blot 
analysis of test bleeds against the original source of immunogen revealed that all mice raised 
an immune response against the 23kd protease and the co-purified 35kd E.coli protein (figure 
3.4b). Antibodies specific for the 23kd protease were detected by immunoblotting against 
recombinant 23kd protease purified from insect cells (figure 3.5a and b).
This source of antigen was used to screen test bleeds prior to cell fusion (figure 3.5c). Mice 
S2, S3 and S5 (immunised with soluble antigen only), and M2, M3 and M4 (immunised with 
the soluble/insoluble mix) were the most responsive to the immunisation regime and were 
given an intravenous boost of soluble antigen (without adjuvant) three days prior to cell
fusion. Interestingly, Ml and M5 appeared to have been the least responsive to the 
immunisation regime. This was unexpected as aggregated antigens (or antigens immobilised 
to a particulate matrix) have been shown to induce prolonged and more effective immune 
response if incorporated within an immunisation schedule (Harlow and Lane, 1988).
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Figure 3.4: Recombinant 23kd protease used for immunisations. Part A: 15% Polyacrylamide 
gel stained with Coomassie blue showing SBTI standards and a lOpl sample of 23kd protease which was 
known to be enzymatically active. Stock solutions of 23kd protease were prepared fresh prior to each 
immunisation and analysed for enzyme activity. Part B: Lane 1: Purified 23kd protease (Coomassie blue 
stained 15% SDS-PAGE). Lanes 2 and 3: Electroblotted purified 23kd protease probed witli a test bleed from 
mouse S2 and antiserum R11 respectively.
3.1.3 Screening hybridoma cell lines for antibody production.
Spleens were removed from mice M2 and S2 and splenocytes fused with myeloma SP2/0 
cells. The cell mixture was aliquoted into 96 well tissue culture plates as an undiluted stock 
(plates A to F) or diluted 1/5 in selective media (plates G to T). Excess cells from the diluted 
stock were aliquoted into two 96 well plates containing a recommended 
(Dr.P.W.Szawlowski, pers.comm.) final concentration of interleukin-2 (Sigma), then 
prefixed IL1 and IL2 for identification. When cells reached approximately 70% confluence (1 
to 2 weeks), 50(ll of supernatant from appropriate wells was transferred into another 96 well 
plate and used for screening antibodies specific to the 23kd protease (section 2.3.2).
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A total of 80 hybridoma colonies from plates A to F (figure 3.6a) were identified as being 
positive for antibody production, and an aliqout of cells from each colony was transferred to 
a single well in a 24 well tissue culture plate. These hybridoma colonies were re-screened in 
the case that false positives had originally been detected. Although splenocytes do not grow 
in standard tissue culture medium, they do not die immediately, and will continue to secrete 
antibodies which may be detected in early screens. After confirmation that hybridoma 
colonies were positive for antibody production, aliquots of cells from separate colonies were 
pooled and stored (section 2.3.5). None of the hybridoma cell lines from plates A to F were 
used for single cell cloning.
B
Figure 3.6: Screening hybridoma cell culture supernatants. Cell culture supernatants were 
screened for antibodies using the methods described in section 2.3.2. Antiserum R11 was added to the top left 
well in the Teraski plate for all screens (shown in parts A and B) to ensure correct identification of positive 
immunoreactions. Cell culture supernatants (lOpl) from colonies in plate A were added to appropriate wells 
and are shown in part A. Colonies from plates O and P are shown in part B, with colony PD10 highlighted. 
Exposure times were approximately 30 seconds.
F/G G/H H/A A/B B/C C/D D/E
A further 58 hybridoma colonies from plates G to T and 6 colonies each from IL1 and IL2 
were detected (figure 3.6b). These colonies were also expanded into 24 well plates, re­
screened, and stored. From the 70 colonies (table 3.1), 33 were single cell cloned after re­
screening in batches of 11 staggered over an interval of 3 days. Four days after subcloning, 
individual wells were marked and screened where it was clear that groups of cells had arisen
from an individual cell. This procedure was repeated for colonies screened positive. It was 
evident that many hybridoma cell lines could not tolerate single cell cloning, for instance, no 
subclones were isolated from plates I and L. However, many single cell clones were isolated 
from plates O, J, and IL2 (table 3.1).
3.1.4 Characterisation of monoclonal antibodies.
i) Isotyping and Immunoblotting:
Using the Serotec isotyping kit, either IgM or IgGl antibody valiants were detected from cell 
culture supernatants of appropriate hybridoma subclones (table 3.1). IgM's are the major 
component of the primary immune response and are generally considered to be unsuitable for 
immunocytochemical studies due to the lower affinity for antigens compared to IgG's 
(Griffiths, 1993). It is noteworthy that in this study, monoclonal antibodies of the IgM class 
failed to recognise recombinant 23kd protease following electroblotting, and therefore, were 
not characterised further.
In contrast, monoclonal antibodies subclassed as IgGl recognised electroblotted recombinant 
23kd protease, with the notable exceptions being antibodies derived from RG2, MD7, and 
JB4 hybridoma cell lines (figure 3.7/table 3.1). Cell culture supernatants from these 
hybridoma cell lines also exhibited poor immunoreactivity with 4% (v/v) formaldehyde fixed 
(figure 3.8), or 4% (v/v) paraformaldehyde fixed Ad2 infected HeLa cells in 
immunofluorescence microscopy studies. Additionally, no immunoreactions were detected 
when cell culture supernatants were screened with GST-(Ad4)23kd fusion protein bound to 
nitrocellulose membranes (purified fusion protein (50gg/ml) was kindly donated by Dr Ailsa 
Webster, University of St.Andrews). These results suggested that monoclonal antibodies 
derived from RG2, MD7, and JB4 hybridoma cell lines were specific to conformation 
dependant epitopes. Monoclonal antibodies isolated from subclones of OA10, OFIO, GB4, 
IL2G5, PD10, IL2E4 and OC11 were amenable with electroblotting studies (table 3.1/figure 
3.7) and exhibited distinctive punctate immunofluorescent staining patterns with Ad2 infected 
HeLa cells (figure 3.8).
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Stock Positive wells Subcloned colonies Isotype Western
plate blotting
ELI Al C7 DI E2 F5 G8 none n/d n/d
EL2 A3 A4 A7 E4 G1 G5 E4- (b3 e8 c!6 h6 g2 d2 g6 c4 13) IgGl +
G5-(h9 c2 g2 ell cl2 b6 f3 e4) IgGl + '
A3-(a6) IgM -
G A9 A10 B4 CS G4 G5 G6 B4-(f3 g7 bll g4) IgGl +
I-I A2 A5 A6 B2 B3 B9 C9 B3-c3 IgM
I A3 A6 C6 CIO none n/d n/d
J B3 B4 D3 E6 F4 H8 B4-(f6 h4 e8 b8 blO elO g8 c9 c6) IgG -
D3-(e4) IgM -
K Cl D3 FlO H5 H5-(b3 f3 e4 f4) IgM
L Gil H2 none n/d n/d
M B5 D7 Dll G4 D7-(el0 dlO h6 bl2) IgGl
N D6 E10 none n/d n/d
0 A6 A9 A10 Cll El F10 A10-(a4 h3 ell fll b2 b5 fl2 el hlO All IgGl All +
Hll b3) F10-(c5) Cll-(bll d8 dll gll)
P C3 DIO GIO H10 D10-(g5 c4) IgGl +
0 C4 C7 D7 E2 C7-(e5 flO) IgM
R A5 B3 G2 G2-(hll) IgGl
s A8 C9 E6 none n/d n/d
T F2 F2-(f8 flO) IgM -
Table 3.1: Derivation and partial characterisation of monoclonal antibody secreting cell 
lines. Hybridoma colonies within stock plates (after cell fusion) which were screened positive for antibody 
production were re-plated and re-screened then single cell cloned as described in methods section 2.3.4. 
Colonies that were subcloned are highlighted in bold. Single cell cloned colonies determined to be positive for 
antibody production are listed in brackets. Antibodies were not isotyped or characterised further (n/d) in cases 
where no subclones were isolated from stock hybridoma colonies.
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Figure 3.7: Monoclonal antibodies that recognise electroblotted 23kd protease. 
Recombinant Ad2 23kd protease (part A) and GST(Ad4)23kd fusion protein (part B) were electroblotted (15% 
SDS-PAGE) and probed with specific antibodies using the methods described in section 2.4.3. Prestained 
molecular weight markers and 23kd protease were added in lane 1 and probed with antiserum Rll. Antibody 
titres were determined for individual cell culture supernatants prior to immunoblotting. Exposure time of 30 
seconds.
Figure 3.8: Immunofluorescent staining of Ad2 infected HeLa cells. A typical fluorescent 
cell staining pattern using antibody OCllbll (part A) shows a diffuse nucleoplasmic staining in addition 
to the speckled pattern also present in cells stained with antibodies OA10b3 (part B), GB4g4, PD10c4 and 
OF10c5. Cells were fixed at 28 h.p.i and processed using the methods described in section 2.7. FITC 
conjugated second antibody was preabsorbed onto permeabilised non-infected cells prior to fluorescent 
staining at recommended dilution’s. None of the monoclonal antibodies showed any fluorescent staining 
in non-infected cells. Automatic exposure times were typically of between 60 to 120 seconds.
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ii) Specificity of Mabs OC11 b 11 and OA10b3:
The specificity of monoclonal antibodies derived from OC11 subclones differed from the 
others in several respects. For instance, OCllbll did not recognise denatured or 
nitrocellulose bound GST-(Ad4)23kd fusion protein, but did immunoreact with denatured 
Ad2 23kd protease (figure 3.7). Of particular interest was the diffuse immunofluorescent 
staining of infected HeLa cell nuclei which was additional to the punctate patterns also 
observed with monoclonal antibodies OAl()b3 and GB4g4. To determine whether cross­
reactions with other viral antigens were being detected, extracts of infected HeLa cells were 
immunoprecipitated (figure 3.9) using OC1 lbl 1 and OA10b3 cell culture supernatants with 
monoclonal antibodies cross-linked to Dynabeads (section 2.9.1). All monoclonal antibodies 
specifically recognised 23kd protease with no cross reactions being detected.
Figure 3.9: Immunoprecipitation of Ad2 infected cell extracts. Nuclear and cytoplasmic cell 
extracts were prepared from infected HeLa cells (grown as a monolayer) using the methods described in section 
2.7.4i. Antibodies OA10b3 and OCllbl 1 were coupled to Dynabeads using the method recommended by the 
manufacturer (section 2.9.Ii). Lysates were precleared using Dynabeads prior to immunoprecipitation and 
electroblotting (15% SDS-PAGE). 23kd protease (lane 1), OA10b3 (lanes 2) and prestained molecular weight 
markers were used as standards. OA10b3 and OCllbl 1 immune-complexed with purified recombinant 23kd 
protease (lanes 3 and 4 respectively), and specifically recognised 23kd protease from nuclear extracts (lanes 5 
and 6 respectively), and cytoplasmic extracts (lanes 7 and 8 respectively) of infected HeLa cells (28 h.p.i). An 
immunoprecipitation of purified recombinant 23kd protease using non-coupled OA10b3 is shown in lane 9.
It is likely that the immunofluorescent staining patterns observed with antibodies OA10b3 and 
OC1 lbl 1 are due to the availability of different epitopes for immunoreaction within infected
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cells. This might occur through physical loss of epitopes (which can result from extraction of 
molecules and structures), or that epitopes recognised by antibodies OA10b3 and GB4g4 are 
non-immunoreactive within particular nuclear subcompartments following chemical fixation 
(possibly due to steric hindrance of epitopes by fixative-induced cross-links). Similarly, 
chemical alteration of epitopes by direct reactions with fixatives may also account for fixative- 
induced denaturation effects that render conformation dependant epitopes non- 
immunoreactive.
iii) Affect of antibody binding on proteolytic activity:
Observed differences in immunofluorescent staining may also be a direct consequence of the 
physical nature of the antigen in lytically infected cells. For instance, the activity of 
recombinant 23kd protease in vitro has been shown to be dependent on the addition of 
activating peptide, and it has been proposed that activation in vivo is required for production 
of infectious particles. Therefore, specific protein-protein interactions may affect epitope 
binding within post-fixed infected HeLa cells. In determining whether monoclonal antibodies 
could distinguish between the activated and non-activated forms of the 23kd protease, 
antibodies OA10b3, GB4g4 and OC1 lb 11 were used to immunoprecipitate both forms of the 
recombinant enzyme . It was evident that all three antibodies recognised both forms of the 
enzyme in vitro (results not shown), which suggested that the antibodies might recognise the 
non-activated and activated viral protease in vivo.
The same antibody solutions were used to determine whether antibody binding to 
recombinant 23kd protease affected enzyme activity in vitro. Cell culture supernatants 
(protein free media) from 75cm^ flats were filtered, then concentrated into 23kd protease 
elution buffer (150mM NaCl/50mM Tris-HCl, pH 8.0) by ultrafiltration to a final volume of 
0.5ml. The approximate concentrations of antibody and antigen were determined by SDS- 
PAGE (figure 3.10). Appropriate volumes of both solutions were mixed briefly, then 
incubated on ice for one hour before addition of pVI-ct and assessment of enzymatic activity. 
Similarly, assays were performed one hour after antibody solutions had been added to pre­
activated 23kd protease.
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Figure 3.10: Effect of antibody binding on enzyme activity. Approximate concentrations of 
antibody and 23kd protease were estimated by 15% SDS-PAGE. Assays were performed as described in 
methods section 2.2.5. 10pl of 23kd protease was incubated with lOpl of antibody solution (in 23kd elution 
buffer/methods section 2.3.8) and kept on ice for one hour before addition of 25pl assay buffer and pVI-ct to a 
final concentration of 0.2mM. Substrate peptide LSGAGFSW was added (5gl from a stock of 2mg/ml) after 5 
minutes and the assay allowed to proceed for one hour at 37°C. Reactions were stopped by addition of 10pl 
0.1% TFA. Part A: A capillary electrophoresis trace showing peaks corresponding to LSGAGFSW 
(approximately 9 minutes (also shown in part C)), LSGA and GFSW (between 6 and 7.5 minutes). Peaks 
corresponding to cleavage products were absent when OAl()b3 was added to non-activated 23kd protease (part 
D), however an additional peak was evident at approximately 8 minutes. This peak was also evident when 
antibody solution was incubated with the assay mixture in the absence of 23kd protease (part B). Peaks 
corresponding to cleavage products were evident when OA10b3 was added to activated enzyme as shown in part 
E (antibody solution added after assay buffer/pVI-ct).
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Capillary electrophoresis traces (measured at 200nm) indicated that addition of OA10b3 to 
non-activated 23kd protease resulted in the inhibition of enzymatic activity (figure 3.10). A 
minimal level of activity was consistently observed when the same antibody solution was 
added to pre-activated enzyme. Initially it was thought possible that the epitope for OA10b3 
might be located at the site of activation, however, epitope mapping results later indicated 
that inhibition through antibody binding was likely due to steric interference of pVI-ct binding 
(section 3.1.5iii). None of the other antibodies tested (OCllbll, GB4g4, JB4b8, PD10c4, 
IL2G5b6 and IL2E4f3) appeared to have any effect on enzyme activity (results not shown).
It is noteworthy that cell culture supernatants contained cellular aminopeptidases that partially 
digested the LSGAGFSW peptide substrate. This non-specific digestion was eliminated if 
acetylated synthetic substrate Ac-LRGAGRSR was added in place of LSGAGFSW (results 
not shown). Anti-pVII monoclonal antibody supernatants (protein free media) exhibited 
similar aminopeptidase activity when the non-acetylated substrate was used. Non-specific 
digestion was also eliminated if monoclonal antibodies were purified using a Q~Sepharose 
column, which also acted as a useful concentration step, or using a DEAE-Sepharose ion 
exchange column (figure 3.11 on page 112).
3.1.5 Epitope Mapping.
i) Chemical cleavage and limited proteolysis:
In acidic conditions, cyanogen bromide specifically cleaves methionine containing proteins 
and peptides at the carboxylic side of methionine in the amino acid chain (Carrey, 1990). 
CNBr reacts with the sulphur-containing side chain and generates a mix of homoserine, 
homoserine lactone, and methylcyanate. The Ad2 23kd protease has six Met-X bonds 
(including the N- and C-terminal methionines), which if cleaved, would generate 6 peptides 
of 55, 72, 6, 13, 10 and 47 amino acid residues in length (figure 3.12). Synthetic peptides 
(15 residues in length) corresponding to sequences within the 55 residue (N-terminal) and 47 
residue (C-terminal) cleavage products have previously been used to generate polyclonal 
antiserum against the 23kd protease (Webster, 1992).
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Figure 3.11: Monoclonal antibody purification. OA10b3 cell culture supernatants (500ml/protein 
free media) were purified using a pre-equilibrated (50mM Tris-HCl, pH 8.8) Mono-Q column as described in 
section 2.3.8. A sample of eluted antibody is shown in gel A (lane iii) with a sample of die original 
supernatant (ii) mid prestained molecular weight markers (i) included for comparison. Concentrated OA10b3 
cell culture supernatants (5ml total volume) were also injected into a pre-equilibrated DEAE-Sepharose 
column. A typical elution profile is shown with a Coomassie blue stained 15% Polyacrylamide gel (gel B) 
containing How through fractions 14 to 36 superimposed. At pH 8.0, some antibody was retained by the 
matrix and eluted as described in section 2.3.8. Abs 280nm (—). % of buffer B (—).
MGSSEQELKA IVKDLGCGPY FLGTYDKRFP GFVSPHKLAC 
AIVNTAGRET GGVHWl^FAW NPRSKTCYLF EPFGFSDQRL 
KQVYQFEYES LLRRSAIASS PDRCITLEKS TQSVQGPNSA 
ACGLFCCI^FL HAFANWPQTP JdHNPTI^JLI TGVPNSmLnS 
PQVQPTLRRN QEQLYSFLER HSPYFRSHSA QIRSATSFCH
LKNM
Figure 3.12: CNBr cleavage sites within the Ad2 23kd protease. Potential CNBr cleavage sites 
are indicated by arrows. Regions of the 23kd protease which are recognised by specific polyclonal antiserum 
(Webster, 1992) are highlighted in bold.
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Recombinant 23kd protease (estimated final concentration of 0.8mg/ml) was purified from a 
one litre culture of E.coli BL21 (DE3) cells using DEAE-Sepharose and Mono-S columns, 
then freeze dried over a period of 24 hours. The lyophilised powder was resuspended in 
0.5ml of 0.1M ammonium bicarbonate buffer (pH 8.0), then injected into a pre-equilibrated 
(same buffer) fast-desalting HR 10/10 column, with eluted protein again freeze-dried for a 
further 24 hours. Resuspended protein was subjected to chemical cleavage (section 2.4.2), 
and samples of the reaction mix, and original protein stock, examined by SDS-PAGE (figure 
3.13a).
It was clear from the Coomassie blue stained gel that chemical cleavage of the 23kd protease, 
and co-purified E.coli proteins, resulted in the generation of numerous low molecular weight 
products, the most prominent being a polypeptide of approximately 16kd. However, the 
multiscreen immunoblot (figure 3.13b) indicated that a fraction of the enzyme remained 
uncleaved. Partial hydrolysis may have occurred because the desalting/freeze-drying step 
rendered a proportion of the purified protein insoluble, thereby burying potential cleavage 
sites within a hydrophobic environment. Additionally, some reactions do not go to 
completion because of competition from nearby side chains, or because residual folded 
structures in the protein reduce access of CNBr to susceptible bonds. Nevertheless, the panel 
of monoclonal antibodies used immunoreacted with 3 major cleavage products, with antibody 
OA10b3 immunoreacting with 2 major cleavage products, and OCllbll exclusively 
recognising the third, lower molecular weight peptide.
Interestingly, none of the polyclonal antisera immunoreacted with the 3 major reaction 
products, which suggests that none of the monoclonal antibodies recognised epitopes within 
either the 55 or 47 residue peptides, which contain epitopes for polyclonal antiserum Rll and 
R12/R13 respectively. This suggested that epitopes for OA10b3 and OCllbll could be 
located within region M56 to Ml57 of the enzyme. To determine whether the epitopes were 
within this region, aliquots of the reaction mix, and original protein stock, were electroblotted 
for protein sequencing (section 2.4.4). After comparing the immunoblot (figure 3.13c), and 
amido black stained blot (not shown), it was evident that neither of the 2 major cleavage 
products recognised by OA10b3 corresponded to the 16kd polypeptide (which was not 
sequenced). Instead, both co-migrated with several lower molecular weight peptides and
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therefore could not be accurately identified. Similarly, the peptide recognised by OC1 lbl 1 
was not identified, and therefore not isolated for sequencing.
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Figure 3.13: CNBr cleavage of the 23kd protease. Part A: lOpl samples of the original protein 
stock solution (lane i) and reaction mix (lane ii) were electrophoresed (20% SDS-PAGE) with molecular 
weight standards then stained with Coomassie blue. CNBr cleavage reactions were performed as described in 
section 2.4.2. Part B: a lOOpl sample from the same reaction mix was electrophoresed (20% SDS-PAGE), 
then electroblotted and probed (within a Protean II multiscreen apparatus/section 2.4.3) using a panel of 
monoclonal antibodies. Polyclonal antisera (see text) and anti-pVII monoclonal antibody (kindly provided by 
Professor W.C.Russell) were included as controls. Part C: Two 20pl samples of the original 23kd protease 
stock solution (lane i) and cleavage reaction mix (lane ii) were electrophoresed simultaneously (12.5% SDS- 
PAGE) and electroblotted for sequencing (section 2.4.4). The electroblot was divided and one part probed with 
antibody OA10b3 and the other amido black stained (not shown).
Limited proteolysis is much less predictable than chemical cleavage and is dependant on the 
experimental conditions used. In the native conformation, most proteins are almost entirely 
resistant to attack by low concentrations of protease’s, with proteolysis occurring only at the 
most exposed, or disordered regions of the polypeptide backbone (Carrey, 1990). In this 
study, a panel of enzymes with contrasting specifities were chosen that included 
endoproteinase Glu-C (cleaves at Glu-Y and Asp-Y), and the pancreatic enzymes, trypsin
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(Arg-Y and Lys-Y), and a-chymotrypsin (Phe-Y, Trp-Y and Tyr-Y). The enzymes were 
diluted from stock solutions with 23kd protease elution buffer (all enzymes exhibiting 
optimum activity at pH 7.5 to 8.5) to give a ratio of enzyme to substrate (w/w) of 1/1000 
(section 2.4.1). Cleavage reactions were maintained at 37°C for 1 hour, then stopped by 
addition of SDS-PAGE loading buffer. After boiling for 5 minutes, the reaction mix was 
electroblotted as described in section 2.4.3. The multiscreen immunoblots of a-
chymotrypsin, trypsin, and endoproteinase Glu-C cleavage reactions are shown in figures 
3.14a, b and c respectively.
Although the immunoblots do not provide any information regarding the location of particular 
epitopes, they do indicate which epitopes are likely to be shared by antibodies of interest. For 
instance, following a-chymotrypsin cleavage, all of the monoclonal antibodies (with the 
exception of OCllbll) recognised the same 5 cleavage products, 2 of which, were also 
recognised by polyclonal antiserum Rll (lane lin figure 3.14a). However, following trypsin 
cleavage of the 23kd protease, GB4g4 and OF10c5 recognised an additional peptide not 
detected by OA10b3. These results indicated that epitopes for GB4g4, OF10c5 and OA10b3 
may be located within the same region of the 23kd protease, possibly adjacent to each other, 
yet the epitope for OA10b3 may have been cleaved directly, or elements of secondary 
structure required for antibody binding may have been removed. It was thought that low 
antibody titres were likely to be responsible for poor immunoreactions exhibited by 
antibodies PD10c4 and IL2G5b6.
Despite using low concentrations of all three enzymes, proteolysis resulted in the generation 
of numerous cleavage products which hindered the accurate identification of peptides of 
interest. For instance, although 2 major cleavage products of the 23kd protease were 
recognised by OA10b3 after endoproteinase Glu-C proteolysis (figure 3.14c), an examination 
of the reaction mix by SDS-PAGE (results not shown), indicated that these peptides could 
not be isolated for sequencing using the methods outlined in section 2.4.4,
In order to isolate these peptides, reaction mixtures (50|il) were diluted with 350|4L of 0.1% 
TFA/water, then filtered (0.2pm Acrodisc) and cleavage products seperated by HPLC 
purification (section 2.6.3). The elution profile of an a-chymotrypsin and 23kd protease 
(1/1000) reaction mixture is shown in figure 3.16. Collected fractions were vacuum dried 
(Howe Gyrovap GT) and contents resuspended in 50pl PBS. The fractions were incubated
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Figure 3.14: Limited proteolysis of the 23kd protease. lOOfll samples from a stock solution of 
23kd protease (estimated concentration of 0.8mg/ml) were incubated with chymotrypsin, trypsin, and 
endoproteinase Glu-C (all for one hour at 37°C) at a 1/1000 dilution (methods section 2.4.1). The reaction 
mixtures were electrophoresed (20% SDS-PAGE), then immunoblotted within the multiscreen apparatus using 
a panel of monoclonal antibodies and polyclonal antisera. Lanes which were probed with polyclonal antisera 
are included in the immunoblot of die chymotrypsin reaction mixture only (part A). Prestained molecular 
weight markers were added to lane one of the gel and probed later in the multiscreen apparatus using antisera 
Rll (lane i). Antiserum Rll was also added to lane ii to ensure correct identification of other positive 
immunoreactions. Some cleavage products associated with trypsin (part B), and endoproteinase Glu-C (part C) 
reaction mixtures were difficult to identify, and consequently immunoblots were typically overexposed 
(approximately 30 min).
with a pre-equilibrated PVDF membrane strip, within the multiscreen apparatus for 2 hours, 
then the strip was incubated with blocking buffer and processed as described in section 
2.4.3.
Peptides containing the epitope for OA10b3 were not detected in any of the fractions 
screened, despite the antibody recognising peptides from the original reaction mix. It seemed 
likely that addition of 0.1% TFA/water to the reaction mix rendered some of the peptides 
insoluble, which in turn, would have been removed by filtration prior to HPLC purification. 
Similar results were obtained from trypsin, endoproteinase Glu-C, and CNBr cleavage 
mixtures.
The panel of monoclonal antibodies were also screened against the four peptides that were 
previously used to generate the polyclonal antisera against the 23kd protease. The peptides 
were resuspended from lyophilised powder (lmg/ml in PBS), then incubated with 1% 
glutaraldehyde treated 96 well microtitre plates at a final concentration of lqg/well (overnight 
at 4°C) and/or incubated with pre-equilibrated PVDF membranes at a concentration of 
100(ig/ml for 2 hours. Monoclonal antibodies were screened using the methods outlined in 
sections 2.9.2 and 2.3.2, with appropriate polyclonal antisera included as controls. None of 
the monoclonal antibodies immunoreacted with any of the peptides (results not shown) and it 
was assumed that corresponding sequences of the 23kd protease did not contain epitopes for 
antibodies used.
ii) Deletion mutagenesis:
All of the protease deletion mutants that were expressed as GST fusion proteins (with the C- 
terminal PK tag) are schematically presented in figure 3.15. Monoclonal antibody 336, that 
specifically recognises the 14 amino acid PK tag (Hanke etal., 1994), was used to determine 
whether full length fusion proteins had been expressed (figure 3.16). Polyclonal antiserum 
Rll was used to verify that deletion mutants containing the N-terminal 15 amino acids of the 
23kd protease had been cloned in reading frame with the PK tag (figure 3.17). In addition, 
purified fusion proteins were examined by SDS-PAGE and compared with standard 
molecular weight markers (figure 3.18).
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Figure 3.15: Schematic representation of deletion mutants. Deletion mutants were cloned into the pGEX-cPK vector (section 2.5) with the N-terminus and C-terminus of mutants 
linked to GST and the PK tag respectively.
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Figure 3.16: Detection of intact deletion mutants using Mab 336. Fusion proteins were 
expressed, purified and electroblotted (15% SDS-PAGE) as described in section 2.5.10. Part I: Initially, 
deletion mutants M1-H54 (33.6kd), M1-A96 (38.3kd), M1-P137 (42.9kd), M1-S194 (49.4kd), V53-S194 
(43.4kd) and I97-S194 (38.5kd) (lanes 1, 2, 3, 4, 5 and 6 respectively) were used for screening monoclonal 
antibodies. Part II: Deletion mutants M1 -LI58 (45.3kd), M1-R180 (47.8kd), I97-L158 (34.4kd) and I97-P137 
(32kd) (lanes 2, 3, 6 and 7 respectively) were later cloned and expressed to identify the region containing the 
epitope for OC1 lbl 1 (see text). Included in immunoblot II are deletion mutants M1 -Pl37 (lane 1), V53-S194 
(lane 4) and I97-S194 (lane 5). The Mr of GST was assumed to be 26kd and the PK tag to be approximately
1.5kd.
Although full length fusion proteins for all the deletion mutants were isolated, it was evident 
that all were susceptible to proteolytic degradation, in particular fusion proteins of deletion 
mutants M1-A96, I97-S194 and Ml-SI94 (figure 3.16). A significant reduction in 
proteolytic degradation was observed when Pefabloc was added to cell lysis buffer (4mM 
final concentration). Additionally, it was evident that a significant amount of expressed fusion 
protein was retained in the insoluble fraction of bacterial cell lysates (results not shown). 
However, sufficient quantities of deletion mutants were purified for the purpose of screening 
monoclonal antibodies. Purified fusion proteins were subjected to thrombin cleavage (30 
minutes al 25 C in cleavage buffer) and analysed using monoclonal antibody 336 and 
polyclonal antiserum R1 1 (where appropriate).
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Figure 3.17: Identification of intact fusion proteins and thrombin cleavage products 
using antiserum Rll and Mab 336. Part I: Immunoblot using with Mab 336: 23kd protease standard 
(lane 1), and purified M1-P137 fusion protein plus thrombin (lane 2) and minus thrombin (lane 3). Part II: 
23kd protease standard and Ml-Pl37 (+/- thrombin in cleavage buffer) are shown in the Rll probed 
immunoblot (lanes 1, 2, and 3 respectively). The Rll antisera also immunoreacted with mutants M1-L158 
(lane 4) and M1-R180 (lane 5), but did not detect V53-S194 (lane 6). The cleavage product in lane 2 (parts I 
and II) was assumed to be the intact M1-P137-PK polypeptide with an approximate Mr of 16.9kd (see text). 
All samples were electrophoresed using 15% SDS-PAGE with Biotinylated molecular weight markers, and 
prestained molecular weight markers included. Biotinylated markers were detected using streptavidin linked 
peroxidase (Sigma) at recommended dilution’s.
Figure 3.18: Purification of deletion mutant M1-P137. All deletion mutants were purified as 
described in section 2.5.10, then resolved by 15% SDS-PAGE, and Coomassie blue stained. 23kd protease 
standard (lane 1) and Dalton V molecular weight markers were included. A sample of purified fusion protein 
Ml-Pl37 is shown in lane 2 mid a sample of the soluble lysate extract shown in lane 3. The molecular weight 
of deletion mutant M1-P137 was estimated to be approximately 42.9kd.
Thrombin cleavage of mutant M1-S194 resulted in the generation of a polypeptide of 
approximately 23kd (presumed to be M1-S194-PK) as shown in figure 3.19. Similarly, 
cleavage of the fusion protein containing region Ml-Pl37 would be expected to generate a
16.9kd product (M1-P137-PK). This appeared to be the case when the relative mobility of 
the cleavage product was compared to biotinylated molecular weight markers (figure 3.17 
parts I and II). These protein markers were compared with prestained markers, and Dalton V 
molecular weight markers (used in figure 3.18), to determine whether biotinylation had 
altered the relative mobilities of proteins involved. The biotinylated 20kd marker protein had 
the correct mobility, although the 40kd marker protein migrated slower giving an apparent Mr 
of approximately 45kd (result not shown).
120
Figure 3.19: Thrombin cleavage of mutant M1-S194. The fusion protein considered to represent 
die full lengdi 23kd protease (minus the C-terminal 10 amino acids which were known not to comprise any 
epitopes of interest (section 3.1.5i)) was incubated with lOOng of dirombin in cleavage buffer (section 3.1.1), 
then electroblotted and probed using antibody OA10b3. 23kd protease standard is shown in lane 1 and a sample 
of soluble extract from the bacterial lysate shown in lane 2. A degradation product with an approximate Mr of 
28 to 30kd (which was also detected using the 33bc antibody and the R11 antisera) was not evident after 
purification (lane 3), although two degradation products of higher molecular weight were co-purified and also 
detected using the Rll antisera and 33bc antibody (results not shown). Thrombin cleavage resulted in the 
generation of a polypeptide with an approximate Mr of 23kd (lane 4), which was also detected using antibody 
33bc and the R11 antisera.
None of the monoclonal antibodies immunoreacted with M1-H54 (figures 3.20a, b and c), 
which was consistent with CNBr cleavage results. Instead, all the monoclonal antibodies 
(with the exception of OC1 lbl 1) immunoreacted with deletion mutants containing the region 
V53 to A96. Antibody IL2E4f3 differed from the rest in that no immunoreaction with deletion 
mutant V53-S194 was detected. This was unexpected as the antibody did not recognise Ml- 
H54, but did immunoreact with deletion mutant M1-S194. This suggested that critical
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residues required for antibody binding may have been missing from deletion mutants Ml- 
H54 and V53-S194, or that elements of secondary structure necessary for antibody binding 
were not present. It is noteworthy that IL2E4f3 had previously been shown not to 
immunoreact with the peptide 48RETGGVHWMAFAWN.
23kd 
protease
Figure 3.20: Screening monoclonal antibodies against deletion mutants. Purified fusion 
proteins were resolved by 15% SDS-PAGE then electroblotted and probed using titred antibody solutions. Part 
A: Mab's OA10b3 (shown), GB4g4, PD10c5, IL2g5b6 and OF10c5 immunoreacted with deletion mutants 
M1-A96, M1-P137, M1-S194 and I97-S194 (lanes 2, 3, 4 and 5 respectively). Part B: IL2E4f3 detected the 
same fusion proteins with the exception of V53-S194. Part C: OC1 lbl 1 recognised M1-S194, V53-S194 and 
I97-S194 only. Part D: OCllbll was also screened against deletion mutants M1-L158 and M1-R180 (lanes 2 
and 3 respectively). Deletion mutants M1-P137 (lane 1), V53-S194 (lane 4), and I97-S194 (lane 5) were also 
included. OCllbll only immunoreacted with electroblotted V53-S194 and I97-S194 or either deletion mutant 
immobilised to nitrocellulose (result not shown). Part E: OA10b3 immunoreacted with M1-L158 and Ml- 
R180. None of the monoclonal antibodies immunoreacted with deletion mutants M1-H54 (lane 1 in parts 
A,B, and C) or I97-L158 and I97-P137 (results not shown).
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The epitope for antibody OCllbll was initially localised to region P137 to S194 (figure 
3.20c). However, the antibody did not immunoreact with synthetic overlapping peptides 
corresponding to this region, and therefore the antibody was subsequently screened against 
fusion proteins containing the sequences I97-L158, I97-P137, M1-L158 and M1-R180 
(figure 3.20d). None of these deletion mutants were recognised by OCllbll, which 
suggested that the epitope for this antibody was in the region R180 to SI94. None of the 
other antibodies immunoreacted with mutants containing regions I97-L158 and 197-Pl37 
(figure 3.20e), which was consistent with previous results which indicated that epitopes were 
within the region V53 to A96.
iii) Overlapping peptides:
Peptides which extended over two regions of the 23kd protease (R48 to P101 and F133 to 
S194) were designed and synthesised as outlined in section 2.6. All the peptides used are 
schematically presented in figure 3.21. Freeze-dried peptides were dissolved in 0.1% 
TFA/water (lmg/ml), then filtered (0.2pm Acrodisc) and purified by HPLC. The elution 
profile was monitored at 226nm (figure 3.22a) and collected fractions analysed by capillary 
electrophoresis (figure 3.22b, c, d and e). When appropriate, peptide sequences were 
confirmed using the Procise Protein Sequencer. Several peptides that were relatively 
insoluble were also resuspended in PBS (lmg/ml) and used without HPLC purification. 
Monoclonal antibodies OA10b3, OCllbll, GB4g4, PD10c4, IL2G5b6 and IL2E4f3 were 
initially screened against appropriate peptides which had been immobilised in 96 well 
microtitre plates (lpg/well) and nitrocellulose (lOOpl/ml in PBS), using the methods outlined 
in sections 2.9.2 and 2.3.2 respectively. None of the antibodies immunoreacted with peptides 
using these methods, irrespective of whether peptides had been HPLC purified, or simply 
resuspended in PBS (results not shown). Because immobilisation of peptides resulted in loss 
of antigenicity, antibodies were re-screened using the competitive ELISA method. A doubling 
dilution series of antibody solution (50|il/well) was incubated with peptide (5qg/well in PBS) 
for one hour at 37°C before being transferred to a 96 well microtitre plate pre-coated with 
purified recombinant 23kd protease (0.05pg/well). After a one hour incubation at 37°C, 
microtitre plates were processed as described in section 2.6.4.
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Figure 3.22: Typical purification and assessment of a synthesised peptide. Peptides were synthesised as described in section 2.6.2 (final yields typically 
of 5mg lyophilised powder), then resuspended in 1ml 0.1% TFA/water, filtered and injected into a pre-equilibrated Rsil C18 HL column (section 2.6.3). Part A: 
the HPLC elution profile for peptide FANWPQTPMDHNPT. 1ml fractions were collected then samples analysed by capillary electrophoresis. A sample of the 
peptide solution prior to HPLC purification is shown in part B. Fractions 13,14 and 15 from the HPLC are shown in parts C, D and E respectively.
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None of the overlapping peptides corresponding to sequences within the region F133 to S194 
affected OC1 lbl 1 binding to immobilised 23kd protease (figures 3.23a and b).
—♦—23k
23456789 10 11
Well number
Figure 3.23: Determination of the epitope for OCllbll by competitive ELISA. 
Overlapping peptides which corresponded to sequences within the region FI33 to SI94 (shown in Figure 
3.21ii and listed within the legend) were incubated with cell culture supernatants containing antibody 
OCllbl 1 for one hour at 37°C before addition of antibody to immobilised 23kd protease (section 2.6.4). As a 
control, OCllbll was added directly to immobilised 23kd protease (labelled as 23k within the figure). None 
of the peptides affected antibody binding to immobilised 23kd protease when compared to the control 
immunoreaction. An identical result (not shown) was determined for peptide 175/189.
As deletion mutagenesis results indicated that the epitope for OC1 lbl 1 may be located within 
the region R180 to S194, it was of interest that the antibody did not immunoreact with any of 
the synthesised peptides corresponding to this region (figure 3.2 lii).
Overlapping peptides of 15 residues in length corresponding to region D102 to K202, 
synthesised on cellulose membranes, were probed using the method outlined in section 2.6.5 
(Spots test). A faint immunoreaction was detected with peptides 10 and 11 (figure 3.24a) 
which correspond to peptides l74LYSFLERHSPYFR and 182SPYFRSHSAQIRS (figure 
3.2liv). This suggested that the epitope for OC1 lbl 1 was in the region LI74 to SI94, which 
partially confirmed results from the deletion mutagenesis studies (localised to R180 to S194). 
However, it is noteworthy that the immunoreaction detected using the Spots test was weak 
and that the peptides 175YSFLERHSPYFRSHS, 183PYFRSHS AQIRS and 
176SFLERHSPYFRS were not recognised.
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Figure 3.24: Determination of epitopes using the Spots test. Part A: peptides shown 
schematically in figure 3.21iv were screened (using the method described in section 2.6.5) with titred 
OCllbll cell culture supernatant. Fuji RX film was placed over the cellulose membrane strip and pierced 
using a needle at each end of the membrane to aid identification of positive immunoreactions. Cellulose 
membranes were treated with the peroxidase linked antibody alone, and anti-pVII monoclonal antibody then 
peroxidase linked antibody as controls for non-specific immunoreactions. A separate membrane (figure 3.21 iii) 
was probed by the same methods with antibodies OA10b3 (part B), PD10c4 and IL2B5b6 (part C), and GB4g4 
and OF10c5 (part D). The membrane was regenerated according to the methods specified by the manufacturer 
(Genosys).
It is possible that the epitope for OCllbll is composed of non-contiguous amino acid 
sequences that are not fully represented by the synthesised peptides used. For instance, the 
epitope for a monoclonal antibody generated against lysozyme was shown to be composed of 
two distant stretches of the primary amino acid sequence (residues 18-27 and 166-129). 
Although separated from each other in the primary sequence, these stretches of amino acids 
are adjacent on the protein surface (Harlow and Lane, 1988). Similarly, the 3 a-helices that 
comprise the secondary structure of region L158 to R180 (figure 3.25) may contain residues 
that, although separated on the amino acid sequence, are spatially oriented to comprise the 
epitope recognised by OC1 lbl 1. It is has been shown that elements of secondary structure 
(in particular a-helices) are not completely unfolded/disordered during the course of thermal, 
or chemical denaturation (Pace et al., 1990). Therefore, it is possible for OCllbll to
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immunoreact with denatured antigen, but not synthesised peptides that are missing elements 
of secondary structure necessary for antibody binding. It is noteworthy that OCllbll did not 
recognise native or denatured GST-(Ad4)23kd fusion protein. Differences in the amino acid 
sequence between Ad2 and Ad4 23kd protease within the L158 to S194 region (figure 3.21) 
might confer subtle changes in secondary structure and/or involve the substitution of residues 
that are critical to antibody binding. It is best to consider the epitope for OCllbll to be 
within the region L158 to S194 in the absence of data which would confirm its location 
within region R180 to S194.
Five overlapping peptides corresponding to region R48 to P101 (figure 3.21 i) were used in 
competitive ELISA's to determine the location of epitopes for the remainder of the 
monoclonal antibodies. Although OA10b3 did not recognise immobilised peptide 3 
(77DQRLKQVYQFEYESL), an immunoreaction with this peptide was detected using the 
competitive ELISA method (figure 3.26). The epitope was confirmed by screening peptides 
corresponding to region R63 to 1105 (figure 3.21iii) using the SPOTs test. OA10b3 
recognised peptides 75FSDQRLKQVYQFE and 77DQRLKQVYQFEYE (figure 3.24b), 
which suggested that the N- and C-termini of peptide 77DQRLKQVYQFE were essential 
for antibody binding. The epitope for OA10b3 appears to span a-helix H2 and part of the 
loop extending to a-helix H3 (figure 3.25). The residues which appear to be essential for 
antibody binding are located at the N-terminal end of H2 (Asp-77 and Gln-78), and those 
which comprise the H2 to H3 loop (Tyr-84, Gln-85, Phe-86 and Glu-87).
The peptide 77DQRLKQVYQFE also contained antigenic determinants for antibodies 
PD10c4 and IL2G5b6, although immunoreactions were relatively weak (figure 3.26 and 
3.24c), which suggested that epitopes on the native antigen comprised of conformational 
elements not presented on synthesised peptides.
The epitopes for antibodies GB4g4 and OF10c5 were not determined using the competitive 
ELISA method (figure 3.26). However, immunoreactions with peptides 
83VYQFEYESLLRRS, 85QFEYESLLRRSAI and 87EYESLLRRSAIAS were detected using 
the SPOTs method (figure 3.24d). It was significant that immunoreactions were 
progressively weaker as residues VY and then QF were removed, and also that neither 
antibody recognised the peptide 81KQVYQFEYESLLR. This suggests that the N- and C- 
termini of the peptide 84YQFEYESLLRRS were important for antibody binding. This may
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Figure 3.25: Location of epitopes within the 23kd protease. The epitope for OC1 lbl 1 is thought to be 
within the H6 to H7 region although residues within H5 may be involved in antibody binding The location of 
residues Leu-158, Arg-180 and Ser-194 are indicated. The epitope for OA10b3 is believed to span a-helix H2 
(77-DQRLKQVYQFE) and comprise part of the H2-H3 loop. The positions of Asp-77, Gln-85 and Glu-87 are 
indicated. The epitopes for antibodies GB4g4 and OF10c5 (84-YQFESLLRRS) are thought to span a-helix H3 
and part of the H2-H3 loop. Residues that may be involved in antibody binding include Arg-94 and 95, Gln- 
85 and Glu-87 and 89. His-54 is located at the end of the loop extending between p-sheets S2 and S3 (not 
labelled) and Cys-122 is located at the N-terminal end of a-helix H4. The precise location of residues 
indicated on the structure was possible through the invaluable assistance of Gonzalo Cabrita (University of 
St.Andrews). The schematic representation was originally derived from Ding et al (1996).
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Figure 3.26: Competitive ELISA of monoclonal antibodies with 
epitopes within region R48 to 101. Peptide solutions were incubated 
with titred antibody cell culture supernatants before addition of antibody 
solution to microtitre plates containing 23kd protease. A decrease in 
absorbance at 655nm (in comparison to the non-peptide control) was 
detected in instances were immunoreactions with peptides had occurred
130
be partly supported by the competitive ELISA results which indicated that neither peptide 3 
(77DQRLKQVYQFEYESL) or peptide 4 (87EYESLLRRSAIASSP) were recognised by 
antibodies GB4g4 or OF10c5. However, it is possible that the two arginines in peptide 4 may 
not have been deprotected, and therefore, not recognised by either antibody. The Mtr 
protecting group on arginine is removed slowly and requires longer cleavage times and the 
presence of phenol as a scavenger. The sequence 84YQFEYESLLRRS corresponds to part 
of a-helix H3 (LLRRS) and the loop linking H2 and H3 (figure 3.25).
None of the peptides used in the competitive ELISA, or included in the Spots test were 
recognised by antibody IL2E4f3. These results, and those from the deletion mutagenesis 
study, suggest that the epitope for this antibody, like others that have been partially 
characterised, may comprise of elements of secondary structure or non-contiguous amino 
acid sequences.
3.1.6 Discussion.
Although antibodies OA10b3, PD10c4, GB4g4, and IL2G5b6 share common antigenic 
determinants within region H2 to H3, only OA10b3 binding affected activation of the 
enzyme. This may be due to steric hindrance of pVI-ct binding, although it would be 
expected that GB4g4, PD10c4, and IL2G5b6 would exert similar effects after binding. 
Alternatively, OA10b3 may 'trap' the 23kd protease in a transient conformational state, in a 
manner similar* to which pVI-ct binding stabilises the proteolytic apparatus by aligning two 
distant mini-domains of the enzyme (figure 3.25). Binding of OA10b3 to a-helix H2 (and the 
loop between H2 and H3) may inhibit pVI-ct induced realignment of a-helix H4 and render 
the enzyme in an inactive conformational state. Similarly, Goldberg (1991) showed that Mab- 
93, which preferentially recognised denatured E.coli tryptophan synthase, inactivated the 
enzyme after a long period of time. The author proposed that the protein exists in solution in 
an equilibrium between the native and locally dissociated state (in which the epitope becomes 
available). Antibody binding appeared to inhibit enzyme activity by preventing or restricting 
the molecular movements that accompanied pyridoxal-5'-phosphate binding during the 
catalytic cycle.
It was of particular interest that epitopes for all the monoclonal antibodies (with the exception 
of OC1 lbl 1) were initially localised to region V53 to A96, yet only the epitope for OA10b3
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was accurately identified using synthetic overlapping peptides. Constraints imposed by the 
dimensions of the antigen binding sites of antibodies limits the size of antigenic determinants 
to 6 to 8 amino acid residues, and therefore, it was expected that the remaining monoclonal 
antibodies would immunoreact against epitopes on appropriate synthesised peptides. 
However, other studies which have involved the determination of epitopes on Ad2 DBP 
(Cleghon et al., 1993), myoglobin, lysozyme, and influenza virus haemagglutinin 
(HA)(Harlow and Lane, 1988; Griffiths, 1993), have indicated that many antigenic states 
may be dependant upon secondary, tertiary and even quaternary structure since they may be 
composed of discontinuous segments which are often found to incorporate loops or turns in 
the polypeptide chain. Cleghon et al (1993) have shown that a panel of monoclonal antibodies 
generated against DBP recognise both the native and denatured forms of the protein, 
suggesting that their epitopes consist of primary or limited secondary structures that are 
exposed on the native molecule. Additionally, these authors have shown (via limited 
proteolysis experiments) that the epitope for one of these antibodies (Mab B6) was 
discontinuous, being ascribed to the C-terminal domain of DBP and the hinge between the bl­
and C-terminal domains. It is possible that the epitopes for OCllbll, IL2E4f3, PD10c4, and 
IL2G5b6 are likewise composed of discontinuous segments of the 23kd protease.
It was clear from a comparison of the amino acid sequence and of the crystallographic 
structure of hens egg white lysozyme that the epitope for a monoclonal antibody generated 
against this protein was formed by Lys-116, Arg-114, Asn-113, and, Phe-34 and Lys-33 
(Harlow and Lane, 1988). The epitopes for all the antibodies appeared to be composed of 
charged or polar amino acids, for instance, out of the 16 amino acids that were mapped to 
these sites, nine were either lysine or arginine. Likewise, 77DQRLKQV¥QFE contains 
three glutamines, an arginine and a lysine that may constitute the antigenic determinants for 
OA10b3. It is possible that this peptide does not contain all of the antigenic determinants for 
PD10c4 and IL2G5b6, and therefore, like OCllbll, it was assumed that these antibodies 
recognised non-contiguous amino acid sequences. As previously mentioned, the antigenic 
determinants for antibodies GB4g4 and OF10c5 were not easily determined, however, it is 
possible that the arginines in a-helix H3, and residues within the H2 to H3 loop, are 
recognised by these antibodies. The residues which are suspected to be critical for OA10b3
and GB4g4 binding are highly conserved amongst human serotypes which have been 
sequenced (figure 3.27).
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Figure 3.27: Comparison of the sequence that comprises the Ad2 H2 to H3 region with 
14 other adenovirus serotypes. Protease sequence alignments and numbering are based on Ad3. 
Conserved residues are highlighted in red. Residues that are not conserved are highlighted in green if they are 
similar in respect to charge or polarity, and in bold if they do not share any characteristics with the conserved 
residues. The Serine residue which is not conserved (but present within the Ad2 sequence) is highlighted in 
blue.
It is evident that the epitopes for OA10b3 and GB4g4 are highly conserved amongst the 
human serotypes. The Ad2 enzyme contains 2 residues that are not considered to be 
conserved (Val-83 and Ser-90) that are located within a-helices H2 and H3 respectively. 
Residues that compose the loop between these helices (Tyr-84 to Glu-89) are highly 
conserved, particularly Tyr-84 which is totally conserved amongst all the serotypes shown in 
figure 3.27. Other residues which have been thought to be essential for antibody binding are 
highly conserved in particular Asp-77 (for OA10b3 binding), and Arg-95 and Ser-96 (for 
GB4g4 binding).
It is noteworthy that none of the monoclonal antibodies generated against the Ad2 23kd 
protease immunoreacted with electroblotted Avian strain 127 recombinant protease (Lewis 
Murray, University of St.Andrews, pers.comm.). It is evident from figure 3.27 that residues
which are thought to be required for antibody recognition are absent in this enzyme. The 
extent to which these differences affect the conformation of the H2 to H3 region is unclear. 
Both native (known to be active) and denatured forms of the 23kd protease were injected into 
Balb/c mice throughout the immunisation regime, and it was expected that a broad range of 
antibody specificities would be isolated. However, the finding that the majority of 
monoclonal antibodies recognised antigenic determinants within the H2 to H3 region may be 
significant. For instance, other studies have also shown that native proteins possess only a 
very limited number of sites against which antibodies are preferentially made during an 
immune response. In the case of influenza HA, most antibodies were found to be directed 
against particular regions of the protein and it was surmised that many segments of the 
protein were non-immunogenic. Likewise, a panel of monoclonal antibodies which were 
generated against adenovirus core proteins pVII and mu, all recognised common antigenic 
determinants within arginine rich regions of both proteins (Lunt et al., 1988). It is 
noteworthy that none of the monoclonal antibodies generated against the 23kd protease were 
mapped to region T45 to H54, which forms an extended loop between S2 and S3 (figure 
3.25). Webster (1992) immunised rabbits with peptide RETGGVHWMAFAWN conjugated 
to HSA, which contains residues corresponding to part of the loop region. The resultant 
polyclonal antiserum was shown to immunoreact poorly with the native and denatured form 
of the antigen.
Only antibodies that were used in immunocytochemical studies were characterised, however, 
several of the monoclonal antibodies which recognised conformation dependant epitopes 
(such as JB4b8 and MD7elO) can be epitope mapped to a limited extent now that other 
epitopes have been determined. For instance, The ELISA additivity test (Friguet et al., 1990) 
could be utilised to determine the number of antigenic sites simultaneously available to two 
antibodies on the antigen. As the epitopes for antibodies OA10b3 and OC1 lbl 1 have been 
localised to regions H2 to H3 and H5 to H7 respectively, the approximate location of the 
conformation dependant epitope of JB4b8 could be determined with relative ease, although 
care should be taken when interpreting results as antibody binding may be subject to steric 
hindrance, even though epitopes may be located on apparently distinct regions of the 23kd 
protease. Once characterised, antibodies JB4b8 and MD7elO could be powerful tools for 
investigating conformational changes that are assumed to occur when the 23kd protease
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interacts with DNA (Ding et al., 1996), and peptides containing the VEGGS motif (Diouri et 
al., 1996). Although these antibodies did not immunoreact with 23kd protease in 4% 
formaldehyde fixed virus infected HeLa cells, they can be used to immunoprecipitate the 
enzyme from infected cell lysates, and therefore, may prove useful in distinguishing isoforms 
of the protease in vivo.
3.2 Isoforms of the 23kd protease.
Several recent reports have indicated that isoforms of the 23kd protease can be detected in 
vivo and in vitro (Webster et al., 1993; Greber et al., 1996; Keyvani-Amineh et al., 1996). In 
order to determine whether monoclonal antibodies would preferentially immunoreact with one 
isoform over another, recombinant Ad2 and Ad2(tsl) 23kd enzymes were first expressed in 
E.coli BL21 (DE3) cells (cells were transformed with plasmid p250A for Ad2(tsl) 23kd 
protease expression, Anderson (1992)), then purified using the methods outlined in section 
2.1.7.
It was evident that the level of Ad2(tsl) 23kd protease expression was poor in comparison to 
the wild type equivalent (results not shown). However, lOpl samples from fraction 25 (from 
the Mono-S column) of the Ad2(tsl) protease (hereafter referred to as tsl 25), and fraction 18 
of Ad2 wild type protease (wt 18), were both shown to digest approximately 50% of the 
synthetic peptide substrate LSGAGFSW over a period of one hour at 37°C (figure 3.28) 
using the conditions described in section 2.2.5. A similar level of activity was observed with 
tsl 25 at 39°C (the non-permissive temperature) after one hour. 10(ll samples from wt 18 and 
tsl 25 were examined by SDS-PAGE (figure 3.28), from which it was evident that a higher 
concentration of the tsl enzyme, over the wild type equivalent, was required to digest the 
same amount of substrate. This is consistent with results described elsewhere (Rancourt et 
al., 1995). These authors determined that recombinant Ad2 tsl enzyme was active regardless 
of the temperature of synthesis, or the temperature of the enzyme reaction, and like the wild 
type recombinant enzyme, was dependent on the addition of pVI-ct for activity. These 
authors also noted the level of recombinant Ad2 tsl protease expression was poor in 
comparison to recombinant wild type. Keyvani-Amineh et al (1995) provided additional
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information to suggest that the tsl mutation destabilises protein structure, and therefore 
renders the protein less soluble.
Figure 3.28: Relative activities of recombinant wild type (wt) and tsl enzymes. 
Recombinant wt and tsl 23kd protease enzymes were expressed and purified as described in section 2.1.3. The 
wt enzyme was examined by 15% SDS-PAGE (lane 3 of the Coomassie blue stained gel) together with 
molecular weight markers and 23kd protease standard (lane 1). The fraction (referred to as wt 18) was estimated 
to contain approximately 10|ig/ml 23kd protease (using SBTI standards as a comparison). 10pl of this source 
of 23kd protease was estimated to cleave approximately 50% of the synthetic substrate LSGAGFSW (using 
the methods outlined in section 2.2.5) over a period of one hour at 37°C (part A). Recombinant tsl 23kd 
protease (referred to as tsl 25) is shown in lane 2 (estimated final concentration of approximately 30pg/ml ). 
A 10pl sample was determined to cleave approximately 50% of LSGAGFSW at both 37°C and 39°C (the 
latter is shown in part B).
To determine whether any of the monoclonal antibodies affected tsl 25 activity, or indeed, 
whether the P137L substitution affected antibody binding, monoclonal antibodies ()A10b3, 
OC1 lbl 1 and GB4g4 were incubated with l()pl fractions of wt 18 and tsl 25 for one hour
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on ice, and, at 37°C and 39°C for 30 minutes. After addition of pVI-ct and substrate 
(LSGAGFSW), assay mixtures were left for one hour at 37°C or 39°C then analysed by 
capillary electrophoresis. Both wt 18 and tsl 25 enzyme activities were inhibited by OA10b3 
binding at 37°C and 39°C (figure 3.29a and c). Neither OC1 lbl 1 or GB4g4 affected enzyme 
activity (figures 3.29c, d, e and f) regardless of the temperature of antibody-antigen 
incubation, or temperature of the enzyme reaction.
time (minutes)
Figure 3.29: Effect of antibody binding on recombinant wt and tsl enzyme activity. 
Antibody solutions were incubated with samples of wt 18 and tsl 25 for one hour on ice prior to peptide assay 
(section 2.2.5). OA10b3 was shown to inhibit wt 18 and tsl 25 protease activity (parts A and B respectively) 
whilst OCllbll (parts C and D) and GB4g4 (parts E and F) did not appear to significantly affect activity of 
either enzyme. Several other peaks evident on capillary electrophoresis traces shown in parts B, D and F (tsl 
profiles), but not those of the wt enzyme, suggest that aminopeptidases present within concentrated cell 
culture supernatants may have cleaved co-purified polypeptides in the tsl 25 sample.
None of the antibodies were added to the pre-activated wt 18 or tsl 25 using the above assay 
system, although all three monoclonal antibodies were shown to recognise immobilised
C-term
N-terrn
'ys-199
Cys-122 Pro-168
Cys-17-
Cys-40—
Ile-150
Pro-137
Activating peptide
Cys-104
Figure 3.30: Location of cysteines and P137 within the 23kd protease. Cysteines 
involved in the activation (Cys-104) and known to comprise the active site triad (Cys-122) 
are highlighted in appropriate locations (Ding et al, 1996). Other cysteines are 
highlighted in bold at predicted sites (locations predicted by Gonzalo Cabrita. University 
of St.Andrews). Proline-137 is believed to be located within the loop hidden from view by 
the N-terminal region of the activating peptide. The proline rich region extends from Pro- 
137 to Pro-168 (Ile-150 is highlighted) A portion of this region appears to fold around a 
loop extending from Cys-104 to Cys-122.
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activated, and non-activated wt 18 and tsl 25 using the direct ELISA method (results not 
shown). It was evident that any changes in the enzymes conformation as a consequence of 
the P137L substitution did not affect regions H2 to H3 and H5 to H7 which contained the 
epitopes for the antibodies used. Keyvani-Amineh et al (1995) suggested that the tsl mutation 
could alter the size, shape and stability of the proline rich region (Pl37 to Pl65) that stretches 
from a-helices H4 to H5 (figure 3.30 on the previous page). Interestingly, the authors 
proposed that this region may be an important regulatory signal in determining the lifetime 
and degradation rates of the enzyme. The region forms a surface loop that may be required 
for protein trafficking in vivo.
Oxidising and reducing agents were used to investigate the effects of redox modulation on wt 
18 and tsl 25 sulphydryl groups. The thiol oxidising agent diamide [diazinedicarboxylic acid 
bis (N,N-dimethylamide), Aldrich] was prepared fresh as a 50mM stock solution in lOmM 
Tris-HCl, pH 8.0, and added to recombinant 23kd protease (10|il samples of wt 18 and tsl 
25) to a final concentration of lOmM. Likewise, pVI-ct and B-mercaptoethanol (B-MeSH) 
were added to final concentrations of 0.2mM and ImM respectively. Treated and non-treated 
samples were left at room temperature for 5 minutes, then electrophoresed under denaturing 
conditions (without reduction) and either electroblotted (then examined using antibodies 
OA10b3 and OCllbll, figure 3.31a) or silver stained (figure 3.31b).
Two isoforms were detected when both wt 18 and tsl 25 were pre-incubated with ImM B- 
MeSH and 0.2mM pVI-ct/ ImM B-MeSH, with the slower migrating form assumed to be the 
23kd protease/pVI-ct heterodimer. Greber et al (1996) showed that protease extracted from 
reduced virus particles migrated faster than protease from non-reduced virus particles (when 
electrophoresed under denaturing conditions) and suggested that the aberrant gel mobility was 
due to the inter-chain disulphide that connects the protease with pVI-ct. unexpectedly, both 
forms were detected in the non-treated wt 18 and tsl 25 samples, which suggested that pVI-ct 
binding alone was not responsible for the differences in migration. In addition, the non- 
treated wt 18 sample contained what was presumed to be a dimeric form of the enzyme. This 
form was not detected in the non-treated tsl 25 sample, nor has it been described elsewhere. 
Keyvani-Amineh et al(Y)96) also observed two closely migrating forms of the non-treated 
recombinant wild type protease, and also a faster migrating form (appeared at 12kd) which 
they assumed contained one or more disulphides. Differences between results presented here
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and those provided by Keyvani-Amineh et al (1996) may be a consequence of different 
purification protocols used. For instance, Keyvani-Amineh et al (1996) included 13-MeSH 
(5mM final concentration) in all buffers used throughout their purification regime, to increase 
the overall yield of soluble protease. 6-MeSH was not included in buffers used in this study 
and as a consequence, recombinant protease may have been subject to oxidation throughout 
the course of the lengthy purification.
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Figure 3.31: Isoforms of recombinant wt and tsl protease. Part A: lOpl samples of wt and tsl 
were reduced (ImM B-MeSH/assay buffer) (lane 1), incubated with pVI-ct (0.2mM final concentration in ImM 
B-MeSH/assay buffer)(lane 2), treated with diamide (lOmM final concentration)(lane 3), or non-treated (assay 
buffer added without B-MeSH)(lane 4). Treated and non-treated samples (all 20pl total volume) were left at 
room temperature for 5 minutes, then electrophoresed (15% SDS-PAGE without B-MeSH), probed using 
OA10b3. Immunoblots were over-exposed (approximately 1 hour) and consequently some levels of 
background were evident. Part B: silver stained 15% Polyacrylamide gel (samples prepared for electrophoresis 
as outlined above) of fully reduced (5mM B-MeSH)(lane 1), pVI-ct treated (lane 2), non-treated (0.2mM)(lane 
3) and diamide treated (10mM)(lane 4) wt and tsl recombinant enzymes.
ts1 wt
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A slow migrating dimeric form of wt 18 (but not tsl 25) was detected after diamide treatment. 
Additionally, one other iso form was detected for both wt 18 and tsl 25 which appeared to 
have migrated slower than the two close migrating isoforms detected in the non-treated, and 
B-MeSH treated samples. It is generally accepted that oxidised proteins migrate faster than 
reduced equivalents when electrophoresed under denaturing conditions (Creighton, 1990). It 
is unclear why in this instance the oxidised form has migrated more slowly. It is possible that 
lOmM diamide in the sample may affect the migration of proteins during electrophoresis. 
However, if this was the case then co-purified E.coli proteins did not appear to be affected 
(figure 3.31b). The dimeric form of wild type (but not tsl mutant) was consistently detected 
from several batches of purified enzyme. It is possible that the geometry of cysteine residues 
in the tsl mutant enzyme are disturbed, and consequently, has affected the occurrence of 
inter-chain disulphides.
In an attempt to isolate the dimeric isoform, 200pi of recombinant wild type protease (from 
an estimated 0.5mg/ml stock solution, figure 3.32a(i)) was injected into a pre-equilibrated 
(150mM NaCl; 50mM Tris-HCl, pH 8.0) Superdex-75 gel filtration column (section 
2.1.7iii). The flow rate was 0.5ml/min, with 0.5ml fractions collected. Fractions 12 to 16 
were examined by Western blotting using antibody OA10b3 (figure 3.32a(ii)). The same 
fractions were examined in the absence of B-MeSH (figure 3.32b) and after the addition of 
pVI-ct (figure 3.32c). It was evident that fractions 12 and 13 contained the dimeric form of 
the enzyme only, which after pVI-ct addition, appeared to be converted into a monomeric 
form that was presumed to represent the activated enzyme. This was suggestive that Cys-104 
was involved in the inter-chain disulphide exchange required for pVI-ct binding and 
dimerisation. In addition to the isoform that migrated at 23kd, fractions 14 and 15 also 
contained a faster migrating form that was assumed to contain one or more intra-molecular 
disulphides. Only this form and the dimeric form were detected in fraction 16, It was unclear 
whether pVI-ct addition affected the gel mobility of the fast migrating oxidised isoform. 
Fraction 14 was found to be active after pVI-ct addition, and exhibited minimal activity in the 
absence of pVI-ct. No activity was detected from fractions 12 and 16 after pVI-ct addition, 
although this was likely due to the low concentrations of enzyme present in both samples.
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Figure 3.32: Isolation of the dimeric form of recombinant wt 23kd protease. Part A (i): 
10p.l sample of recombinant wt 23kd protease (Coomassie blue stained 15% SDS-PAGE). Part A (ii): 
Immunoblot (OA10b3) of eluted fractions 12 to 16 (section 2.1,7iii). lOpil samples from the same fractions 
were also electrophoresed under denaturing conditions without reduction (immunoblot B) and after addition of 
pVI-ct (final concentration of 0.2mM)/without addition of B-MeSH (immunoblot C).
Further evidence to support the suggestion that Cys-104 may be directly involved in 
dimerisation is given in figure 3.33. Wt 18 and tsl 25 were treated with diamide, pVI-ct, and 
6-MeSH as described previously. When diamide (lOmM final concentration) was added to 
pre-activated enzyme no dimers were detected. However, it was clear from the immunoblots 
that diamide addition had caused the pre-activated wt 18 and tsl 25 enzymes to migrate more 
slowly than the non-activated diamide treated wt 18 and tsl 25 equivalents. Interestingly,
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addition of pVI-ct to diamide treated protease did not lead to the conversion of the dimeric 
form to the activated monomer as previously observed in non-treated samples, although 
again, an aberrant gel mobility was evident. It is possible that the inter-chain disulphide is 
extremely stable in the presence of diamide resulting in the inability of pVI-ct to convert the 
protease to the inactive form. It was of particular interest that there did not appear to be any 
difference in mobilities of the fast migrating forms of wt 18 and tsl 25. This suggested that 
both contained the same number of intra-chain disulphides and/or free thiols in both the 
diamide treated and non-treated samples. It was also apparent that fully reduced/denatured wt 
18 and tsl 25 enzymes exhibited the same gel mobility as the non-reduced/denatured 
heterodimer.
Figure 3.33: Redox modulation of recombinant wt and tsl 23kd protease. lOpl samples of wt 
18 and tsl 25 were electrophoresed (15% SDS-PAGE) as non-treated (lane 1), reduced (B-MeSH added to gel 
loading buffer)(lane 2), activated (0.2mM pVI-ct/lmM B-MeSH in assay buffer)(lane 3), non-activated (ImM 
B-MeSH in assay buffer)(lane 4), oxidised (lOmM diamide)(lane 5), activated then oxidised (0.2mM pVI-ct 
added then incubated for 5 minutes before addition of lOmM diamide)(lane 6), and oxidised (lOmM diamide 
added and sample incubated for 5 minutes) before addition of pVI-ct (0.2mM pVI-ct)(lane 7). All incubations 
prior to electrophoresis were 5 minutes in duration at room temperature. Except for fully reduced samples, no 
B-MeSH was added to gel loading buffer. The exposure time was approximately one hour.
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The Ad2 protease contains eight cysteines (figure 3.30), three of which are highly conserved 
(Cys-104,-122, and -126), four others are less conserved (Cys-17, -40, -67, and -127), and 
one is unique to the Ad2 protease (Cys-199). In order to determine which cysteines were 
involved in intra- and/or inter-chain disulphides, protease mutants C17A, C40A, C67A, 
C104S, C104/122S, C122S, C126A, C104/126A, 026/127A, 027A, and C199A (site 
directed mutagenesis had previously been carried out by Grierson et al (1994)) were 
expressed, then purified using the methods outlined in section 2.1.7. It is noteworthy that 
low yields of purified mutants C67A and C126A were obtained. It was not determined 
whether this was due to low levels of expression, or if mutants were insoluble and retained in 
lysed cell pellets. All of the protease mutants (including tsl 25), and two sources of wild type 
enzyme (wt 18 and wt 6 (donated by Dr.Munir Iqbal, University of St.Andrews)) were 
electrophoresed under denaturing conditions, then electroblotted, and examined using an 
antibody mix of OA10b3/OCllbll. As expected, the two close migrating isoforms of wt 18 
and tsl 25, and the dimeric form of wt 18 were detected from the non-treated samples (figure 
3.34). The three isoforms were also detected with mutants C199A, C17A, C40A, C127A 
and surprisingly C104S. This suggesed that these cysteine residues were not required for 
intra- and/or inter-chain disulphides. The faster migrating isoform of the protease (which was 
assumed to be the oxidised monomer) was absent with mutants C67A, Cl26A and the double 
mutant C126/127A. It was less apparent whether this isoform was absent with mutants 
C122S and C104/122S. The absence of the oxidised monomer was suggestive that these 
cysteine residues were required for intra-chain disulphides. In addition, the dimeric form of 
the enzyme was not detected with mutants C67A, Cl26A or Cl26/127A.
Keyvani-Amineh et al (1996) noted that the fast migrating (apparent 12kd) isoform was 
absent when mutants C67G, C126G and C104G (later re-identified as C122G) were 
electrophoresed under denaturing conditions. The authors did not specify whether or not this 
was due to low levels of expression and/or insolubility of the enzyme, but did suggest that 
these residues may be important for disulphide bond formation. An examination of the atomic 
structure of the activated 23kd protease revealed that Cys-122 and Cys-126 are in close 
proximity, and therefore may form an intra-chain disulphide upon oxidation. Interestingly, 
the proline rich region (P137-P165) loops around B-sheet S6, and therefore the tsl mutant
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P137L substitution in this region, may exert conformational constraints on a-helix H4, and 
consequently affect the orientation of Cys-122.
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Figure 3.34: Isoforms of site directed mutants. Cysteine mutants were expressed and purified using 
the methods described in section 2.1.3 and 2.1.7. Samples were electrophoresed after addition of B-MeSH to 
the gel loading buffer (part A), or in the absence of reducing agent (part B). Prestained molecular weight 
markers (lane i) in immunoblot A (probed with OA10b3) confirmed that all protease samples had an Mr of 
23kd. Biotinylated molecular weight markers are included in blot B.
Results presented in this section have suggested that the likely candidates for intra- and/or 
inter-disulphide bond formation are Cys-67, Cys-122, Cys-126 and Cys-104. These results 
were based solely on SDS-PAGE and immunoblotting analysis, and to implicate these 
cysteine residues directly requires other methodological approaches. For instance, chemical
determination of disulphides involves the disruption of protein conformation, and degradation 
of the protein into peptides, whilst ensuring that manipulations do not alter the disulphide 
bonds that were initially present. Thiols are blocked using thiol reagents such as iodoacetate 
or iodoacetamide, thus minimalising the likelihood of disulphide rearrangements before 
identifying peptides that contain cysteine residues of interest. This type of approach may 
provide further information regarding the involvement of particular cysteines in intra-chain 
disulphide bond formation, and consequently, the effects of the P137L substitution on tsl 
mutant protease structure.
The relevance of results presented in this section to the role of the protease in virus infected 
cells is discussed in section 4.
3.3 Subcellular localisation of the Ad2 23kd protease.
3.3.1 Morphology of an adenovirus infected cell.
i) Determination of intranuclear structures by electron microscopy (EM):
The eukaryotic cell nucleus performs a series of tasks including replication and packaging of 
DNA and transcription, splicing, polyadenylation, and transport of RNA. The nucleus is 
organised into a series of structural domains of which the nucleolus is best characterised. 
Much of the nuclear interior is occupied by chromatin (in various degrees of condensation) 
and interchromatin regions that contain several characteristic structures, including 
perichromatin fibrils and granules, interchromatin granules, and other nuclear bodies 
including coiled bodies (Brasch and Ochs, 1992; Chaly and Chen, 1993; Puvion-Dutilleul 
and Puvion, 1995; Bridge and Pettersson, 1995). In this study, mock infected cells, and non­
infected cells, were examined to form a basis for comparison with nuclei of infected cells. By 
conventional EM, the nuclei of mock infected HeLa cells exhibited few distinctive features 
(figures 3.35 and 3.36). The nucleoplasm was quite homogenous in appearance with 
condensed chromatin, nucleoli and nuclear bodies detected. It was beyond the scope of this 
study to accurately identify specific structures within non-infected HeLa cell nuclei (for 
instance coiled bodies), however, based on comparisons with micrographs presented in 
publications by Brasch and Ochs (1992) and Chaly and Chen (1993), it appears likely that
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Figure 3.35: Electron micrograph of a mock-infected HeLa cell. Mock-infected HeLa cells were 
fixed with 2% paraformaldehyde/ 0.05% glutaraldehyde (pH 7.4) for one hour then dehydrated and embedded in 
epon as described in section 2.8. Thin sections were contrasted with uranyl acetate/lead citrate then viewed at 
80kv. The nucleolus (Nu), regions containing condensed chromatin (CC), nuclear membrane (NM), cytoplasm 
(C), and mitochondria (M) are easily identified. Automatic exposure at x5700 magnification.
Figure 3.36: Intranuclear domains of the non-infected HeLa cell. Higher magnification 
(x25000) view of the nucleus of a HeLa cell from the same thin-section as that shown in figure 3.35. Nucleoli 
(Nu), condensed chromatin (CC), and possible nuclear bodies (Nb). Automatic exposure.
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many of the domains shown in figures 3.35 and 3.36 are genuine and are not artefacts of 
fixation methods, or dehydration and/or embedding in hydrophobic resin.
Nuclei of adenovirus infected cells progressively accumulate new induced structures as a 
consequence of viral replication. Due to the low multiplicity of infection (10 p.f.u/cell) used 
during the course of this study, some of these structures were detected, and are highlighted in 
figures 3.37 and 3.38.The earliest ultrastructural changes detected are small, irregularly 
shaped masses of thin fibrils (Puvion-Dutilleul and Puvion, 1995) that rapidly increase in size 
and become pleomorphic, appearing as crescents, rings and spheres (figure 3.37). These 
fibrillar inclusions contain DBP-ssDNA (ssDNA accumulation sites are discussed in more 
detail in section 3.3.4) and are present in the fibrillogranular network of the peripheral 
replicative zone, which appears to be the main site of viral replication and transcription. At 
late stages of nuclear transformation, DBP-ssDNA accumulation sites are located at the 
periphery of the viral genome storage sites (which are frequently associated with crystalline 
arrays of virus particles), and become smaller and more homogenous in shape, appearing as 
globular inclusions rather than crescents and rings (figure 3.38). Viral genome storage sites 
are typically detected within nuclei after 20 h.p.i (Bridge and Pettersson, 1995), and it has 
been suggested that DNA from these compartments may be incorporated into virions. 
Structures which are thought to be viral genome storage sites (VGSS) are highlighted in 
figures 3.37 and 3.38, although it should be noted that the identification of these structures is 
based only on comparisons with data presented by Chaly and Chen (1993) and Puvion- 
Dutilleul and Puvion (1995). However, a viral genome storage site identified by Puvion- 
Dutilleul et al (1995b) is shown in figure 3.53 (page 163).
Clusters of interchromatin granules are more discernible as infection progresses (figure 3.37) 
and have been shown to contain snRNP proteins, regardless of the stage of infection 
(Puvion-Dutilleul et al., 1994). Electron microscopic studies of non-infected HeLa cells 
(Puvion-Dutilleul et al., 1994; Rebelo et al., 1996) have shown that snRNPs are present in 
clusters of interchromatin granules, interchromatin granule-associated zones, coiled bodies 
and perichromatin fibrils. It was not possible to accurately identify these structures in this 
study (figures 3.35 and 3.36), although in late-phase adenovirus infected cells the 
interchromatin granules and less commonly observed compact rings (not shown) were easily 
identified after comparing data presented here, and that provided by Chaly and Chen (1993)
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Figure 3.37: The nucleus of an adenovirus infected cell (I). Adenovirus infected HeLa cells (28 
h.p.i) were fixed with 4% formaldehyde (pH 7.4) for 10 minutes then dehydrated, embedded, and contrasted as 
described in section 2.8. Thin-sections were viewed at 80kv. Residual nucleolus (rNu), ssDNA-accumulation 
sites (fibrillar inclusions; FI), interchromatin granules (IG),viral genome storage site (possible)(VGSS), clear 
amorphous inclusions (CAI), condensed chromatin (CC), and virions (V). Automatic exposure at x9100 
magnification.
Figure 3.38: The nucleus of an adenovirus infected cell (II). Ad2 infected HeLa cells (28 h.p.i), 
were fixed with 2% paraformaldehyde/ 0.05% glutaraldehyde (pH 7.4) for one hour then dehydrated, embedded, 
and contrasted as outlined in section 2.8. Crystalline arrays of virions (V), randomly distributed virions (rV), 
condensed chromatin (CC), viral genome storage site (possible)(VGSS), and fibrillar inclusions (FI), viewed at 
80kv, automatic exposure at x7100 magnification.
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and Puvion-Dutilleul et al (1994). The latter authors have detected spliceosome components, 
viral RNA and poly(A)+ RNA within the fibrillogranular network and clusters of 
interchromatin granules and suggest that these could be the sites of active splicing and/or 
post-splicing events. Pulse-chase labelling studies undertaken by the same authors (Puvion- 
Dutilleul et al., 1992 and 1994) have also indicated that clusters of interchromatin granules 
might contribute to some sorting of viral RNA molecules before their transport to the 
cytoplasm.
During the course of an adenovirus infection nucleolar proteins (B23, NOR90, Poll, and 
NuFl; Bridge and Pettersson, 1995) and nucleolus-associated proteins such as fibrillarin 
(Puvion-Dutilleul and Christensen, 1993) and P80-coilin (Rebelo et al., 1996) are 
redistributed, some of which are later detected within and/or near ssDNA accumulation sites. 
Data is consistent with idea that adenovirus infection disrupts the organisation of the 
nucleolus (figure 3.37), with viral replication being associated with pseudonucleoli.
Many of the cellular and virus-induced structures emphasised within the micrographs 
presented so far, have been tentatively compared with published data from studies which 
have been primarily focused on the elucidation of structure-function relationships of specific 
cellular compartments involved in the replicative cycle of the virus. Comparisons are made 
difficult for several reasons. Firstly, other studies have described the formation of several 
types of nucleoplasmic inclusions that differ in size, morphology, and in some instances, 
whether they incorporated [3H]uridine, [3H] thymidine, or neither. Since these studies used 
different cell types, Ad strains, stages of infection (most studies have focused on events 
occurring from 1 to 20 h.p.i), and inclusion body nomenclatures, it is difficult to compare the 
results directly.
Comparisons were made more difficult when different methods of fixation (in particular if 
cryo-fixation was used instead of chemical fixation), or different types of embedding media 
were utilised (in most studies hydrophilic acrylic resins or hydrophobic epoxy resins were 
used, although in a few cases cryo-electron and embedment-free section electron microscopy 
techniques were employed), and whether or not thin sections were contrasted, or post-fixed 
with osmium tetroxide. Even during the course of this study there were observed differences 
in the apparent structure of clear amorphous inclusions (figure 3.37), which appeared to be
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dependant on the chemical fixative used, and/or the duration time of fixation. This is 
discussed in detail below.
ii) The balance between fine structure preservation and immunolabelling: 
Chemical fixation of non-infected, and adenovirus infected, HeLa cells is the only method by 
which intracellular structure can be preserved to as near as possible the 'native' organisation, 
as well as protecting the intracellular structure against later stages of preparation for 
immunocytochemical analysis. However, treatment with many chemical fixatives can lead to 
the physical loss of epitopes such as by extraction of molecules and structures (which can 
occur with osmium tetroxide treatment), volume and shape changes in cellular architecture, 
steric hindrance of epitopes by fixative-induced cross-links, and chemical alteration of 
epitopes by direct reaction with fixatives (fixative-induced denaturation effects).
It was thought possible that any one of these effects might be observed during the course of 
this study and therefore several chemical fixatives were utilised. 4% formaldehyde, 4% 
paraformaldehyde, 1% glutaraldehyde and 2% paraformaldehyde/0.05% glutaraldehyde 
(prepared fresh prior to use as described in section 2.7.5) were all used, with the duration 
times of fixation being 10, 30 and/or 60 minutes. In some instances, fixed cells were post­
fixed osmium tetroxide prior to embedment.
The fine structural preservation of 4% formaldehyde fixed (10 minutes fixation time) infected 
(figure 3.39) and non-infected (not shown) HeLa cells was poor in comparison with 1% 
glutaraldehyde and 2% paraformaldehyde/0.05% glutaraldehyde fixed cells. This may be in 
part due to the extraction of soluble antigens from the cytoplasmic and nucleoplasmic 
compartments. For instance, although formaldehyde penetrates both the cytoplasmic and 
nucleoplasmic compartments relatively quickly, the time taken for optimal fixation is slow in 
comparison to glutaraldehyde fixation. There appears to be two different modes by which 
formaldehyde cross-links amino groups of proteins, depending on the concentration of 
fixative (Griffiths, 1993). At concentrations (below 2%) where the monomer methylene 
glycol predominates, the major types of cross-links are methylene bridges. Evidence suggests 
that methylene bridges form relatively slowly and inneficiently in comparison to 
polyoxymethylene cross-bridges which are rapidly formed when high (>10%) concentrations 
of formaldehyde are used.
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Figure 3.39: Preservation of nuclear structure after 4% formaldehyde fixation. Ad2 infected
HeLa cells (28 h.p.i) were fixed with 4% formaldehyde (pH 7.4) for 10 minutes then dehydrated, embedded, and 
contrasted as described in sections 2.7.5 and 2.8. Residual Nucleolus (rNu), virions (V), condensed chromatin 
(CC), and clear amorphous inclusions (CAI). Viewed at 80kv. Automatic exposure at x7100 magnification.
Figure 3.40: Fine structural preservation after 2% paraformaldehyde/ 0.05% 
glutaraldehyde fixation. Infected HeLa cells (28 h.p.i) were fixed as described in section 2.7.5 for 10 
minutes prior to dehydration and embedding. Residual nucleolus (rNu), clear amorphous inclusions (CAI), 
electron dense nuclear bodies (DNb), interchromatin granules (IG), fibrillar inclusions (FI),condensed 
chromatin (CC), and virions (V). Viewed at 80kv. Automatic exposure at x7100 magnification.
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Formaldehyde cross-links tend to be less stable than those of glutaraldehyde, as 
formaldehyde will most likely give rise to networks of linear cross-links as opposed to the 
branched cross-links that predominate within glutaraldehyde fixed cells. The linear cross­
links are generally thought to be more amenable to access of antibodies to antigen, and 
therefore there is a balance between access of antibody to available antigen and preservation 
of fine structure to determine the localisation of the antigen of interest.
Many of the intranuclear structures that were identified in figures 3.37 and 3.38 are less 
discernible in figure 3.39. However, it is possible to distinguish clusters of interchromatin 
granules, ssDNA accumulation sites, and what is thought to be the late-phase nucleolus. The 
clear amorphous inclusions are also evident (typically found within regions of high virion 
density, and interestingly, close to the nucleolus), and have a fibrillar appearance. Typically, 
several clear amorphous inclusions were observed to be joined together, often in pairs, 
although in many instances 'chains' of several inclusions were detected. The nature and 
possible function of these structures is discussed in more depth in section 3.3.2. It is also 
noteworthy that many of the intracytoplasmic structures are missing and/or difficult to 
identify within 4% formaldehyde fixed cells.
Fine structural preservation was improved with the 2% paraformaldehyde/0.05% 
glutaraldehyde mixture (10 minutes fixation time), with very little extraction of intracellular 
antigens (figure 3.40). All the virus-induced structures which had been previously identified 
were observed. Importantly, the clear amorphous inclusions had a fibrillar appearance, and 
were surrounded by high densities of virus particles. The clear amoiphous inclusions had a 
different appearance within cells fixed (same fixative) for 60 minutes instead of 10 minutes 
(figure 3.41). The inclusions appeared to be less fibrillar, appearing as opaque circles that 
either appeared as single inclusions or joined with other identical inclusions. Likewise, in 1% 
glutaraldehyde fixed cells (10 minutes duration) the amorphous inclusions also had an opaque 
appearance (figure 3.42) with no discernible fibrillar structure.
Glutaraldehyde in solution is uncharged and can rapidly cross all biological membranes. It 
can produce significant intracellular cross-linking in a matter of seconds and forms a large, 
three-dimensional network of cross-links in the cytoplasm in tenths of seconds (Griffiths, 
1993). The observed differences in the structural composition of clear amorphous inclusions 
using the different fixatives is difficult to explain. The differences are more evident
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Figure 3.41: Fine structure of virus-induced inclusions. Ad2 infected HeLa cells (28 h.p.i) were 
fixed with 2% paraformaldehyde/0.05% glutaraldehyde (pH 7.4) for one hour, then dehydrated, embedded, and 
contrasted as described in sections 2.7.5 and 2.8. Residual nucleolus (rNu), clear amorphous inclusions (CAI), 
electron dense nuclear bodies (DNb), interchromatin granules (IG), ssDNA-accumulation sites (FI), possible 
site of condensed cellular chromatin (CC),possible viral genome storage sites (VGSS), randomly distributed 
virions (rV) and crystalline arrays of virion particles (V). Viewed at 80kv. Automatic exposure at x9100 
magnification.
after post-fixation with osmium tetroxide. Clear amorphous inclusions within 
2%paraformaldehyde/0.05% glutaraldehyde fixed cells (10 minutes) that were post-fixed 
with osmium tetroxide (section 2.7.5) were darker and more fibrillar in appearance (figure 
3.43). The characteristic appearance of many structures, in particular membranes, in epoxy 
resin sections depends to a large extent on the effect of osmium tetroxide. Although it is 
unclear what protein(s) clear amorphous inclusions are comprised of, osmium tetroxide is 
known to be reactive to nucleophiles such as amino and sulphydryl groups and with 
unsaturated acyl chains of membrane lipids (Griffiths, 1993).
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Figure 3.42: Fine structural preservation with 1% glutaraldehyde fixation. Infected HeLa 
cells (28 h.p.i) were fixed as described in section 2.7.5 for 10 minutes. Residual nucleolus (rNu), electron 
dense nuclear bodies (DNb), clear amorphous inclusions (CAI), fibrillar inclusions (FI). Viewed at 80kv. 
Automatic exposure at x57O() magnification.
Figure 3.43: Post-fixation with osmium tetroxide. Ad2 infected HeLa cells (28 h.p.i) were fixed 
with 2% paraformaldehyde/0.05% glutaraldehyde (10 minutes) then post-fixed with osmium tetroxide as 
described in section 2.7.5. Electron dense fibrillar structures thought to correspond to clear amorphous (CAI) 
tutd the 'classical' railway track appearance of the nuclear membrane (NM) are changes thought to be dependent 
on osmium tetroxide fixation. Viewed at 8()kv. Automatic exposure at x7100 magnification.
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The ability of most antibodies to bind antigens is generally considered to be far less affected 
by formaldehyde treatment when compared to glutaraldehyde treatment (Griffiths, 1993).
This was found to be the case in this study with the level of immunolabelling of 23kd 
protease and protein pVIII on thin sections of 4% formaldehyde fixed cells (figure 3.44a) 
significantly greater than that of cells that had been fixed with 1% glutaraldehyde (figure 
3.44b) (fixation times of 10 minutes). The double immunolabelling technique for electron 
microscopy (Monaghan and Robertson, 1993) was used throughout the immunocytochemical 
study (section 3.3.2). It is clear from figure 3.44b that pVIII was not immunodetected within 
1% glutaraldehyde fixed cells despite a significant level of immunolabelling being detected 
within cells fixed with 4% formaldehyde.
It has been estimated (Griffiths, 1993) that approximately 15% of epitopes presented on the 
surface of thin sections of cells fixed by 1% glutaraldehyde are available for antibody 
binding, partly as a consequence of the nature of cross-links, but also because 
glutaraldehyde, like osmium tetroxide, can significantly affect the secondary and tertiary 
structures of many proteins. However, because the fine structural preservation within 
formaldehyde fixed cells was relatively poor in comparison to glutaraldehyde fixed cells 
(particularly within nucleoplasmic regions containing high densities of virions), a 
compromise was made with the fixative 2%paraformaldehyde/0.05% paraformaldehyde (10 
and 60 minutes fixation times) being preferred for immunolabelling studies. The results of 
these studies are presented and discussed in the following sections. It is noteworthy that 
neither the 23kd protease or pVIII were detected in infected cells that were fixed with 2% 
paraformaldehyde/ 0.05% glutaraldehyde (10 minute fixation) then post-fixed with osmium 
tetroxide (figure 3.44c).
3.3.2 Colocalisation of the viral protease and pVIII/VIII.
i) Intranuclear colocalisation within clear amorphous inclusions:
Intranuclear and/or nucleus associated punctate spot and 'thread like' immunofluorescent 
staining patterns were detected using antibodies OA10b3 and GB4g4 within 4% 
formaldehyde fixed (10 minutes)/detergent permeabilised Ad2 infected HeLa monolayer cells 
late in infection (figure 3.45a). An identical immunofluorescent staining pattern for pVIII was
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Figure 3.44: Immunocytochemical detection of pVIII and the 23kd protease. Ad2 infected 
HeLa cells (28 h.p.i) were fixed (10 minutes) with 4% formaldehyde (part A), 1% glutaraldehyde (part B) or 
2% paraformaldehyde/0.05% glutaraldehyde and post-fixed with osmium tetroxide (part C). Double 
immunolabelling against pVIII (6nm gold particles) and 23kd protease (lOnm gold particles) was performed as 
described in section 2.8.4. All thin-sections viewed at 80kv. Automatic exposures at x34000 magnification.
observed within the same cells (figure 3.45b), when both proteins were examined using the 
double immunolabelling technique for light microscopy (Jackson and Blythe, 1993).
The two step indirect method was used with unlabelled primary antibody (rabbit polyclonal 
antiserum specific for pVIII was kindly donated by W.S.A. Annan, University of 
St.Andrews) and labelled secondary antibody (Texas-red conjugated anti-rabbit 
immunoglobulin and FITC conjugated anti-mouse immunoglobulin). This method is 
generally considered to be more sensitive than the direct method because several secondary 
antibodies may react with different antigenic sites on the primary antibody . Additionally, the 
technique is more versatile than the direct method as the same labelled secondary antibody can 
be used with a variety of primary antibodies raised from the same animal species, as was the 
case throughout the course of this study.
The colocalisation of both proteins was examined further using the BIO-RAD MRC-600 laser 
scanning confocal imaging system. The fluorescent staining patterns of both proteins were
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Figure 3.45: Colocalisation of pVIII and the 23kd protease (I). Ad2 infected HeLa cells (28 
h.p.i) were fixed for 10 minutes using 4% formaldehyde. The methodology of immunofluorescent staining is 
descibed in section 2.8.2. Part A: Immunostaining of pVIII using anti-pVIII polyclonal antiserum and Texas- 
Red conjugated anti-rabbit IgG. Part B: immunodetection of the viral protease using cell culture supernatant 
containing antibody OA10b3 and FITC conjugated anti- mouse IgG. Automatic exposure times were typically 
30 seconds for pVIII and 1.5 minutes for the viral protease. x40 objective.
Figure 3.46: Colocalisation of pVIII and the 23kd protease (II). Ad2 infected HeLa cells (28 
h.p.i) were fixed and treated as outlined in figure 3.45 and section 2.8.2. Immunolabelled cells were examined 
using the BIO-RAD MRC-600 laser scanning confocal imaging system at xlOO magnification (oil 
immersion). Part A: pVIII. Part B: 23kd protease (stained using OA10b3). Part C: merge of both images with 
pVIII stained red, the viral protease stained green and colocalisation of both antigens identified through yellow 
fluorescent staining.
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examined using a lOOx oil immersion objective, recorded, stored (figure 3.46a and b) and 
merged (figure 3.46c). Colocalisation of pVIII and the viral protease was clearly evident and 
is indicated in regions of the cell highlighted in yellow. A disadvantage of the laser confocal 
system over conventional light microscopy is that fluorescent staining patterns within a single 
plane are recorded. Therefore, the threads of fluorescent staining characteristic to the 23kd 
protease and pVIII were less obvious. However, it was thought these images were more 
likely to resemble sections of ultrathin cell slices examined using immunocytochemistry.
As previously mentioned, both proteins were immunolocalised to clear amoiphous inclusions 
(figure 3.47). The 23kd protease was not detected within or (associated with) any other 
nuclear structures using antibody OA10b3, with the exception of minor levels of 
immunolabelling at regions of high virion density (section 3.3.3). pVIII/VIII was also 
localised exclusively to clear amorphous inclusions, although similar to the viral protease, 
some immunolabelling of virions was detected. This suggested that the punctate spots and/or 
thread immunofluorescent staining patterns shown in figures 3.45 and 3.46 were likely to be 
immunolabelling of both proteins within these inclusions.
Interestingly, there appeared to be observable differences in the infrastructure of clear 
amorphous inclusions as highlighted in figure 3.47. Two inclusions with fibrillar 
arrangements of different contrasts appear to be linked, with the 23kd protease being 
localised (using antibody OA10b3) predominantly to the darker contrasted inclusion (dai). 
Significant immunolabelling of pVIII is observed in both, although the majority is associated 
with the light contrasted amorphous inclusion (lai). As mentioned in section 3.3.2, the 
fibrillar infrastructure was absent within clear amorphous inclusions after 2% 
paraformaldehyde/ 0.05% glutaraldehyde fixation (60 minutes). Significant immunolabelling 
of pVIII/VIII and 23kd protease was detected within these structures (figure 3.48) which had 
a 'thread like' appearance and were surrounded by virions.
The shape of clear amorphous inclusions within Ad2tsl infected HeLa cells at 28 h.p.i 
differed markedly from the wild type equivalent (figure 3.49). The inclusions had an irregular 
appearance and perhaps more importantly were not immediately surrounded by virus 
particles. Although the 23kd protease (detected using OA10b3) and pVIII/VIII were 
immunolocalised to these domains (figure 3.50), the apparent levels of both proteins within 
these structures was significantly reduced.
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Figure 3.47: Colocalisation of pVIII and the viral protease within clear amorphous 
inclusions (I). Ad2 infected HeLa cells (28 h.p.i) were fixed using 2% paraformaldehyde/0.05% 
glutaraldehyde (pH 7.4) for 10 minutes, then dehydrated and embedded as descibed in section 2.8. Thin-sections 
were treated as described in section 2.8.4. pVIII and the 23kd protease are immunolabelled with 6nm and lOnm 
gold particles respectively. Clear amorphous inclusions (CAI) are subdivided into dark contrasted (DAI), and 
light contrasted inclusions (LAI). Viewed at 80kv. Automatic exposure at x34000 magnification.
Figure 3.48: Colocalisation of pVIII and the viral protease within clear amorphous 
inclusions (II). Ad2 infected HeLa cells (28 h.p.i) were fixed with 2% paraformaldehyde/0.05% 
glutaraldehyde (pH 7.4) for 60 minutes (section 2.7.5) then dehydrated and embedded (section 2.8). pVIII and 
the viral protease are immunolabelled with 6nm and lOnm gold particles respectively within the elongated 
clear amorphous inclusion (CAI). Viewed at 80kv. Automatic exposure at x34000 magnification.
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Figure 3.49: Alterations in nuclear structure upon Ad2tsl infection. HeLa cells were infected 
with Ad2tsl arcton extract at approximately 10 p.f.u/cell and maintained at the non-permissive temperature 
(39.5°C). Monolayers were fixed at 28 h.p.i with 2% paraformaldehyde/0.05% glutaraldehyde (pH 7.4) for one 
hour, then dehydrated and embedded (section 2.8). Clear amorphous inclusions are highlighted (CAI). Viewed 
at 80kv. Automatic exposure at x7100 magnification.
Figure 3.50: Colocalisation of pVIII and the viral protease within inclusions of Ad2tsl 
infected cells. HeLa cells (same thin sections as shown in figure 3.49) were immunolabelled as described 
in section 2.8.4. Part A: Irregular shaped inclusion containing the viral protease and pVIII (immunolabelled 
with lOnm and 6nm gold respectively) but not immediately surrounded by virions (x34000 magnification). 
Part B: Immunolabelled clear amorphous inclusion with virions in close proximity (x25000 magnification). 
Part C: Lower magnification of clear amorphous inclusions (x9100) within regions of high virion density. All 
viewed at 80kv. Automatic exposures.
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It was of interest that even when the clear amorphous inclusions within Ad2tsl infected cells 
were in the proximity of regions containing high densities of virions, the virions were not 
observed to be closely associated with the virus-induced structures (figure 3.50 parts a and b) 
as observed within wild type Ad2 infected cells.
Immunofluorescent staining patterns of both pVIII and the 23kd protease in Ad2tsl infected 
cells (28 h.p.i) maintained at the non-permissive temperature (39.5°C) and permissive 
temperature (33°C) are shown in figure 3.51 (parts a and b respectively). The punctate spots 
and threads observed within wild type infected HeLa cells were detected using OCllbll, 
however, the diffuse nucleoplasmic immunofluorescent staining patterns also detected in wild 
type Ad2 infected cells using antibody OCllbll (figure 3.8a), were not detected in the 
Ad2tsl (non-permissive) infected cells (figure 3.51a). A similar nucleoplasmic distribution of 
the 23kd protease to the wild type infection was detected within Ad2tsl infected HeLa cells 
maintained at the permissive temperature for 48 h.p.i (discussed in more depth in section 
3.3.3). Interestingly, the structural integrity of clear amorphous inclusions also appeared to 
be restored within Ad2tsl infected cells maintained at the permissive temperature for 48 h.p.i, 
with clusters of vims particles observed to be in close proximity (figure 3.52).
ii) The origin of clear amorphous inclusions:
The clear amorphous inclusions to which pVIII and the 23kd protease have been shown to be 
localised to late in infection, are believed to be identical to the amorphous inclusions which 
Puvion-Dutilleul et al (1995b) determined to be the sites of PML accumulation during the 
course of Ad5 infection (figure 3.53). However, as cells were only examined at 28 h.p.i, 
only speculations can be made as to their origin.
A direct comparison can be made with the amorphous inclusions described in this study with 
those of Puvion-Dutilleul et al (1995b) because no other inclusions in either study were 
identified as having the same electron translucent appearance. In addition, the amorphous 
inclusions reported by these authors were also identified as being in close proximity to virus- 
induced protein crystals, which the authors noted, also contained redistributed PML protein. 
Puvion-Dutilleul et al (1995b) noted that as soon as virus-induced intranuclear changes 
became visible, clear amorphous inclusions were present in infected nuclei, and persisted 
until cell lysis. These structures which although were initially small and irregularly shaped,
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Figure 3.51: Immunofluorescent staining of pVIII and the 23kd protease within Ad2tsl 
infected cells at the nonpermissive temperature. Ad2ts 1 infected HeLa cells were fixed and double- 
immunolabelled as described in section 2.8.2. Localisation of pVIII (left) and 23kd protease (right) within 
Ad2tsl infected HeLa cells (28 h.p.i) maintained at 39.5°C
Figure 3.52: Immunofluorescent staining of pVIII and the 23kd protease within Ad2tsl 
infected cells at the permissive temperature.Localisation of pVIII (left) and the viral protease (right) 
within Ad2tsl infected cells (48 h.p.i) maintained at 33°C. OCllbll was used to immunodetect the viral 
protease. xlOO magnification (oil immersion).
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Figure 3.53: The morphology of clear amorphous inclusions within Ad2tsl (permissive) 
infected cells. Infected HeLa cells were fixed al 48 h.p.i using 2% paraformaldehyde/0.05% glutaraldehyde 
(pH 7.4) for one hour, then dehydrated, embedded and contrasted (section 2.8). Viewed at 8()kv. Automatic 
exposure at x34000 magnification.
became larger, spherical, and more abundant as the infection progressed. It was uncertain 
whether the inclusions were derived from nuclear bodies of non-infected cells. At the late 
phase of nuclear transformation (when virus clusters were numerous) clear amorphous 
inclusions were excluded from the region of the nucleus occupied by the viral genome storage 
site and were localised to the nuclear periphery.
The significance of the simultaneous presence of PML within clear amorphous inclusions and 
among the regular arrays of viral capsids is unknown. The authors noted that cellular hnRNP 
proteins were also localised to these virus-induced structures which suggested that crystal 
structures probably resulted from the assembly of both viral and cellular proteins. The 
authors speculated that the delocalisation of PML to these structures might facilitate the 
intranuclear development of progeny genomes and viruses. In that sense they demonstrated
that PML was a target gene of interferon and induces an antiviral state. Therefore, 
sequestration of PML into clear amorphous inclusions and crystal structures might indicate 
that PML is inactivated during adenovirus infection.
Protein crystals were not detected in this study, although it is clear from all the electron 
micrographs presented within this report, that the amorphous inclusions are located in regions 
of the nucleus containing high densities of virus particles.
A study undertaken by Wills and Russell (1973) involved the examination of the fine 
structure of Ad5 induced-protein crystals using temperature sensitive mutants for hexon, fibre 
and penton base. An electron micrograph of an intranuclear crystal published by these authors 
is shown in figure 3.54a together with an electron micrograph (from this study) of a clear 
amorphous inclusion in the proximity of crystalline arrays of virus particles (figure 3.54b). 
These authors have shown that there is a direct relationship with capsid synthesis and 
intranuclear crystal formation, with crystal formation being related to fibre, but not hexon, 
antigen expression. It was apparent that although the hexon deficient mutant tsl7 was unable 
to form virus particles at the non-permissive temperature, crystal formation could still take 
place. Interestingly, the authors also observed the formation of irregularly shaped intranuclear 
inclusions when the temperature sensitive mutant ts36 (the fibre, hexon and penton base 
defect is a consequence of the Ad5 polymerase mutation (Professor R.T. Hay, pers.comm)) 
was maintained at the non-permissive temperature. It is thought possible that the intranuclear 
inclusions described by these authors (and highlighted in figure 3.54a) are early-phase clear 
amorphous inclusions.
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Figure 3.54: Adenovirus-induced protein crystals. Part A (1): Portion of a nucleus early after 
infection with wild strain Ad5 at 38°C, showing crystaline inclusions. Part A (2): Crystals in the nucleus of a 
cell infected with ts36 at 33°C (48 h.p.i at the permissive temperature). Reproduced from Wills and Russell 
(1973). Inclusions which are thought to be early forms of the clear amorphous inclusions presented within 
this study are highlighted (CAI) Part B: Arrays of virus particles (immunolabelled with anti-pVII) at 28 h.p.i 
(this study, x34000 magnification). A lower magnification (x9100) of this section is shown in figure 
3.41.(highlighted as V).
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It is noteworthy, that many of the clear amorphous inclusions detected during the course of 
this study, were observed to be in close proximity to electron dense nuclear bodies (figure 
3.55). None of the cellular or viral antigens examined during the course of this study were 
localised to these structures and it is presently unclear what functional significance (if any) 
they have on virus assembly.
Figure 3.55: Ad2-induced inclusions at the nuclear periphery. Higher magnification (x34000) 
of the infected HeLa cell presented in figure 3.41. The thin section was immunolabelled with anti-pVII 
monoclonal antibody. lOnm Gold particles are evident within regions containing virions (V) and condensed 
cellular chromatin found at the nuclear priphery (CC), but not within clear amorphous inclusions (CAI) or 
electron dense nuclear bodies (DNb), and fibrillar inclusions (FI). The electron dense structures were 
commonly found to be in close proximity with clear amorphous inclusions at the nuclear periphery.
CAI
iii) The redistribution of PML and P80-Coilin:
Doucas et al (1996) have shown that at least two early transcribed viral proteins namely, the 
E4 ORF3 (llkd protein) and the E1B 55kd protein, are targeted to PML nuclear bodies, 
which in turn, undergo reorganisation into novel structures which the authors referred to as 
tracks. These structures had an identical appearance to the thread-like structures which were 
shown to contain pVID/Vni and the 23kd protease late in infection.
Interestingly, prolonged infection of HeLa cells with HSV-1 results in the localisation of 
PML, and another nuclear autoantigen SP100, to translucent patches of fine granular
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material, and viral capsids, at the nuclear border (Puvion-Dutilleul et al., 1995c). These 
authors also determined that HSV-1 infection induces the redistribution of at least some of the 
components of interchromatin granule-associated zones and coiled bodies, in particular U1 
snRNA, U2 snRNA and P80-coilin, to translucent patches. The translucent patches are 
detected only at the late stage of nuclear transformation, and contain a high concentration of 
capsid proteins (and also viral capsids), which suggested a possible role for these structures 
in the assembly of capsid proteins into capsid shells. Direct comparisons were made with the 
adenovirus induced clear amorphous inclusions, which the authors noted did not contain 
redistributed P80-coilin and snRNAs.
It was thought possible that 23kd protease may play an active role within clear amorphous 
inclusions in the inactivation of cellular proteins relocated to these intranuclear structures. A 
SWISSPROT findpatterns database search of all human proteins containing the consensus 
cleavage sequences for the Ad2 23kd protease ((M,L,I)xGxG and (M,L,I)xGGx, with zero 
mismatches) revealed that PML, P80-coilin, SP100, fibrillarin and U1 snRNP proteins all 
had potential cleavage sites for the viral enzyme. For PML, the potential cleavage sites are 
679-LWGPG and the C-terminal 869-LAGRG, Likewise, P80-coilin has two potential 
cleavage sites which are 61-LEGGL and 512-MRGRG. Polyclonal antiserum and monoclonal 
antibody cell culture supernatant generated against P80-coilin were generously provided by 
Dr.C. Lyons and Dr.A.I. Lamond from the University of Dundee. Cell culture supernatant 
containing Mab 5E10, which specifically recognises PML protein (Stuurman et al., 1992) 
was kindly donated by Professor Roel Van Driel (University of Amsterdam).
The distribution of both PML and P80-coilin within non-infected HeLa cells was examined 
using the BIO-RAD MRC-600 laser scanning confocal imaging system (figure 3.56). Both 
proteins were immunolocalised to specific foci within non-infected nuclei, with partial 
colocalisation observed within most cells examined. This was not surprising as Schul et al 
(1996) have described trios of coiled bodies, PML bodies and cleavage bodies (not examined 
here) which partially overlap within nucleoplasmic domains.
The distribution of both proteins late in infection (28 h.p.i) was markedly different (figure 
3.57), with the track-like staining patterns of PML described by Doucas et al (1996) easily 
identified. P80-coilin was likewise shown to be redistributed, but was not shown to
colocalise with PML.
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Figure 3.56: Immunofluorescent staining of PML and P80-coilin within non-infected 
HeLa cells. Part A: BIO-RAD MRC-600 laser scanning confocal image of PML (green) and P80-coilin 
(red) partial colocalisation within non-infected cells. Part B: Immunolocalisation of PML (top right) and P80- 
coilin (bottom right) using the Nikon-microphot light microscope. Mab 5E10 (anti-PML) and polyclonal 
antiserum 204/4 (anti-P80-coilin) were immunodetected using FITC and Texas-red conjugated anti-mouse and 
anti-rabbit IgG respectively (section 2.8.2). Both parts xlOO magnification (oil immersion).
Figure 3.57: The distribution of PML and P80-coilin within Ad2 infected HeLa cells (28
h.p.i). BIO-RAD MRC-600 laser scanning confocal image of PML (part A) and P80-coilin (part B). The 
merge of both images is shown in part C with PML showing as red and P80-coilin as green (channel leads 
reversed). The same antibody solutions were used as outlined in figure 3.56. Viewed at xlOO magnification 
(oil immersion).
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Surprisingly, PML and pVIII were also found to be differentially localised within infected 
cell nuclei at 28 h.p.i (figure 3.58). Puvion-Dutilleul et al (1995b) detected PML within clear 
amorphous inclusions at 17 h.p.i, and it may be that PML inactivation during the subsequent 
later phases of infection has resulted in the protein (or cleaved products of the protein) being 
relocated from these structures.
Figure 3.58: Immunolocalisation of PML and pVIII within Ad2 infected HeLa cells (28 
h.p.i). BIO-RAD MRC-600 laser scanning confocal image of PML (part A) and pVIII (part B). The merge 
of both images is shown in part C with PML shown as green and pVIII as red. Viewed at xlOO magnification 
(oil immersion).
Figure 3.59: Immunolocalisation of the 23kd protease and P80-coilin within Ad2 
infected HeLa cells (28 h.p.i). BIO-RAD MRC-600 laser scanning confocal image of the 23kd 
protease (detected using OA10b3)(part A) and P80-coilin (part B). The merge of both images is shown in part 
C with the 23kd protease shown as green and P80-coilin as red. Viewed at xlOO magnification (oil 
immersion).
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These authors also noted that P80-coilin was not localised to the clear amorphous inclusions 
during adenovirus infection. However, some colocalisation of the 23kd protease and P80- 
coilin was detected in this study (figure 3.59). Colocalisation appeared to occur at specific 
foci which contain the viral protease. It is possible that both proteins are localised to different 
intranuclear structures, which may overlap during the late stages of nuclear transformation. 
Rebelo et al (1996) have shown that coiled bodies are disassembled during adenovirus 
infection into microfoci, which they have determined using electron microscopy to be electron 
dense microbodies which contain both P80-coilin and fibrillarin. It is unclear whether these 
dense microbodies are the same electron dense nuclear structures which have been found in 
this study to be in close proximity to the clear amorphous inclusions at the nuclear periphery 
(figure 3.55). These electron dense nuclear bodies are discussed in more detail in section
3.3.6.
PML and P80-coilin were not detected in 4% formaldehyde or 2% paraformaldehyde/0.05% 
glutaraldehyde fixed (10 minutes) non-infected or infected HeLa cells. The post-embedding 
technique for immunocytochemistry which was used throughout this study has also been 
found to be unsuitable for immunodetection of P80-coilin in other studies (Dr.Carol Lyons, 
University of Dundee, pers.comm.). The pre-embedding technique, with immunolabelling of 
P80-coilin prior to infiltration of hydrophilic acrylic resins such as Lowicryl K4M, was 
found to be more suitable. Likewise, Stuurman et al (1992) used the pre-embedding 
technique to determine the intranuclear distribution of PML within permeabilised T24 and 
HeLa cells.
iv) Cleavage of P80-coilin, PML and pVIII:
In order to determine whether PML and/or P80-coilin were cleaved during the later stages of 
infection, nuclear extracts of infected cells (prepared at 28 h.p.i using the methods described 
in section 2.7.4) were electroblotted and examined using Mab 5E10 and antiserum specific to 
P80-coilin (figure 3.60 parts a and b respectively).
A major polypeptide was detected from both the Ad2 wild type and Ad2tsl nuclear extracts 
using Mab 5E10, which may be a cleavage product of PML. The intact protein has an 
approximate Mr of 126kd (Stuurman et al., 1992), however, the authors have noted that
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small quantities of higher and lower molecular mass polypeptides are recognised by Mab
5E10.
A 1 2 3
Bi 1 Bii 1 2 3
Figure 3.60: Possible cleavage of PML and P80-coilin. HeLa cell nuclear extracts (28 h.p.i) were 
prepared as described in section 2.7.4ii, then electroblotted (with prestained molecular weight markers). 
Samples of extracts from non-infected cells (lane 1), wild type infected cells (lane 2) and Ad2tsl infected cells 
(lane 3). Part A: Immunoblot using Mab 5E10 (anti PML) at a 1/100 dilution. Part B: Immunoblot using 
anti-P80-coilin polyclonal antiserum 204/4 (1/1000 dilution). 10 minute exposure times (except part Bi/lane 1 
which was an overnight exposure of Bii/lane 1).
The intact protein was not easily identified from the non-infected HeLa cell nuclear fraction 
and unfortunately, because there was only a limited quantity of Mab 5E10 available for these 
experiments, it was not possible to repeat the immunoblot presented in figure 3.60. As a 
consequence, it is also unclear whether the polypeptides detected in both wild type and tsl 
infected nuclear extracts correspond to a cross-reaction of Mab 5E10 with a viral antigen. The 
immunoblot is by no means conclusive evidence that PML is cleaved during infection,
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however, if the major polypeptides detected in the Ad2 wild type and Ad2tsl nuclear extracts 
do correspond to a cleavage product of PML, then this might suggest that the viral protease is 
active within clear amorphous inclusions, and therefore possibly play some part in PML 
inactivation. This would be of particular interest in the context of the Ad2tsl protease, which 
until relatively recently was thought to be inactive at the non-permissive temperature 
(Rancourt et al (1995). Additionally it is possible that cleavage products may be relocated 
from clear amorphous inclusions prior to the late-stages of infection as PML has not been 
observed to be colocalised with pVIII (and therefore potentially with the 23kd protease) at 28 
h.p.i.
Intact P80-coilin, like PML, was difficult to identify from immunoblotted nuclear extracts of 
non-infected cells (10 minute exposure time), although a major polypeptide with an Mr of 
approximately 80kd was detected in wild type and tsl infected cell nuclear extracts and over­
exposed non-infected cell nuclear extracts. There also appeared to be a significant level of 
degradation despite the addition of a cocktail of protease inhibitors to lysis buffers (kept at 
4°C). Similar levels of degradation have been observed elsewhere (Dr. Carol Lyons, 
pers.comm.). However, two additional bands were detected from the wild type Ad2 infected 
cell nuclear extract, which were not present in the equivalent non-infected, or the Ad2tsl 
nuclear extracts. The upper band had an Mr of approximately 35kd and the lower band of 
approximately 20 to 25kd. It is unclear whether these polypeptides are cleavage products of 
P80-coilin, although their absence (and the higher concentration of the intact protein) within 
the Ad2tsl nuclear extract suggested that the viral protease may be in part responsible for 
their occurrence.
The possible cleavage of P80-coilin was investigated further using in vitro 
transcribed/translated protein (plasmid pBS 751.2A (coilin cDNA in pBSSK-) was donated 
by Dr. Carol Lyons, University of Dundee), which in turn, was incubated with purified 
recombinant Ad2 23kd protease (section 2.9.3). Using the polyclonal antiserum specific to 
P80-coilin, the intact protein was immunoprecipitated from rabbit reticulolysates which also 
contained approximately lOfil (from a 50qg/ml stock solution) of non-activated recombinant 
protease (figure 3.61). The intact protein was not isolated from reticulolysates in which 
activated protease was added (section 2.93ii). Although no cleavage products were 
immunopecipitated from the reaction mixture, it appeared likely that the viral protease had
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cleaved the intact protein. Additionally, the cleavage products were not detected within the 
original reticulolysate reaction mixture which was examined using 15% SDS-PAGE (20pl 
sample of the 100|il). However, two additional polypeptides were detected from a crude 
reaction mixture containing 5p.l of activated protease and 25pl of rabbit reticulolysate 
containing P80-coilin (one hour incubation/37°C). It is unclear whether these correspond to 
cleavage products of P80-coilin, or other proteins present within the reticulolysate which 
were 35S-methionine labelled.
Figure 3.61: In vitro cleavage of P80-coilin. In vitro translated P80-coilin was incubated with 
activated and non-activated recombinant 23kd protease as described in section 2.9.3. 20|il samples from a crude 
TNT lysate containing P80-coilin, and P80-coilin plus non-activated and activated 23kd protease are shown in 
lanes 7, 6 and 5 respectively. P80-coilin was immuneprecipitated using polyclonal antiserum 204/4 from the 
TNT lysate/non-activated reaction mixture (lane 4), but not from the TNT lysate/activated protease reaction 
mixture (lane 3). 20pl samples from both reaction mixtures after immuneprecipitations are shown in lanes 1 
and 2 respectively. Samples were electrophoresed (15% SDS-PAGE), then Coomassie blue stained/destained 
and dried prior to examination using the Fujix phosphoimager (section section 2.9.3iii)..
In the absence of cleavage products which can accurately be identified as being the result of 
23kd protease activity, it is still uncertain whether cleavage does occur in vivo. However, if 
cleavage does occur then this might suggest that the both proteins are spatially distributed 
within nuclei of cells infected with Ad2tsl. As mentioned previously, the clear amorphous 
inclusions and electron dense bodies (which are thought to contain P80-coilin) were only 
found in close proximity with each other in wild type infected cells during the late-phase of 
nuclear transformation. The distribution of P80-coilin within Ad2tsl infected cells was not 
determined using the laser scanning confocal imaging system. It may be that the partial
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colocalisation observed within nuclei of wild type infected cells does not occur within nuclei 
of Ad2tsl infected cells which in turn would explain why the possible cleavage products 
were not isolated from Ad2tsl nuclear extracts.
It was of interest that P80-coilin cleavage was only detected when activated 23kd protease 
was added to reticulolysates, particularly as non-activated protease has been shown to cleave 
pTP (Webster et al., 1994), and ovalbumin (Keyvani-Amineh et al., 1995c).
The pVI-ct dependent activation of recombinant 23kd protease was examined further with in 
vitro transcribed/translated pVIII (pVIII cDNA in pRSET provided by W.S.A. Annan, 
University of St.Andrews) incubated with activated and non-activated recombinant 23kd 
protease as described above. Cleavage products of pVIII (assumed to be VIII with an 
approximate Mr of 15kd) were detected only after addition of the activated enzyme (figure 
3.62). The in vitro requirement for pVI-ct activation of the 23kd protease suggests that pVIII 
may not be cleaved at sites of colocalisation (for instance the nuclear clear amorphous 
inclusions) which do not contain pVI during the late-phase of nuclear transformation.
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Figure 3.62: In vitro cleavage of pVIII. pVIII cleavage reactions and immuneprecipitations were 
carried out as described in section 2.9.3. Samples were resolved using 15% SDS-PAGE (Coomassie blue 
stained/destained) and bands examined using die Fujix Phosphoimager. Part A: Crude TNT lysate containing 
pVIII (lane 1). Immuneprecipitated products from reaction mixtures of pVIII incubated with activated 23kd 
protease, and non-activated 23kd protease are shown in lanes 2 and 3 respectively. Samples of these reaction 
mixtures which were not immuneprecipitated are shown in lanes 4 and 5 respectively. TNT lysate containing 
in vitro translated 23kd protease (lane 6). Part B: Samples of crude TNT lysates (samples were not 
immuneprecipitated) containing pVIII (lane 1), pVIII and non-activated 23kd protease (lane 2), and activated 
protease (lane 3). Part C: Sample of crude TNT lysate (no cDNA)/activaled 23kd reaction mixture.
175
v) Colocalisation of pVTO and the protease within the cytoplasm:
The 23kd protease and pVIII were found to colocalise within the cytoplasm of infected cells 
from 24 h.p.i onwards (figure 3.45). One of the cytoplasmic structures that was 
immunolabelled during the course of the cytochemical study were the irregularly shaped 
electron dense structures shown in figure 3.63a. Although infrequently observed, these 
virus-induced structures were intensely labelled and detected only within infected cells fixed 
with 2% paraformaldehyde/0.05% glutaraldehyde, with extraction of components of these 
structures assumed to have occurred with 4% formaldehyde fixation. The significance of 
pVIII and 23kd protease colocalisation at these structures is unknown, as is the relevance to 
the functional roles both proteins have late in infection.
The protease and pVIII were more frequently detected within clear fibrillar structures that 
were typically found within close proximity to the nuclear membrane (figure 3.63b). Again, it 
is unclear what functional significance these structures have in relation to late-phase 
development of Ad2 infection, although their proximity to the nuclear membrane, and 
retention within 4% formaldehyde fixed/epon embedded cells, suggested that these structures 
were probably those most frequently detected by immunofluorescent staining. Rarely, and 
only within 4% formaldehyde fixed cells, clusters of lOnm colloidal gold particles were 
detected within the cytoplasm but did not appear to be localised to any specific structure 
(figure 3.63c). It was thought possible that these clusters may have been sites of cytokeratin 
cleavage, although these intermediate filaments were never identified.
Although after 24 h.p.i the viral protease is almost exclusively colocalised with pVIII within 
the cytoplasm, it is still unclear whether the protease is active (or available for activation) but 
unable to perform proteolytic cleavages on pVffl. Very little is known regarding the function 
of protein VIII apart from its proposed role in 'cementing' the capsid of the intact virion. 
Proteolytic cleavage pVIII is generally considered to occur within the maturing virion after 
pVI mediated activation of the viral protease.
vi) Cleavage of Cytokeratin K18:
It was of interest that the spheroid globules and cytoplasmic clumps associated with
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Figure 3.63: Cytoplasmic colocalisation of pVIII and the 23kd protease. Ad2 infected HeLa 
cells (28 h.p.i) were fixed with 2% parafonnaldehyde/0.05% glutaraldehyde (part A) and 4% formaldehyde 
(parts B and C) for 10 minutes then dehydrated, and embedded in epon (section 2.8). Thin-sections were 
immunolabelled (OA10b3 used for detection of the 23kd protease) as described in section 2.8.4, then 
contrasted. Colocalisation of pVIII (6nm gold particles) and the viral protease (lOnm gold particles) was 
detected at irregularly shaped electron dense structures (part A; asterisk), and clear fibrillar structures (Part B; 
asterisk). Clusters of the viral protease alone were also detected (part C; asterisk). All viewed at 80kv. All 
automatic exposures at x34000 magnification.
cytokeratin K18 cleavage (Chen et al., 1993) were detected within the infected cells as early 
as 22 h.p.i (figure 3.64). The viral protease was normally detected within infected cells from
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approximately 24 h.p.i onwards, with intracellular levels of the enzyme assumed too low to 
be detected by immunofluorescence prior to this stage in the development of infection. The 
distribution of pVIII prior to 24 h.p.i was almost exclusively intranuclear, appearing as 
punctate spots (figure 3.64). Nuclear and cytoplasmic colocalisation of pVIII and the 23kd 
protease was observed from 24 h.p.i onwards. pVIII was never detected within regions of 
the cytoplasm which were shown to contain cytokeratin spheroid globules and clumps, which 
initially suggested that the capsid protein was colocalised with the inactive form of the
enzyme.
Figure 3.64: Cytokeratin cleavage during the late-phase of Ad2 infection. Ad2 infected HeLa 
cells were examined for cytokeratin K18 cleavage by direct-immunofluorescent staining (FITC-conjugated Mab 
K5.B17.2 is specific for cytokeratin peptide K18) at 12 h.p.i (part A), 22 h.p.i (part B) and 28 h.p.i (part C). 
Non-infected HeLa cells were also stained (part D). All were viewed at x60 magnification with approximately 
30 second exposure times (automatic). Part E: Double immunolabelling of infected cells (22 h.p.i) showing 
pVIII (left) and cytokeratin K18 (right). xlOO magnification (oil immersion).
It was of interest that the fluorescent staining pattern of pVI was entirely intranuclear from 16 
h.p.i onwards (section 3.3.3). This suggested that other factors, either of viral or cellular 
origin, might be required for the activation of the protease in vivo. A database search 
(FASTA) of cellular proteins that contain sequences that might mimic the activating peptide 
(GVQSLKRRRCF), indicated that the aclivin receptor precursor protein is currently the only 
known human protein which contains a similar sequence (YGDKDKRRHCF). As this 
sequence does not have the N-terminal glycine and valine residues which have been shown to 
be important in binding of pVI-ct to the 23kd protease (Cabrita et al, 1997), it is unlikely that 
intracytoplasmic protease activity is regulated via this cellular protein. It is noteworthy that 
proteolytic activity in vitro has been determined in the absence of the activating peptide 
(reviewed within Weber, 1995).
As expected, cytokeratin cleavage was not detected within Ad2tsl infected cells maintained at 
39°C, but was detected within these cells maintained at the permissive temperature (figure 
3.65). These observations were consistent with those presented by Chen et al (1993). 
Interestingly, Rancourt et al (1995) have shown that the temperature-sensitive phenotype was 
rescued by the provision of pVI-ct to the cell culture medium. The authors suggested that at 
39°C the P137L mutation causes a small but crucial structural change in the protein that 
prevents it being in a position to be activated by cleavage of the pVI-ct peptide from the pVI 
protein. As activation is thought to occur within the immature virion, the significance of this 
finding is not absolutely clear in respect to cleavage of cytokeratin K18.
3.3.3 The intranuclear distribution of pVI.
i) Colocalisation of the 23kd protease and pVI/VI at assembly centres:
Using the anti-pVI/VI rabbit antiserum (kindly donated by Dr.D. Mathews, University of 
St.Andrews) it was evident that distribution of pVI/VI within Ad2 (wt) infected cells was 
exclusively intranuclear, with a diffuse nucleoplasmic immunofluorescent staining pattern 
consistently observed at 28 h.p.i (figure 3.66). It was not surprising that pVI/VI localised to 
the nucleus as Ad2 pVI has two potential nuclear localisation sequences, 246-KRRR (within 
the C-terminal 12 amino acids), and 132 KRPRP (a known targeting sequence from the C- 
terminus of Ad2 EIA proteins, Shin Hong and Engler, 1991). A comparison of known
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mammalian adenovirus pVI sequences (human types 2, 5, 12, 31, 40 and 41 from the 
GenEMBL databases) indicates that these sequences are highly conserved.
Figure 3.65: Cytokeratin is not cleaved within Ad2tsl infected cells maintained at 39°C. 
AD2tsl infected HeLa cells were maintained at 39°C and 33°C, then fixed with 4% formaldehyde at 28 h.p.i 
and 48 h.p.i respectively. Parts A (Ad2tsl (39°C)) and B (Ad2tsl (33°C)): Double immunofluorescence of 
cytokeratin K18 (left) and pVI (right)(using the polyclonal antiserum provided by Dr.D.Mathews (section 
3.3.3)). x60 magnification. Part C: Corresponding Ad2 wild type infection (28 h.p.i) with staining of pVI 
(left) and cytokeratin K18 (right). xlOO magnification (oil immersion). Automatic exposure times for pVI 
were approximately 15 to 30 seconds.
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Figure 3.66: Intranuclear colocalisation of pVI and the 23kd protease. BIO-RAD MRC-600 
laser scanning confocal image of the 23kd protease (detected using OCllbll)(part A) and pVI (part B). The 
merge of both images is given in part C with the viral protease showing as green and pVI showing as red 
(with yellow representing colocalisation). Viewed at xlOO magnification (oil immersion).
From figure 3.66 it is clear that the 23kd protease (stained using OC1 lbl 1) and pVI/VI do 
colocalise within specific subnuclear domains late in infection, although it is unclear whether 
both proteins are in direct association. The distribution of the 23kd protease and pVI/VI 
within infected cell nuclei was further investigated at a series of time points during the course 
of Ad2 infection (from 12 to 28 h.p.i). At early-late times post infection (16 to 20 h.p.i) pVI 
appeared to accumulate at sites distinct from those which have been identified as containing 
DBP (figures 3.67a), and had the appearance of punctate spots and/or doughnut shaped 
spheres. These structures are also evident in figure 3.66 within infected cell nuclei where the 
23kd protease was not detected. As infection progressed, the distribution of pVI/VI within 
the nucleus became more diffuse, with intense labelling observed at the nuclear periphery 
(from 20 h.p.i to 28 h.p.i). It was assumed that these were sites of virion assembly as they 
were distinct from regions containing pTP and DBP (figures 3.67b).
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Figure 3.67: pVI/VI distribution within Ad2 infected HeLa cells. Part A: Ad2 infected HeLa 
cells (18 h.p.i) were fixed with 4% formaldehyde then double immunolabelled using the methods described in 
section 2.8.2. pVI (left) and DBP (right). Part B: pVI (left) and pTP (right) distribution within late-phase Ad2 
infected cells (28 h.p.i) was examined using the same methodology. Mab 3Dllbll (anti-pTP) was kindly 
provided by Dr. Ailsa Webster (University of St.Andrews). pVI did not colocalise with pTP at 18 h.p.i, or 
DBP during the late-phase. Viewed at xlOO magnification (oil immersion).
Immunogold labelled pVI/VI was detected in nuclear domains that contained high densities of 
virions (figure 3.68). Using antibody OCllbll, lOnm immunogold labelled 23kd protease 
was also detected within these assembly centres and within the clear amorphous inclusions 
which were usually in close proximity. It is likely that these virion containing assembly 
centres are the nuclear domains in which pVI/VI and 23kd protease were shown to colocalise 
in figure 3.66. OC1 lbl 1 did not detect 23kd protease within any other intracellular structures
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apart from the virus induced clear amorphous inclusions and electron dense cytoplasmic
structures.
Figure 3.68: pVI/VI and the viral protease colocalise at assembly centres. Ad2 infected 
HeLa cells (28 h.p.i) were fixed (2% paraformaldehyde/ 0.05% glutaraldehyde, pH 7.4; for one hour), 
dehydrated and embedded as described in section 2.8, dien immunolabelled using the anti-pVI polyclonal 
antiserum and Mab OCllbll. Viral protease (lOnm gold particles) is distributed within the regions containing 
arrays of virions and within clear amorphous inclusions. pVI/VI (6nm gold particles) is distributed within the 
regions of high virion density only. Viewed at 80kv. Automatic exposure at x34000 magnification.
Mathews and Russell (1995) investigated the role of the protease in the processing of pVI to 
VI (via iVI which is thought to be pVI minus the C-terminal 11 amino acids (pVI-ct)), and 
found that no other factors were required in vitro. Their results led them to suggest that the 
protease might become closely associated with pVI within the 'young virion', and following 
activation, cleave the C-terminus of pVI to produce iVI. The authors noted that processing of 
pVI to iVI and finally to VI improved hexon binding and may therefore be important during 
assembly to prevent VI from prematurely associating with gestating hexon trimers.
Although pVI was not detected within clear amorphous inclusions during the late-phase of 
nuclear transformation, some colocalisation with the 23kd protease was detected (albeit 
infrequendy) using antibody OA10b3, which appeared to specifically recognise the viral
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Figure 3.69: Localisation of pVI within intranuclear inclusions (I). BIO-RAD MRC-600 
laser scanning confocal image of the 23kd protease (detected using Mab OA10b3)(part A) and pVI (part B). 
The merge of both images is given in part C with the viral protease showing as green and pVI showing as red 
(with yellow representing colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as 
described in sections 2.7.5 and 2.8.2. Viewed at xlOO magnification (oil immersion).
Figure 3.70: Localisation of pVI within intranuclear inclusions (II). Ad2 infected HeLa cells 
(28 h.p.i) were fixed with 2% paraformaldehyde/0.05% glutaraldehyde (pH 7.4)(one hour) and treated for 
immunocytochemistry as described in section 2.8. pVI detected (6nm gold particles) at the periphery of the 
clear amorphous inclusion (CAI), and present within the darker contrasted amorphous inclusion (DAI). 
Automatic exposure at x34000 magnification. Viewed at 80kv.
protease within the threads and/or punctate spots (figure 3.69) as well as cytoplasmic 
structures. Although the sites of colocalisation are unknown, pVI was detected (again
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infrequently) within amorphous inelusions (figure 3.70) whieh may be similar in composition 
to the dark contrasted clear amorphous inclusions (dai) previously shown to contain the viral 
protease (figure 3.47).
ii) Intranuclear distribution of pVI/VI and PML:
From the immunofluorescence results it was unclear what intranuclear structures pVI 
localised too during the early-late phase of infection (16 to 20 h.p.i). It was initially thought 
that the punctate spot fluorescent staining of pVI might correspond to the proteins localisation 
within adenovirus-induced crystals (and/or clear amorphous inclusions) as pVI has been 
implicated to be directly involved in the transport of hexon capsomers to the nucleus 
(reviewed by D’Halluin, 1995). Some colocalisation with PML was detected within infected 
cell nuclei which showed a diffuse nucleoplasmic staining of pVI/VI, however, no 
colocalisation was observed within nuclei where punctate spot pVI staining was observed 
(figure 3.71).
Figure 3.71: The distribution of pVI/Vl and PML within Ad2 infected HeLa cells. BIO­
RAD MRC-600 laser scanning confocal image of PML (detected using Mab 5E10)(part A) and pVI (part B). 
The merge of both images is given in part C with PML showing as green and pVI showing as red (with 
yellow representing colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as described 
in sections 2.7.5 and 2.8.2. Viewed at xlOO magnification (oil immersion).
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iii) Intranuclear distribution of pVI/VI within Ad2tsl infected cells:
The distribution of pVI/VI within Ad2tsl infected cells (28 h.p.i) maintained at the non­
permissive temperature differed markedly from the wild type equivalent, with the protein 
predominantly localised to the nuclear periphery (Figures 3.72a). The diffuse nucleoplasmic 
staining pattern of 23kd protease was detected only within Ad2tsl infected cells maintained at 
the permissive temperature, albeit at reduced levels in comparison to wild type infection 
(figure 3.72b). The distribution of pVI within Ad2tsl infected cells maintained at the 
permissive temperature resembled that detected during the wild type infection, although there 
was still intense peri-nuclear fluorescent staining similar to that observed within cells 
maintained at the non-permissive temperature.
Figure 3.72: Intranuclear distribution of pVI during Ad2tsl infection. Ad2tsl infected HeLa 
cells were maintained at 39°C (fixed at 28 h.p.i) and 33°C (fixed at 48 h.p.i) then double immunolabelled as 
outlined in section 2.8.2. Part A: pVI fluorescent staining (left) is predominantly peri-nuclear within Ad2tsl 
infected cells (non-permissive temperature). Only 'thread like' structures are detected using Mab OCllbll 
(right). Part B: The intranuclear distribution of pVI (left) and the viral protease (right) within Ad2tsl infected 
cells (permissive temperature). Viewed at xlOO magnification (oil immersion).
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The absence of the diffuse nucleoplasmic distribution of the 23kd protease within Ad2tsl 
(non-permissive) infected cells suggested that the viral protease does not colocalise with pVI 
within regions of high virion density at the non-permissive temperature. Similarly, Rancourt 
et al (1995) have shown using extracts of Hep-2 cells infected with wt (37°C) and tsl (33°C 
and 39°C) that the synthesis, stability and the transport of the enzyme to the nucleus appears 
to be normal in Ad2tsl (39°C) infected cells. However, the authors did not detect protease 
within virions produced at 39°C, and suggested that the tsl defect resides in a failure of 
enzyme activation and encapsidation at the non-permissive temperature. Interestingly, the 
authors noted that immature virions did contain protease (albeit 25% of that found in wt 
immature virion equivalents).
3.3.4 Immunolocalisation of replication and transcription sites:
The localisation of pTP and DBP to specific domains as shown in figure 3.73 is consistent 
with results derived elsewhere (Murti et al., 1990). These authors detected regions in late- 
phase infected cells which labelled heavily with Adpol and TP but had less DBP. The centres 
heavily labelled with DBP likewise contained only small amounts of Adpol and TP and the 
authors suggested that replication initiates in locations that contain Adpol and TP, while 
elongation, which requires the 72kd DBP, takes place in the ssDNA accumulation sites. 
Collectively, results from other sources suggest that transcription and DNA replication of the 
virus take place in overlapping compartments (Pombo et al., 1994; Besse and Puvion- 
Dutilleul, 1994; and Bridge and Pettersson, 1995) with transcription occurring almost 
exclusively in the peripheral replicative zone where it partially overlaps with areas of ongoing 
DNA synthesis. It is likely that the nuclear structures which are heavily labelled with 6nm 
gold particles in figure 3.74 are late-phase ssDNA accumulation sites. pTP was not detected 
within thin sections despite using solutions of pooled cell culture supernatants containing 
monoclonal antibodies specific to the protein (kindly donated by Dr. Ailsa Webster). Perhaps 
hydrophilic resins such as LR white or Lowikryl K4M would be more suitable for 
immunodetection of this protein in thin sections. In addition, several of the monoclonal 
antibodies (with the exception of 3D 11) were found to cross-react with cellular proteins 
within non-infected cells.
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Figure 3.73: Distribution of pTP and DBP during the late-phase of infection. BIO-RAD 
MRC-600 laser scanning confocal image of pTP (detected using Mab 3dll)(part A) and DBP (part B). The 
merge of both images is given in part C with pTP showing as green and DBP showing as red (with yellow 
representing colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as described in 
sections 2.7.5 and 2.8.2. Viewed at xlOO magnification (oil immersion).
Figure 3.74: Identification of ssDNA accumulation sites. AD2 infected HeLa cells were fixed 
using 2% paraformaldehyde/0.05% glutaraldehyde (pH 7.4) for 10 minutes, then dehydrated, and embedded as 
described in section 2.8. ssDNA accumulation sites (fibrillar inclusions) were intensely labelled with DBP 
(6nm gold particles) and are highlighted (FI). Clear amorphous inclusion (CAI). Viewed at 80kv. x34000 
magnification.
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Partial colocalisation of the viral protease (detected using OA10b3) and DBP was observed in 
late-phase infected cell nuclei (figure 3.75). It is possible that there is some overlap between 
clear amorphous inclusions and ssDNA accumulation sites during the later stages of nuclear 
transformation. DBP was not detected within clear amorphous inclusions (figure 3.74), 
instead being detected within darker contrasted inclusions often found in the peripheral 
regions of the nucleus that contained high densities of virions.
Figure 3.75: Distribution of DBP and the 23kd protease during Ad2 infection. BIO-RAD 
MRC-600 laser scanning confocal image of the viral protease (detected using Mab OA10b3)(part A) and DBP 
(part B). The merge of both images is given in part C with the 23kd protease showing as green and DBP 
showing as red (with yellow representing colocalisation). Infected HeLa cells (28 h.p.i) were fixed and 
immunolabelled as described in sections 2.7.5 and 2.8.2. Viewed at xlOO magnification (oil immersion).
Bosher et al (1992) have shown that in Ad2 infections (but not Ad4) nuclear factor 1 (NF1) is 
colocalised with DBP at intranuclear centres which they identified as being sites of viral DNA 
replication. Their results suggested that host proteins needed for viral replication are recruited 
from their normal locations to sites where viral replication is taking place. In this context the 
partial colocalisation of the 23kd protease with DBP late in infection (possibly at sites where 
specific nuclear domains overlap) is of interest, as NF1 does contain a potential cleavage site. 
Likewise, the Ad2 E1B 55kd protein, which also has a potential cleavage site (199-ISGNG), 
has been shown to colocalise with DBP at clear fibrillar inclusions (CFI) believed to be
ssDNA accumulation sites (Omelles and Shenk, 1991). Doucas etal (1996) have shown that 
the E1B 55kd protein (and the E4 ORF3 llkd protein) colocalises with PML early in 
infection, which in turn undergoes reorganisation into the 'track' structures. During this 
process, some host components are recruited from PML bodies into the viral replication 
domain.
3.3.5 Immunolocalisation of core proteins pVII/VII and V. ‘
In addition to the colocalisation with the 23kd protease, pVI/VI was also observed to 
colocalise with pVIEVII at assembly centres late in infection (figure 3.76). As was the case 
with immunodetection of pTP, the anti-pVII monoclonal antibody used cross-reacted with 
cellular antigen(s). The epitope for the antibody used has been determined as RNYPTP (Dr. 
Paul Szawlowski, pers.comm.). A similar sequence within DNA-directed RNA polymerase 
(PNYTPT) suggests that this protein may have been detected within non-infected cells. 
pVIVVII was predominantly detected within regions of high virion density (figure 3.54b on 
page 165), in particular- regions of the nucleus which comprised of crystalline arrays of virus 
particles. Immunolabelling of pVII/VII was significantly lower in regions of the nucleoplasm 
which contained a random distribution of virus particles (figure 3.79). Some 
immunolabelling of condensed material (most likely cellular chromatin) located at the nuclear 
periphery was also detected (figure 3.55 on page 166). Cellular chromatin is condensed and 
relocated to the nuclear periphery during the late stages of nuclear transformation (Puvion- 
Dutilleul and Puvion, 1995b; Lutz et al, 1996), and it is possible that the anti-pVII 
monoclonal antibody cross-reacted with antigens present within this intranuclear domain. 
Results described elsewhere indicate that the core proteins (V and pVII/VII) appear within 
intact virions 15 minutes after their synthesis (reviewed by D’Halluin, 1995), which is in 
sharp contrast to the lag period of 60 minutes required for the assembly of hexon 
polypeptides into virions (Horwitz et al., 1969). Collectively, the results from studies on 
kinetics of labelling and protein composition suggest that empty capsids contain precursor 
polypeptides, and possibly scaffolding proteins, with viral DNA and core proteins V and 
pVII then incorporated either separately or together, with the final step involving proteolytic 
cleavage of precursor polypeptides. This implies that core proteins become rapidly associated 
with DNA after their synthesis and that DNA and core protein(s) (complexes) are somehow
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Figure 3.76: Colocalisation of pVI/VI and pVII/VII within Ad2 infected HeLa cells. 
Infected Hela cell monolayers were fixed at 28 h.p.i then prepared for immunofluorescence as described in 
section 2.8.2 and examined using the BIO-RAD MRC-600 laser scanning confocal microscope. Part A: pVII. 
Part B: pVI. The merge of both images is given in part C with the pVII showing as green and pVI showing as 
red (with yellow representing colocalisation). Viewed at xlOO magnification (oil immersion).
inserted into previously assembled capsids. Interestingly, core proteins pVII and V only 
colocalised within particular subdomains of the nucleus at 28 h.p.i (figure 3.77). To a large 
extent the proteins appeared to be spatially distributed, colocalising at what appeared to be 
border regions between specific intranuclear structures. Phosphoprotein V appeared to be in 
close proximity to ssDNA accumulation sites during the late-phase of nuclear transformation 
(figure 3.78) and has also been detected within small electron dense nuclear bodies which 
have a similar composition to that of the residual nucleolus (figure 3.79).
Studies which have utilised bismuth staining of phosphorylated proteins (Chaly and Chen, 
1993; Puvion-Dutilleul and Puvion, 1995) have primarily focused on the intranuclear 
distribution of DBP (which contains about a dozen phosphorylated sites which are 
concentrated in the smaller 25kd fragment of the protein). However, other intranuclear 
structures, in particular the dense (and very dense) fibrillar inclusions described by Chaly and 
Chen (1993) also contain significant levels of phosphoproteins. It is unclear whether
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structures described by these authors correspond to the sites of protein V localisation shown 
here.
Figure 3.77: Intranuclear localisation of proteins V and pVII/VII. BIO-RAD MRC-600 laser 
scanning confocal image of pVII (part A) and V (part B). The merge of both images is given in part C with 
the pVII showing as green and V showing as red (with yellow representing colocalisation). Infected HeLa cells 
(28 h.p.i) were fixed and immunolabelled as described in sections 2.7.5 and 2.8.2. Viewed at xlOO 
magnification (oil immersion) then stored at xl.7 magnification.
Figure 3.78: Intranuclear distribution of protein V and DBP. Ad2 infected HeLa cells (28 h.p.i) 
were fixed and double immunolabelled as described in section 2.8.2. DBP (left) and Protein V (right) were 
viewed at xlOO magnification (oil immersion). Antibodies specific to both proteins were generously provided 
by Professor W.C.Russell (University of St.Andrews).
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Figure 3.79: Protein V localises to specific nuclear structures. Infected HeLa cells (28 h.p.i) 
were fixed with 2% paral'onnaldehyde/0.05% glutaraldehyde (one hour)(pH 7.4), then dehydrated and embedded 
as described in section 2.8. Protein V (6nm gold particles) was delected within irregularly shaped electron 
dense structures (asterisk). Low levels of pVII/VII were delected within regions of the nucleoplasm containing 
random distributions of virions (lOnm gold particles), and at the periphery of clear amorphous inclusions 
(CAI). viewed at 80kv. x34000 magnification.
Figure 3.80: Distribution of protein V and the 23kd protease. BIO-RAI) MRC-600 laser 
scanning confocal image of the 23kd protease (delected using OA10b3)(part A) and V (part B). The merge ot 
both images is given in part C with the protease showing as green and V showing as red (with yellow 
representing colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as described in 
sections 2.7.5 and 2.8.2. Viewed at xlOO magnification (oil immersion).
Kinetic labelling studies earned out by Weber and Khitoo (1983) suggested that the protein V 
was incorporated into immature virions prior to DNA encapsidation with the disappearance of 
label being concomitant with DNA encapsidation. Interestingly, these authors have also
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found that the Ad2tsl mutation results in a failure of protein V dephosphorylation within the 
maturing virion. Although protein V was not detected within clear amorphous inclusions, 
some colocalisation with the 23kd protease was detected within nuclei of wt Ad2 infected 
cells (figure 3.80) using the laser scanning confocal imaging system (Ad2tsl infected cells 
were not examined). The sites of colocalisation may be overlapping nuclear domains which 
are in close proximity to virion assembly centres.
3.3.6 Distribution of the 23kd protease and the Ll 52/55kd proteins.
The adenovirus Ll region encodes several proteins important for assembly of infectious virus 
particles namely, the 52kd and 55kd proteins, and the Ilia protein (which is a structural 
component of the virion). The 52/55kd proteins are nuclear phosphoproteins (that are highly 
related in amino acid sequence), which have not been detected in virions. Mutations in either 
the 52/55kd proteins leads to an accumulation of intermediate particles that are blocked in 
viral genome compaction and encapsidation (Hasson et al., 1989 and 1992). Hasson etal 
(1992) have proposed several possible roles for the Ll 52/55kd proteins during infection. 
Firstly, the proteins may have a structural role as scaffolding proteins, and function to 
mediate recognition between capsid and chromosome at the initiation of encapsidation. They 
could also play a catalytic role in the compaction of the viral genome, or they could form a 
portal structure through which the viral genome must enter the virion capsid. Loss of any one 
of these functions could disrupt virion assembly. These authors also proposed that a major 
40kd (doublet) breakdown product detected within empty capsids and intermediate particles 
may result from the cleavage of the 52/55kd proteins (at the consensus cleavage site 348- 
LAGTG) al a late stage during encapsidation by the viral protease. This breakdown product 
can form homodimers with another 40kd cleavage product or with full length 52/55kd 
proteins (which can also dimerise).
In order to determine whether the 23kd protease and the Ll 52/55kd proteins colocalised 
within infected cell nuclei, a monospecific polyclonal antiserum was generated against a 
synthetic peptide corresponding to the region 46-DGYEPPRRRARHYL of both proteins, 
using the methods outlined in section 2.9.2. The antiserum immunoreacted with a doublet 
corresponding to apparent molecular weights of 52kd and 55kd from nuclear extracts of Ad2 
infected cells (28 h.p.i), and a single form of approximately 52kd from cytoplasmic extracts
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from the same cell lysates. No immunoreactions were detected with equivalent extracts from 
non-infected cells (figure 3.81).
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Figure 3.81: Immunoprecipitation of the LI 52/55kd proteins from Ad2 infected cell 
lysates, polyclonal antiserum was added to precleared nuclear and cytoplasmic extracts of Ad2 infected HeLa 
cells (28 h.p.i) and mock infected cells (sections 2.7.4ii and 2.9.3iii). Samples and biotinylated molecular 
weight markers were electroblotted (15% SDS-PAGE) and stained using the same polyclonal antiserum 
(1/3000 dilution). Ad2 Infected nuclear (lane 1) and cytoplasmic (lane 3) extracts. Non-infected nuclear (lane2) 
and cytoplasmic (lane 4) extracts.
Immunofluorescent staining of Ad2 infected HeLa cells (28 h.p.i) revealed that the LI 
52/55kd proteins had a diffuse nuclear staining pattern (similar to that of pVI), with the 
proteins observed to be localised predominantly at the nuclear periphery. Colocalisation of the 
52/55kd proteins and the viral protease was detected within domains likely to correspond to 
assembly centres and amorphous inclusions (figure 3.82). It was of interest that in the 
apparent absence of 23kd protease, the 52/55kd proteins exhibited a punctate staining pattern. 
The LI 52/55kd protein staining patterns shown here are identical to those published by 
Hasson et al (1992). These authors noted that sites of 52/55kd protein staining were distinct 
from replication centres, and appeared to colocalise with assembling virions. They proposed 
that virus assembly begins at multiple sites which coalesce as the infection proceeds, 
eventually filling much of the nuclear periphery. Interestingly, the apparent distribution of the 
23kd protease and 52/55kd proteins within Ad2tsl infected cells (28 h.p.i) was determined to 
be identical to that of the wild type (figure 3.83). This is markedly different to the observed 
pVI/VI distribution which was found to be less diffuse and more intense at the nuclear 
periphery.
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Figure 3.82: Distribution of the 23kd protease and LI 52/55kd proteins within Ad2 
infected cells. BIO-RAD MRC-600 laser scanning confocal image of the viral protease (detected using Mab 
OA10b3)(part A) and die LI 52/55kd proteins (part B). The merge of bodi images is given in part C with the 
protease showing as green and the LI 52/55kd phosphoproteins showing as red (with yellow representing 
colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as described in sections 2.7.5 and 
2.8.2. Viewed at xlOO magnification (oil immersion).
Figure 3.83: Distibution of the 23kd protease and LI 52/55kd proteins within Ad2tsl 
infected cells. BIO-RAD MRC-600 laser scanning confocal image of die viral protease (detected using Mab 
OA10b3)(part A) and the LI 52/55kd proteins (part B). The merge of both images is given in part C with the 
protease showing as green and the LI 52/55kd phosphoproteins showing as red (with yellow representing 
colocalisation). Infected HeLa cells (28 h.p.i) were fixed and immunolabelled as described in sections 2.7.5 and 
2.8.2. Viewed at xlOO magnification (oil immersion).
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The observed colocalisation of the 23kd protease and the 52/55kd proteins within Ad2tsl 
infected cells suggested that the viral protease is unable to cleave the scaffolding proteins at 
these sites, as Hasson et al (1992) have determined that cleavage does not occur within 
Ad2tsl infected cells. The authors have proposed that cleavage occurs within assembly 
intermediates, and therefore prior to maturation cleavages involved in converting young 
virions into mature virions.
Thin sections were not immunolabelled, however Hasson et al (1992) did localise the 
proteins to three different structures using the pre-embedding technique. The first, and 
probably the most relevant in terms of the observed colocalisation with the 23kd protease, 
was the immunolocalisation of the 52/55kd proteins to what these authors termed loading 
centres, which were always surrounded by numerous virions (which were also 
immunolabelled), and may correspond to the clear amorphous inclusions described in this 
study.
The 52/55kd proteins were also localised to circular electron dense bodies which may be the 
same structures as those shown in figure 3.55 (referred to as DNb), which were often found 
to be in close proximity to the clear amorphous inclusions. Electron dense bodies have been 
shown to contain protein IVa2 (figure 3.85; Lutz et al., 1996).
Figure 3.84: Localisation of protein IVa2 within Ad2 infected cells. Part of the nucleus of an 
Ad5 infected HeLa cell (17 h.p.i). Immunogold detection of protein IVa2 within glutaraldehyde fixed cells. 
IVa2 was localised to virus-induced electron dense amorphous inclusions (ai) often found close to protein 
crystals (pc) and the nucleolus. Bar 0.5pm. Reproduced from Lutz et al (1996).
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This is of particular interest, as the proposed 40kd cleavage product of the 52/55kd protein 
has been implicated as the functional partner of IVa2 in the formation of the DEF-A complex 
(Gustin et al., 1996). The DEF-A and DEF-B (which is comprised of a IVa2 homodimer) 
complexes have been proposed to be involved in the late-stage specific transactivation of 
major late promoter activity. If the viral protease is directly involved in DEF-A complex 
formation, then the enzyme must be active outwith the maturing virion, possibly within clear 
amorphous inclusions which are found to be associated with the electron dense bodies located 
at the nuclear periphery.
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4 General Discussion
4.1 The subcellular localisation of the Acl2 protease within 
lytically infected cells.
There is now strong evidence to suggest that the viral protease plays a critical role during the 
final stages of infection in which 'young' virions are matured into infectious particles. 
However, it is currently unknown what mechanism(s) are involved in the prevention of 
premature activation of the enzyme, and consequently, premature cleavage of precursor 
proteins. Likewise, the events and/or factors which facilitate cleavage of cytokeratins K18 
and K7 are also unknown. Results presented within this thesis suggest that intranuclear viral 
protease could be regulated during the late-phase of productive infection by being sequestered 
to virus-induced clear amorphous inclusions.
4.1.1 Clear amorphous inclusions.
Puvion-Dutilleul et al (1995b) noted that clear amorphous inclusions which accumulate PML 
were present within infected nuclei as soon as virus-induced intranuclear changes became 
visible. At the later stage of nuclear transformation, when isolated and clustered viruses were 
more numerous, clear amorphous inclusions were located within the electron translucent area 
of the nuclear periphery (figure 4.1). The authors also observed that as infection progressed, 
these structures, which were initially small and irregularly shaped, became larger and more 
abundant. The authors speculated that sequestration of PML to these virus-induced inclusions 
might inactivate the protein, and facilitate the intranuclear development of progeny genomes 
and viruses.
It is believed that these structures are the same as those observed during the course of this 
study to contain the viral protease, protein pVIII, and possibly the L152/55kd protein. 
However, pVIII was not shown to colocalise with PML at 28 h.p.i, which suggested that 
PML might either be relocated from clear amorphous inclusions (and protein crystals) during 
the late-phase of nuclear transformation (between 18 and 28 h.p.i), or that structurally similar 
(but not identical) virus-induced inclusions have been identified.
It is thought unlikely that the viral protease is active within these inclusions during the late- 
phase of nuclear transformation as activity would presumably result in the premature cleavage
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Figure 3.53: Part of the nucleus of an adenovirus-infected HeLa cell at 17 h.p.i. 
Immunogold labelling using anti-PML polyclonal antibody. Three juxtaposed clear amorphous inclusions 
(arrows) are localised at the border of the nucleus in an electron-translucent region (e) which also contains a 
large protein crystal (pc). Gold particles accumulate over the clear amorphous inclusions and are less numerous 
over the protein crystal. Peripheral replicative zone (p), ssDNA-accumulation sites (a), viral genome storage 
site (asterisk), and crystals of viruses (v), are almost entirely devoid of labelling. Bar 1p.m. Reproduced from 
Puvion-Dutilleul et al (1995b).
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of pVIII. Additionally, pVI was not detected within these structures during the late-phase of 
infection which also suggested that the viral protease may be inactive, as cleavage of pVIII in 
vitro required the addition of pVI-ct to the reaction mixture. However, it is noteworthy that 
the anti-pVIII polyclonal antiserum recognised protein VIII as well as pVIII. Therefore, it is 
unknown which form, if not both, was detected within the virus-induced inclusions. It is also 
noteworthy that the Ll 52/55kd proteins were detected within the thread-like structures 
present within Ad2 and Ad2tsl nuclei, yet Hasson et al (1992) have shown that neither of 
these proteins are cleaved within Ad2tsl infected cells (at the non-permissive temperature). 
Colocalisation of pVI and the 23kd protease (detected using Mab OAlOb3) was detected, 
albeit infrequently, at sites that may be virus-induced inclusions. Unlike Mab OCllbl 1, 
OA10b3 did not immunoreact with viral protease present within assembly centres, but instead 
appeared to exclusively immunoreact with the enzyme present within punctate spots and 
thread-like structures which were later determined to be clear amorphous inclusions. 
Likewise, pVI was also infrequently observed to be within these inclusions, which were 
always small, regularly shaped and isolated from other virus-induced inclusions.
Although it is unclear whether these are the same sites where pVI/PML colocalisation was 
observed, it may be that these inclusions are an early to late-phase form of clear amorphous 
inclusion distinct from the irregularly shaped (early-phase) clear amorphous inclusion 
described by Puvion-Dutilleul et al (1995b). Similar irregularly shaped inclusions were 
detected during the course of this study within nuclei infected with Ad2tsl (non-permissive 
temperature only). At 28 h.p.i these inclusions contained pVIII, the viral protease, and 
possibly the Ll 52/55kd proteins.
Tentatively, it is thought possible that the viral protease might be active within intranuclear 
virus-induced inclusions during the early to late-phase of infection (18 to 22 h.p.i). This is 
not improbable as cytokeratin K18 cleavage (in the apparent absence of pVI) was detected as 
early as 20 to 22 h.p.i. This suggested that in addition to being directly involved in the 
maturation of 'young' virions, the viral protease also plays an active part in the degradation of 
the intermediate filament system (which is believed to facilitate the release of mature progeny 
virions), at least 12 hours prior to cell lysis. Likewise the protease might be involved in the 
inactivation of nuclear proteins such as PML, or other PML-body associated proteins, which 
are thought to play some part in the cellular defence mechanism against viral infections.
Alternatively, sequestration of the viral protease to clear amorphous inclusions may itself 
prevent the enzyme from being prematurely activated. During the late-phase of nuclear 
transformation, the inclusions could be thought of as loading centres from which the enzyme 
is packaged into assembled virions prior to virion release. This is consistent with the 
observation that there was a significantly greater degree of immunogold labelling of clear 
amorphous inclusions which were surrounded by crystalline arrays of virion particles in 
comparison with those which were generally surrounded by randomly distributed virions.
The observed localisation of the LI 52/55kd probable scaffold proteins to the punctate spots 
and thread-like structures also supports the hypothesis that clear amorphous inclusions may 
function as loading centres from which virion components are inserted into pre-assembled 
capsids. Hasson etal (1989 and 1992) have suggested that these probable scaffold proteins 
are critical for packaging of the viral genome within pre-assembled capsid structures. The 
proteins apparently remain associated with the particles until they are cleaved by the viral 
protease.
4.1.2 Distribution of the 23kd protease within Ad2tsl infected nuclei.
The observed localisation of the viral protease within irregularly shaped clear amorphous 
inclusions, but not within crystalline arrays of assembled virion particles is consistent with 
results presented elsewhere (Rancourt et al., 1995). These authors demonstrated that the 
cause of the Ad2tsl protease delect resided in a failure of enzyme activation and enzyme 
encapsidation at the non-permissive temperature. The temperature-sensitive protease was 
synthesised and transported to the nucleus in a manner similar to the wild type protease, but 
was not present within 'young' virions.
The suprising observation within this study was that virion particles did not appear to be in 
close proximity to the clear amorphous inclusions. It therefore seems likely that the tsl defect 
may be, at least in part, due to specific interactions that occur within, or in close proximity to, 
the virus-induced clear amorphous inclusions. In that context, the unexpected finding 
presented by Rancourt et cd (1995) that the in vivo and in vitro temperature sensitive 
phenotype could be rescued merely by provision of the activating peptide is particularly 
significant. The authors suggested that at 39°C the tsl mutation causes a small but crucial 
structural change in the protein that prevents it from being in a position to be activated
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through interaction with protein pVI, although the pVI-ct peptide itself can activate the 
enzyme both in vivo and in vitro.
Because the appearance of the virus-induced inclusions is altered within Ad2tsl infected 
cells, it appears likely that the viral protease itself has some role in determining their structural 
integrity. As mentioned previously, it is thought possible that the viral protease may be active 
within these structures during the early to late stage (18 to 22 h.p.i) of nuclear 
transformation. Perhaps pVI mediated activation of the protease occurs during this period of 
infection and is required for the development of these virus-induced inclusions from the early 
small and irregularly shaped structures, into the larger and more regularly shaped inclusions 
detected during wild type infections at 28 h.p.i and tsl infections (at the permissive 
temperature) at 48 h.p.i.
4.1.3 Does the viral protease localise to 'assemblons'?
The pathway for adenovirus assembly was first analysed using kinetic labelling experiments 
(reviewed by D'Halluin, 1995), however progress was hampered due to the large pool of 
structural proteins within infected cells, and the fact that only a fraction of structural proteins 
in infected cells were shown to be incorporated into virus particles. Another approach has 
involved the use of temperature defective mutants, usually in conjunction with pulse-chase 
experiments, and separation of assembly intermediates using CsCl gradients. Although much 
of the data presented using these techniques has been very informative, the various 
mechanisms involved in virion assembly and maturation are still poorly understood, as are 
the mechanisms by which the infected cell is lysed just prior to virion release.
In recent years there has been significant progress in determining the means by which 
adenovirus causes intranuclear rearrangements necessary for both replication and 
transcription. In contrast to studies which have primarily focused on events occurring during 
the late stage of infection, most of these studies have incorporated ultrastructural and 
cytochemical techniques to full effect.
Likewise, over the past few years there have been many advances in determining the events 
involved in the assembly of HSV-1 capsids within the nuclei of infected cells. Many of these 
studies have utilised both immunofluorescence and electron microscopy techniques as a 
general tool for the molecular dissection of many of the late events in HSV-1 biogenesis.
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Iii cells infected with HSV-1, the viral proteins ICP5 (infected-cell protein 5)(the major 
capsid protein) and VP 19c (the product of the Uj,38 gene) are associated with mature capsids, 
whereas the same proteins, along with ICP35 (also referred to as VP22a), are components of 
immature capsids. All three proteins have been shown to coalesce at late times post-in fee Li on 
(Ward et al., 1996) within structures located at the periphery of nuclei which the authors have 
termed assemblons. The fact that capsid proteins accumulated within assemblons suggested 
that HSV-1 assembly is facilitated by, and is dependant on, protein concentration. 
Furthermore, the presence of assemblon domains late in infection also raised questions 
regarding the mechanisms by which capsid proteins are sequestered to these structures, and 
segregated from proteins involved in DNA synthesis, and those forming the tegument. 
Puvion-Dutilleul etal (1995c) have also noted that the cellular proteins PML, SP100, and 
P80-coilin are redistributed to electron translucent virus-induced structures which also contain 
HSV-1 capsid proteins. The functional significance of these structures, which are likely to be 
the assemblon structures observed using immunofluorescent microscopy, remains unknown. 
These authors proposed that the virus-structures have a potential role in the assembly of 
capsid proteins into capsid shells, and indeed, may be storage sites containing 
oversynthesised viral capsid proteins which may be assembled into non-functional or 
incomplete capsid shells. Additionally, it was thought possible that capsid proteins might 
interfere with sequestered PML and SP100, leading to their inactivation, and therefore, 
possibly contributing to the shutoff of host cell metabolism which occurs in HSV-1 infected 
cells.
Of interest is the fact that the HSV-1 protease (Pra) is involved in the assembly and 
maturation of viral capsids (Thomsen et al., 1995; Robertson et al., 1996). Pra is a 635 
amino acid serine protease encoded by the Ui 26 gene. The full length HSV-1 protease 
undergoes autoproteolytic processing at two sites (the release (R) and maturation (M) sites) 
generating No (the catalytic domain of the protease), Nb and a 25 amino acid C-terminal 
peptide. 1CP35, a substrate of the HSV-1 protease, is encoded by the U[26.5 gene. There is 
a family of ICP35 proteins designated a through to/ however, only ICP35? /is present in 
B capsids (intermediates in assembly) and also found to be absent from mature virions. Since 
ICP35 overlaps, and is in frame with the C-terminal half of Pra, ICP35c,c/ can be trans 
cleaved at its C-terminus by the protease to generate ICP35<?/ and a 25 amino-acid peptide.
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It has been suggested that ICP35<?/has a possible scaffold protein role during capsid 
assembly and therefore may have functional roles similar to that of the Ad2 Ll 52/55kd 
phosphoproteins.
The requirement for HSV-1 protease activity for capsid assembly and maturation has also 
been confirmed further using temperature defective mutants (Robertson et al., 1996). 
Although capsid structures are observed in the absence of functional protease, the major 
capsid protein ICP5 (VP5) does not adopt the correct conformation and viral DNA is not 
encapsidated. It appears that the full length protease (Pra), the catalytic domain (No), and the 
R and M cleavage site mutant protease’s are proteolytically active, however, the catalytic 
domain of the protease alone is insufficient to support viral growth, suggesting that Na (Nb 
and the 25 amino-acid peptide) may be required to direct the catalytic domain to the site of 
capsid assembly. Likewise, it is thought likely that intranuclear interactions (possibly with the 
C-terminus of pVI) governing the localisation of the Ad2 protease to sites of capsid assembly 
are defective within Ad2tsl infected cells. It is possible that the adenovirus-induced clear 
amorphous inclusions and HSV-induced asemblons/eleclron translucent patches have similar 
functional roles during the course of productive infections. In this context, it is of particular 
interest that both viral protease’s are localised to these domains, and certainly in respect to 
HSV-1 infection, proteolytic activity has been shown to necessary for release of ICP35 from 
R capsids.
4.2 Ad2 protease activity: Possible regulation mechanisms.
The pVI-ct mediated activation of the Ad2 23kd protease has now been extensively studied, 
and has been shown to involve the formation of a stable complex. Likewise, modulation of 
Hepatitis C NS3 protease activity by the virus encoded NS4a polyprotein cleavage product 
also appears to involve complex formation, although the mechanism by which NS4A 
modulates proteinase activity is still not known (Bartenschlager etal., 1995). Interaction 
between NS3 and NS4a may be required for localisation of NS3 to the endoplasmic reticulum 
membrane where most of the NS proteins are found. In this case, NS4a would increase the 
local NS3 protease concentration, thereby enhancing substrate cleavage. However, the NS3 
protease has also been shown to be localised to the nucleus of infected hepatocytes, and
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interestingly, this localisation is suppressed by NS4a cofactor but augmented by the cellular 
p53 protein (Muramatsu et al., 1997). Whether pVI-ct exerts similar constraints on the 
subcellular localisation of the Ad2 protease is presently unclear, however, the observation 
that the Ad2tsl protease was packaged within virions at the nonpermissive temperature after 
provision of pVI-ct to the medium (Rancourt et al., 1995), might suggest that pVI-ct, or pVI 
itself, does play some part in intracellular trafficking of the viral protease. In that context, it is 
noteworthy that the viral protease does not appear to contain any known nuclear localisation 
signal, and therefore may be dependant on pVI, or pVI-ct, for nuclear/intranuclear 
localisation.
The HSV-1 (Schmidt and Darke, 1997), hCMV (Margosiak et al, 1996), EBV (Donaghy and 
Jupp, 1994) and HIV-1 (Davis et al, 1995) protease’s appear to be regulated through the 
formation of homodimers. In the case of the protease’s which belong to the Herpes virus 
family, the monomeric forms of these enzymes are inactive in all three cases. The in vivo 
dimerisation of hCMV protease is thought to have an important physiological role in the 
temporal regulation of processes that occur during virus assembly. It is known that during 
capsid maturation the critical proteolytic events are controlled by the oligomerisation or 
aggregation state of full length protease and its substrate. It has been proposed that the 
monomeric form produced in the cytoplasm remains inactive, and that hCMV protease 
becomes activated and performs maturation cleavages only when the local concentration of 
monomeric forms reaches a high enough concentration within immature capsids.
Although dimeric forms of the 23kd protease were not isolated from Ad2 infected HeLa cells, 
dimeric isoforms of the recombinant wild type, but not the tsl mutant, enzyme were observed 
during the course of this study. The ability to form dimers in vitro was the only discernible 
difference between the two recombinant enzymes. After addition of pVI-ct, the recombinant 
tsl protease was shown to be active regardless of the assay temperature. What relavence, if 
any, dimerisation has on regulation of both the wild type and tsl enzymes in vivo is unclear, 
although Cys 104 may be considered a likely candidate for inter-molecular disulphide bonds 
involved in the formation of homodimers. It is noteworthy that Keyvani-Amineh etal (1996) 
have shown that redox conditions other than the pVI-ct peptide were capable of activating the 
protease, although the relevance to virus infected cells was also questioned by these authors.
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4.3 Suggestions for future work.
It is unclear why both pVIII and the 23kd protease eoloealise within virus-induced nuclear 
inclusions and also within distinct cytoplasmic structures late in infection. It would be of 
particular interest to determine what other factors (both cellular and viral) are sequestered to 
these domains, and which, if any, are directly involved in the intranuclear localisation of 
pVIII and the viral protease. Additionally, further investigations might reveal what 
mechanism(s) are involved in regulating in vivo viral protease activity, and whether these 
events are in some way linked to other processes that occur during a typical lytic infection. 
Investigating what protein-protein interactions occur, perhaps using the yeast two hybrid 
sytem, would potentially be usefull in determining further possible roles for pVIII and the 
viral protease late in infection. However, confirmation that pVIII and the viral protease are 
localised to the same virus-induced inclusions which have been shown to contain PML would 
be a prerequisite for any study that was a continuation of work presented within this thesis. 
Likewise, determining whether PML and P80-coilin are cleaved during a typical lytic 
infection, and at what times post-infection they are cleaved, would be of particular interest. In 
that context, an examination of both these cellular proteins and several viral proteins including 
hexon, fibre (which coalesce within protein crystals), pVI, pVIII and the 23 kd protease at 
different times post-infection using immunofluorescence and electron microscopy would be 
required.
Expression of the 23kd protease within virtually any animal cell using Semliki Forest Virus 
vectors, or other transfection vectors, might also be very informative. These systems could 
be utilised to determine whether pVI is required for cytokeratin K18 cleavage and/or nuclear 
localisation of the viral protease.
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